Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
c4175b43e2f9a1e008a5f0febd20e7cbed6a346ce32d1d6712716ff9cb83e061.png
complex
<table><tr><td></td><td colspan="3">Yale University cohort</td><td></td></tr><tr><td>Variable</td><td>No. of patients (%) (n = 651)</td><td>HR</td><td>95% CI</td><td><i>P</i>*</td></tr><tr><td>Age at diagnosis</td><td>645 (99.1)</td><td>0.999</td><td>0.988-1.009</td><td>0.890</td></tr><tr><td> Unknown/missing</td><td>6 (0.9)</td><td></td><td></td><td></td></tr><tr><td>Menopausal status</td><td></td><td></td><td></td><td></td></tr><tr><td> Premenopausal</td><td>196 (30.1)</td><td>1.000</td><td></td><td>0.436</td></tr><tr><td> Postmenopausal</td><td>449 (69.0)</td><td>1.115</td><td>0.848-1.482</td><td></td></tr><tr><td> Unknown/missing</td><td>6 (0.9)</td><td></td><td></td><td></td></tr><tr><td>Tumor size (cm)</td><td></td><td></td><td></td><td></td></tr><tr><td> &#8804; 2</td><td>215 (33.0)</td><td>1.000</td><td></td><td>&lt; 0.0001</td></tr><tr><td> 2-5</td><td>283 (43.5)</td><td>1.682</td><td>1.254-2.258</td><td></td></tr><tr><td> &#8805; 5</td><td>101 (15.5)</td><td>2.911</td><td>2.074-4.086</td><td></td></tr><tr><td> Other</td><td>52 (8.0)</td><td></td><td></td><td></td></tr><tr><td>Nodal status</td><td></td><td></td><td></td><td></td></tr><tr><td> Negative for node metastasis</td><td>327 (50.2)</td><td>1.000</td><td></td><td>&lt; 0.0001</td></tr><tr><td> Positive for node metastasis</td><td>320 (49.2)</td><td>2.286</td><td>1.795-2.910</td><td></td></tr><tr><td> Unknown/missing</td><td>4 (0.6)</td><td></td><td></td><td></td></tr><tr><td>Positive nodes</td><td>320 (49.2)</td><td>1.022</td><td>1.001-1.042</td><td>0.040</td></tr><tr><td>Total nodes</td><td>625 (96.0)</td><td>0.978</td><td>0.961-0.994</td><td>0.010</td></tr><tr><td> Unknown/missing</td><td>26 (4.0)</td><td></td><td></td><td></td></tr><tr><td>Nuclear grade</td><td></td><td></td><td></td><td></td></tr><tr><td> Small/uniform nuclei</td><td>113 (17.4)</td><td>1.000</td><td></td><td>0.0007</td></tr><tr><td> Intermediate nuclei</td><td>315 (48.4)</td><td>1.231</td><td>0.854-1.818</td><td></td></tr><tr><td> Large nuclei</td><td>170 (26.1)</td><td>1.594</td><td>1.192-2.123</td><td></td></tr><tr><td> Other</td><td>53 (8.1)</td><td></td><td></td><td></td></tr><tr><td>ER status</td><td></td><td></td><td></td><td></td></tr><tr><td> ER negative</td><td>289 (44.4)</td><td>1.000</td><td></td><td>0.0005</td></tr><tr><td> ER positive</td><td>326 (50.1)</td><td>0.766</td><td>0.598-0.981</td><td></td></tr><tr><td> Other</td><td>36 (5.5)</td><td></td><td></td><td></td></tr><tr><td>PR status</td><td></td><td></td><td></td><td></td></tr><tr><td> PR negative</td><td>294 (45.2)</td><td>1.000</td><td></td><td>&lt; 0.0001</td></tr><tr><td> PR positive</td><td>302 (46.4)</td><td>0.675</td><td>0.524-0.871</td><td></td></tr><tr><td> Other</td><td>55 (8.4)</td><td></td><td></td><td></td></tr><tr><td>HER2 status</td><td></td><td></td><td></td><td></td></tr><tr><td> HER2 negative</td><td>495 (76.0)</td><td>1.000</td><td></td><td>0.153</td></tr><tr><td> HER2 positive</td><td>109 (16.7)</td><td>1.270</td><td>1.048-1.317</td><td></td></tr><tr><td> Other</td><td>47 (7.2)</td><td></td><td></td><td></td></tr><tr><td>MAP-tau expression</td><td></td><td></td><td></td><td></td></tr><tr><td> MAP-tau low expression</td><td>376 (57.8)</td><td>1.000</td><td></td><td>0.0042</td></tr><tr><td> MAP-tau high expression</td><td>104 (16.0)</td><td>0.691</td><td>0.489-0.974</td><td></td></tr><tr><td> Unknown/missing</td><td>171 (26.3)</td><td></td><td></td><td></td></tr></table>
6187edbb2d4504573a032357c49b973b755b6b2c38f85c5da358d7e41d7a75e6.png
complex
<table><tr><td>Study groups</td><td>N</td><td>Mean</td><td>SD</td><td>P-value</td></tr><tr><td>Live Demonstration</td><td>26</td><td>6.69</td><td>1.4</td><td rowspan="3">.864*</td></tr><tr><td>Procedural Video</td><td>23</td><td>6.78</td><td>2.1</td></tr><tr><td>Total</td><td>49</td><td>6.73</td><td>1.8</td></tr></table>
9de0eb28e3611efc1f374db62bc0c3c94b28d27dc020ec8cf6c4f8217f621250.png
simple
<table><tr><td>Resource</td><td>Connectivity Comments</td><td>Reference</td></tr><tr><td>BindingDB</td><td>Comprehensive ligand-target database, we now cross-reference selected patent extractions from this source</td><td>(43)</td></tr><tr><td>ChEMBL and UniChem</td><td>Inclusion of our target protein pointers and a ChEMBL look-up for our ligand entries loaded in UniChem</td><td>(2,44)</td></tr><tr><td>DrugBank</td><td>Target cross-references and chemical ontology connection <i>via</i> an API</td><td>(45)</td></tr><tr><td>ESTER</td><td>Alpha/beta hydrolase cross-references</td><td>(46)</td></tr><tr><td>GeneCards</td><td>Gene expression and functional data aggregator</td><td>(47)</td></tr><tr><td>GPCRDB</td><td>Specific pointers to their detailed features, curation of mutations, sequence display toolbox and residue numbering system</td><td>(48)</td></tr><tr><td>GUDMAP</td><td>Links to proteins involved in GenitoUrinary (GU) tract development</td><td>(49)</td></tr><tr><td>HGNC</td><td>Long standing and frequent interactions on target family nomenclature issues</td><td>(10)</td></tr><tr><td>IMGT/mAb-DB</td><td>Pointers to provenanced sequences for clinical antibodies, target interactions, display tools and residue numbering system</td><td>(50)</td></tr><tr><td>MEROPS</td><td>Feature details, classification, ligand mapping, other protease-specific issues</td><td>(7)</td></tr><tr><td>neXtProt</td><td>Data and features additional to Swiss-Prot, semantic mining technology</td><td>(51)</td></tr><tr><td>NURSA</td><td>Detailed NHR information including transcriptome mining functionality</td><td>(52)</td></tr><tr><td>Orphanet</td><td>Unique rare genetic disease curation and disease term connectivity</td><td>(53)</td></tr><tr><td>PubChem</td><td>Covering aspects of chemical curation, drug naming and our submitted structures. Plans for future peptide and BioAssay Links</td><td>(4,14)</td></tr><tr><td>UniProtKB</td><td>Maintenance of our own selectable cross-references to proteins with quantitative interactions</td><td>(5)</td></tr><tr><td>Wikipedia</td><td>Updating, adding new target and ligand links, including filling in &#8216;chemistry boxes&#8217;</td><td>(54)</td></tr></table>
081e9128359490aef10a1615fa9b5e50f32b2b55afe343c80ce0cd6ab5b1794e.png
simple
<table><tr><td>Chr</td><td>MS</td><td>AI</td><td>DA</td><td>KA</td><td>NY</td><td>SNP</td><td>AI</td><td>DA</td><td>KA</td></tr><tr><td>1</td><td>D01S0023</td><td>21.60</td><td>41.65</td><td>12.18</td><td>14.59</td><td>C01R0052</td><td>21.53</td><td>47.08</td><td>13.43</td></tr><tr><td>3</td><td>D03S0127</td><td>30.32</td><td>37.70</td><td>26.91</td><td>30.16</td><td>C03R280</td><td></td><td>35.19</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>C03R281</td><td>28.93</td><td><i>35.11</i></td><td>28.86</td></tr><tr><td>5</td><td>D05S0172</td><td></td><td>8.52</td><td></td><td>22.11</td><td>C05R0380</td><td>25.57</td><td>7.65</td><td>34.40</td></tr><tr><td></td><td>D05S0173</td><td>26.98</td><td></td><td>35.24</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>9</td><td>D09S0347</td><td>24.61</td><td>8.61</td><td>37.88</td><td>11.17</td><td>C09R0765</td><td>23.51</td><td>8.11</td><td>34.01</td></tr><tr><td>10</td><td>D10S396</td><td>2.29</td><td></td><td></td><td></td><td>C10R0874</td><td>1.61</td><td></td><td></td></tr><tr><td></td><td>D10S400</td><td></td><td>6.59</td><td>5.67</td><td></td><td>C10R0880</td><td><i>1.06</i></td><td>8.07</td><td>6.49</td></tr><tr><td></td><td>D10S408</td><td></td><td></td><td></td><td>0.73</td><td></td><td></td><td></td><td></td></tr></table>
2d2dfcb6777cfc1889f42a3460c3c27a488331061bba9f95dbf3a81bf58f3c07.png
complex
<table><tr><td>Multivariate Cox regression</td><td></td><td></td><td></td><td></td></tr><tr><td>Factor</td><td><i>P</i></td><td>HR</td><td colspan="2">95% CI</td></tr><tr><td></td><td></td><td></td><td>Lower</td><td>Upper</td></tr><tr><td>INSS Stage (1-3, 4S vs 4)</td><td>0.002</td><td>7.15</td><td>2.08</td><td>24.64</td></tr><tr><td>NB-hypo</td><td>0.007</td><td>2.73</td><td>1.31</td><td>5.69</td></tr><tr><td>Age (&lt; 1y vs &gt; 1y)</td><td>0.801</td><td></td><td></td><td></td></tr><tr><td><i>MYCN </i>(normal vs amplified)</td><td>0.671</td><td></td><td></td><td></td></tr></table>
2d2b63092d79ee33c44baba7b50c861791200d0fc9d473b2fd3c068df2f59b5f.png
complex
<table><tr><td rowspan="2"> </td><td rowspan="2"> </td><td colspan="2">All</td><td colspan="2">Control group</td><td colspan="2">Intervention group</td></tr><tr><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Study group</td><td> </td><td>604</td><td>100</td><td>242</td><td>40.1</td><td>362</td><td>59.9</td></tr><tr><td>Participation rate</td><td>Number of men in units at T0*</td><td>2688</td><td>100</td><td>1430</td><td>53.2</td><td>1258</td><td>46.8</td></tr><tr><td> </td><td>Respondents at T0</td><td>1502</td><td>55.9&#8225;</td><td>645</td><td>42.9</td><td>857</td><td>57.1</td></tr><tr><td> </td><td>Respondents at T1</td><td>1634</td><td>60.8&#8225;</td><td>926</td><td>56.7</td><td>708</td><td>43.3</td></tr><tr><td> </td><td>Respondents at T2</td><td>947</td><td>35.2&#8225;</td><td>589</td><td>62.2</td><td>358</td><td>37.8</td></tr><tr><td> </td><td>Respondents at T0 + T1 + T2&#8224;</td><td>604</td><td>22.5&#8225;</td><td>242</td><td>40.1</td><td>362</td><td>59.9</td></tr><tr><td>Month of military arrival</td><td>January</td><td>358</td><td>59.3</td><td>129</td><td>53.3</td><td>229</td><td>63.3</td></tr><tr><td> </td><td>July</td><td>246</td><td>40.7</td><td>113</td><td>46.7</td><td>133</td><td>36.7</td></tr><tr><td>Garrison</td><td>Armoured Brigade</td><td>313</td><td>51.8</td><td>84</td><td>34.7</td><td>229</td><td>63.3</td></tr><tr><td> </td><td>Kainuu Brigade</td><td>291</td><td>48.2</td><td>158</td><td>65.3</td><td>133</td><td>36.7</td></tr><tr><td>Age</td><td>18</td><td>1</td><td>0.2</td><td>1</td><td>0.4</td><td> </td><td> </td></tr><tr><td> </td><td>19</td><td>131</td><td>21.8</td><td>65</td><td>27.0</td><td>66</td><td>18.4</td></tr><tr><td> </td><td>20</td><td>452</td><td>75.3</td><td>170</td><td>70.5</td><td>282</td><td>78.6</td></tr><tr><td> </td><td>21</td><td>16</td><td>2.7</td><td>5</td><td>2.1</td><td>11</td><td>3.1</td></tr><tr><td>Marital status</td><td>married or co-habiting</td><td>52</td><td>8.7</td><td>20</td><td>8.4</td><td>32</td><td>8.9</td></tr><tr><td> </td><td>single</td><td>545</td><td>91.1</td><td>217</td><td>91.6</td><td>328</td><td>90.9</td></tr><tr><td> </td><td>Widowed</td><td>1</td><td>0.2</td><td> </td><td> </td><td>1</td><td>0.3</td></tr><tr><td>Living status</td><td>alone</td><td>56</td><td>9.3</td><td>24</td><td>10.0</td><td>32</td><td>8.9</td></tr><tr><td> </td><td>with spouse</td><td>42</td><td>7.0</td><td>16</td><td>6.7</td><td>26</td><td>7.2</td></tr><tr><td> </td><td>with parents</td><td>485</td><td>81.0</td><td>198</td><td>82.5</td><td>287</td><td>79.9</td></tr><tr><td> </td><td>other</td><td>16</td><td>2.7</td><td>2</td><td>0.8</td><td>14</td><td>3.9</td></tr></table>
b83d87b7c7806b92640e600d9dafc301eaf30f6759874d06fe25a962f46e9737.png
complex
<table><tr><td>(n = 593)</td><td>One-factor model</td><td colspan="2">Two-factor model</td><td colspan="3">Three-factor model</td></tr><tr><td>Sensation</td><td>Sensitivity</td><td>Pleasant</td><td>Unpleasant</td><td>Pleasant</td><td>Unpleasant</td><td>Buzz</td></tr><tr><td>Cough</td><td>0.27</td><td>&#8722;0.16</td><td>0.52</td><td>0.10</td><td>0.69</td><td>&#8722;0.18</td></tr><tr><td>Sick</td><td>0.15</td><td>0.05</td><td>0.82</td><td>&#8722;0.16</td><td>0.66</td><td>0.29</td></tr><tr><td>Nervous</td><td>0.17</td><td>&#8722;0.04</td><td>0.50</td><td>0.07</td><td>0.57</td><td>&#8722;0.03</td></tr><tr><td>Dizzy</td><td>&#8722;0.46</td><td>0.65</td><td>0.35</td><td>0.06</td><td>0.15</td><td>0.70</td></tr><tr><td>High</td><td>&#8722;0.59</td><td>0.74</td><td>0.21</td><td>0.06</td><td>&#8722;0.03</td><td>0.81</td></tr><tr><td>Relaxed</td><td>&#8722;0.88</td><td>0.79</td><td>&#8722;0.35</td><td>0.73</td><td>&#8722;0.14</td><td>0.15</td></tr><tr><td>Good</td><td>&#8722;0.94</td><td>0.85</td><td>&#8722;0.31</td><td>0.97</td><td>0.00</td><td>0.06</td></tr><tr><td>RMSEA</td><td>0.20</td><td>0.05</td><td></td><td>0.01</td><td></td><td></td></tr></table>
98463272a7b8a18457595e6f6ded1fbb57cf646181c0d2ec675e696468dfc680.png
simple
<table><tr><td>Author (year) of published PCR assay</td><td>PCR target</td><td>PCR technique</td><td>Amplicon size (bp)</td><td>Zika virus lineage analytical</td><td>Zika virus lineage field</td><td>No. of human patients tested in studies</td><td>Sample types positive in field</td></tr><tr><td>Lanciotti et al. (2008)<sup>43</sup></td><td>Zika virus prM/E,target 1</td><td>Hydrolysis probe</td><td>76</td><td>Asian, African</td><td>Asian</td><td> &gt; 200 (combined set)<sup>5</sup><sup>,</sup><sup>10</sup><sup>,</sup><sup>23</sup><sup>,</sup><sup>24</sup><sup>,</sup><sup>34</sup><sup>,</sup><sup>36</sup><sup>,</sup><sup>38</sup><sup>,</sup><sup>40</sup><sup>&#8211;</sup><sup>42</sup><sup>,</sup><sup>49</sup><sup>,</sup><sup>50</sup></td><td>Serum, urine, amniotic fluid</td></tr><tr><td>Lanciotti et al. (2008)<sup>43</sup></td><td>Zika virus E, target 2</td><td>Hydrolysis probe</td><td>76</td><td>Asian, African</td><td>Asian</td><td> &gt; 200 (combined set)<sup>5</sup><sup>,</sup><sup>10</sup><sup>,</sup><sup>23</sup><sup>,</sup><sup>24</sup><sup>,</sup><sup>34</sup><sup>,</sup><sup>36</sup><sup>,</sup><sup>38</sup><sup>,</sup><sup>40</sup><sup>&#8211;</sup><sup>42</sup><sup>,</sup><sup>49</sup><sup>,</sup><sup>50</sup></td><td>Serum, urine, amniotic fluid</td></tr><tr><td>Faye et al. (2013)<sup>51</sup></td><td>Zika virus NS5</td><td>Locked nucleic acid probe</td><td>102</td><td>Asian, African</td><td>African</td><td>3 (B Rockx, personal communication, February 2016)</td><td>Serum</td></tr><tr><td>Tappe et al. (2014)<sup>19</sup></td><td>Zika virus NS3</td><td>Hydrolysis probe</td><td>94</td><td>Asian</td><td>Asian</td><td>5<sup>19</sup><sup>&#8211;</sup><sup>22</sup><sup>,</sup><sup>25</sup></td><td>Serum</td></tr><tr><td>Faye et al. (2008)<sup>52</sup></td><td>Zika virus E</td><td>Conventional</td><td>364</td><td>African</td><td>Asian</td><td> &gt; 15 (combined set)<sup>53</sup><sup>,</sup><sup>54</sup></td><td>Serum</td></tr><tr><td>Pyke et al. (2014)<sup>15</sup></td><td>Zika virus NS1</td><td>Hydrolysis probe</td><td>65</td><td>Asian</td><td>Asian</td><td>1<sup>55</sup></td><td>Serum</td></tr><tr><td>Pyke et al. (2014)<sup>15</sup></td><td>Zika virus E</td><td>Hydrolysis probe</td><td>71</td><td>Asian</td><td>Asian</td><td>1<sup>55</sup></td><td>Serum</td></tr><tr><td>Moureau et al. (2007)<sup>56</sup></td><td>Flavivirus NS5</td><td>SYBR&#174;-green-based</td><td>269&#8211;272</td><td>African</td><td>Asian</td><td>2<sup>18</sup><sup>,</sup><sup>57</sup></td><td>Serum, urine</td></tr><tr><td>Kuno et al. (1998)<sup>58</sup></td><td>Flavivirus NS5</td><td>Conventional</td><td>1079</td><td>Asian, African</td><td>Asian</td><td>51<sup>59</sup></td><td>Serum</td></tr><tr><td>Scaramozzino et al. (2001)<sup>60</sup></td><td>Flavivirus NS5</td><td>Conventional (semi-nested)</td><td>220</td><td>African</td><td>Asian</td><td>1<sup>55</sup> (L Barzon, personal communication, February 2016)</td><td>Serum, urine</td></tr><tr><td>Maher-Sturgess et al. (2008)<sup>61</sup></td><td>Flavivirus NS5</td><td>Conventional</td><td>800</td><td>African</td><td>Asian</td><td>1<sup>15</sup></td><td>Serum</td></tr><tr><td>Ayers et al. (2006)<sup>62</sup></td><td>Flavivirus NS5</td><td>Conventional</td><td>863</td><td>&#8211;</td><td>Asian</td><td>1<sup>17</sup></td><td>Serum, urine, nasopharynx</td></tr></table>
77849470f34ab849a00e615494c9a2958424d06465c7ea17d42063007e6d0689.png
simple
<table><tr><td>Explanatory variable</td><td>OR</td><td>95%CI</td><td>P value</td></tr><tr><td>Presence of C allele in genotype at rs3173798 (Yes=1, No=0)</td><td>0.28</td><td>0.12&#8211;0.67</td><td>0.0043</td></tr><tr><td>Age (years)</td><td>0.97</td><td>0.93&#8211;1.02</td><td>0.27</td></tr><tr><td>Gender (female=1, male=0)</td><td>0.92</td><td>0.39&#8211;2.20</td><td>0.85</td></tr><tr><td>Pre-treatment BCVA (logMAR)</td><td>1.49</td><td>0.50&#8211;4.43</td><td>0.47</td></tr><tr><td>GLD (&#956;m)</td><td>1</td><td>1.00&#8211;1.00</td><td>0.88</td></tr></table>
07bef33c2cc04db0c30aece8ad26d1d5d0ae5e7fab3d704914055a1285ae14b1.png
complex
<table><tr><td rowspan="3">Age group</td><td colspan="6">1990</td><td colspan="6">2015</td></tr><tr><td colspan="3">Global</td><td colspan="3">Brazil</td><td colspan="3">Global</td><td colspan="3">Brazil</td></tr><tr><td>Rate</td><td colspan="2">95% UI</td><td>Rate</td><td colspan="2">95% UI</td><td>Rate</td><td colspan="2">95% UI</td><td>Rate</td><td colspan="2">95% UI</td></tr><tr><td>Under 5</td><td>58.9</td><td>(49.0</td><td>67.0)</td><td>62.8</td><td>(55.3</td><td>71.6)</td><td>22.1</td><td>(18.4</td><td>24.4)</td><td>24.0</td><td>(20.0</td><td>27.9)</td></tr><tr><td>5&#8211;9</td><td>23.0</td><td>(19.9</td><td>26.7)</td><td>29.7</td><td>(24.9</td><td>34.8)</td><td>15.7</td><td>(13.2</td><td>19.0)</td><td>15.5</td><td>(12.4</td><td>19.3)</td></tr><tr><td>10&#8211;14</td><td>45.1</td><td>(37.2</td><td>56.0)</td><td>67.1</td><td>(54.9</td><td>82.0)</td><td>38.0</td><td>(30.0</td><td>49.4)</td><td>39.8</td><td>(30.3</td><td>52.6)</td></tr><tr><td>15&#8211;19</td><td>84.0</td><td>(66.2</td><td>108.9)</td><td>116.0</td><td>(94.4</td><td>145.0)</td><td>91.6</td><td>(69.3</td><td>119.5)</td><td>89.0</td><td>(67.6</td><td>117.8)</td></tr><tr><td>20&#8211;24</td><td>146.9</td><td>(114.1</td><td>186.0)</td><td>170.7</td><td>(136.9</td><td>213.7)</td><td>168.7</td><td>(127.8</td><td>219.0)</td><td>143.9</td><td>(107.9</td><td>186.3)</td></tr><tr><td>25&#8211;29</td><td>214.0</td><td>(165.3</td><td>273.8)</td><td>249.8</td><td>(201.9</td><td>310.2)</td><td>256.8</td><td>(192.9</td><td>333.5)</td><td>224.2</td><td>(170.2</td><td>288.3)</td></tr><tr><td>30&#8211;34</td><td>312.2</td><td>(242.9</td><td>397.8)</td><td>358.0</td><td>(292.9</td><td>440.9)</td><td>384.1</td><td>(289.5</td><td>499.2)</td><td>331.6</td><td>(256.0</td><td>429.6)</td></tr><tr><td>35&#8211;39</td><td>448.2</td><td>(349.4</td><td>567.0)</td><td>523.8</td><td>(434.2</td><td>638.6)</td><td>565.0</td><td>(432.0</td><td>722.6)</td><td>495.0</td><td>(385.6</td><td>626.4)</td></tr><tr><td>40&#8211;44</td><td>659.4</td><td>(520.7</td><td>821.5)</td><td>799.0</td><td>(666.2</td><td>963.0)</td><td>830.7</td><td>(647.7</td><td>1053.6)</td><td>765.0</td><td>(604.4</td><td>958.9)</td></tr><tr><td>45&#8211;49</td><td>1022.3</td><td>(827.8</td><td>1264.5)</td><td>1246.0</td><td>(1037.0</td><td>1512.3)</td><td>1241.7</td><td>(983.4</td><td>1556.5)</td><td>1190.9</td><td>(944.3</td><td>1490.3)</td></tr><tr><td>50&#8211;54</td><td>1435.9</td><td>(1175.5</td><td>1747.8)</td><td>1892.2</td><td>(1591.6</td><td>2277.0)</td><td>1762.3</td><td>(1415.1</td><td>2175.0)</td><td>1820.5</td><td>(1469.0</td><td>2260.6)</td></tr><tr><td>55&#8211;59</td><td>1939.8</td><td>(1631.4</td><td>2336.0)</td><td>2694.1</td><td>(2292.1</td><td>3133.0)</td><td>2361.7</td><td>(1958.5</td><td>2817.1)</td><td>2581.4</td><td>(2160.5</td><td>3110.6)</td></tr><tr><td>60&#8211;64</td><td>2465.1</td><td>(2099.2</td><td>2906.9)</td><td>3533.7</td><td>(3072.4</td><td>4091.9)</td><td>2845.1</td><td>(2409.6</td><td>3360.3)</td><td>3514.3</td><td>(2989.2</td><td>4149.6)</td></tr><tr><td>65&#8211;69</td><td>2946.5</td><td>(2550.2</td><td>3462.3)</td><td>4356.6</td><td>(3836.9</td><td>4975.1)</td><td>3537.8</td><td>(3028.4</td><td>4120.4)</td><td>4461.8</td><td>(3836.4</td><td>5169.2)</td></tr><tr><td>70&#8211;74</td><td>3255.2</td><td>(2844.5</td><td>3752.8)</td><td>5178.5</td><td>(4684.2</td><td>5833.0)</td><td>3843.0</td><td>(3316.1</td><td>4442.0)</td><td>5292.1</td><td>(4631.1</td><td>6052.0)</td></tr><tr><td>75&#8211;79</td><td>3400.7</td><td>(2992.7</td><td>3889.5)</td><td>5702.8</td><td>(5189.1</td><td>6299.8)</td><td>4128.5</td><td>(3594.0</td><td>4741.4)</td><td>5976.1</td><td>(5308.4</td><td>6806.0)</td></tr><tr><td>80 plus</td><td>2441.4</td><td>(2166.5</td><td>2775.3)</td><td>4232.3</td><td>(3888.4</td><td>4643.9)</td><td>3185.4</td><td>(2826.0</td><td>3599.7)</td><td>5570.1</td><td>(5072.8</td><td>6144.9)</td></tr><tr><td>All ages (crude)</td><td>567.9</td><td>(480.5</td><td>672.2)</td><td>641.4</td><td>(558.1</td><td>740.8)</td><td>870.1</td><td>(725.7</td><td>1032.6)</td><td>1015.3</td><td>(865.3</td><td>1191.4)</td></tr><tr><td>Age-standardized</td><td>769.9</td><td>(654.1</td><td>907.0)</td><td>1094.2</td><td>(962.6</td><td>1247.7)</td><td>925.8</td><td>(776.1</td><td>1096.3)</td><td>1102.8</td><td>(948.7</td><td>1285.4)</td></tr></table>
19388fced408bffa4c9c9c0022ab85a14f10358cac4aab545cc730ec35257e68.png
complex
<table><tr><td></td><td colspan="3">The GP and the patient are a well-functioning team (<i>n</i> = 270)</td></tr><tr><td></td><td>OR</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td colspan="4">Age</td></tr><tr><td> 16&#8211;39</td><td>1.30</td><td>0.63&#8211;2.71</td><td>0.471</td></tr><tr><td> 40&#8211;59<sup>a</sup></td><td>1.00</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> 60+</td><td>0.90</td><td>0.36&#8211;2.24</td><td>0.816</td></tr><tr><td colspan="4">Education</td></tr><tr><td> Primary</td><td>0.56</td><td>0.19&#8211;1.69</td><td>0.306</td></tr><tr><td> High school</td><td>1.69</td><td>0.77&#8211;3.70</td><td>0.192</td></tr><tr><td> University 1&#8211;4 years<sup>a</sup></td><td>1.00</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> University 5 years +</td><td>0.53</td><td>0.25&#8211;1.13</td><td>0.101</td></tr><tr><td colspan="4">Self-rated degree of CFS/ME</td></tr><tr><td> Mild</td><td>0.66</td><td>0.32&#8211;1.35</td><td>0.250</td></tr><tr><td> Moderate<sup>a</sup></td><td>1.00</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Severe/very severe</td><td>0.38</td><td>0.14&#8211;0.99</td><td>0.047</td></tr><tr><td colspan="4">GP duration</td></tr><tr><td> 0&#8211;2 years<sup>a</sup></td><td>1.00</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> 3 years+</td><td>2.32</td><td>1.09&#8211;4.95</td><td>0.030</td></tr><tr><td colspan="4">GP frequency<sup>b</sup></td></tr><tr><td> 0 visits</td><td>0.75</td><td>0.27&#8211;2.10</td><td>0.590</td></tr><tr><td> 1&#8211;4 visits<sup>a</sup></td><td>1.00</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> 5&#8211;9 visits</td><td>1.13</td><td>0.56&#8211;2.29</td><td>0.730</td></tr><tr><td> 10+ visits</td><td>2.12</td><td>0.75&#8211;5.99</td><td>0.155</td></tr></table>
e362f246ab0037323067d9923df79a0a20fd614831f87c2346ca66f9ca052304.png
simple
<table><tr><td>Age group</td><td>Patients, no.</td><td>%</td></tr><tr><td>Infant</td><td>9</td><td>0</td></tr><tr><td>Child</td><td>12</td><td>0</td></tr><tr><td>Adolescent</td><td>4</td><td>0</td></tr></table>
f124df5d8fddbc0fa6b32d2cdc4da06b58d2109f04a63f60116ee797191e528c.png
simple
<table><tr><td></td><td>Calcium score zero (<i>N</i> = 239)</td><td>Calcium score abnormal (<i>N</i> = 103)</td><td><i>P</i> value</td></tr><tr><td>Age, years</td><td>47.0 (6.4)</td><td>52.6 (6.6)</td><td>&lt;0.001</td></tr><tr><td>Gender, female %</td><td>66 (27.6)</td><td>11 (10.6)</td><td></td></tr><tr><td>Height, cm</td><td>165.9 (7.5)</td><td>167.7 (7.5)</td><td>0.09</td></tr><tr><td>Weight, kg</td><td>65.9 (11.3)</td><td>68.9 (10.1)</td><td>0.008</td></tr><tr><td>BMI, Kg/m<sup>2</sup></td><td>23.8 (3.1)</td><td>24.4 (2.7)</td><td>0.013</td></tr><tr><td>Waist, cm</td><td>81.4 (9.1)</td><td>85.0 (7.9)</td><td>&lt;0.001</td></tr><tr><td>Waist to hip ratio</td><td>0.88 (0.07)</td><td>0.91 (0.06)</td><td>&lt;0.001</td></tr><tr><td>SBP, mmHg</td><td>116.7 (14.9)</td><td>125.1 (15.1)</td><td>0.003</td></tr><tr><td>DBP, mmHg</td><td>74.5 (10.2)</td><td>77.9 (9.7)</td><td>0.002</td></tr><tr><td>Biochemistry</td><td></td><td></td><td></td></tr><tr><td> Sugar (AC), mg/dL</td><td>93.3 (21.2)</td><td>102.0 (20.9)</td><td>0.086</td></tr><tr><td> Sugar (PC), mg/dL</td><td>105.9 (31.6)</td><td>118.5 (44.4)</td><td>0.082</td></tr><tr><td> HbA1c, %</td><td>5.8 (0.6)</td><td>6.0 (0.6)</td><td>0.32</td></tr><tr><td> Insulin, U/mL</td><td>6.25 (4.24)</td><td>6.91 (3.75)</td><td>0.046</td></tr><tr><td> HOMA-IR</td><td>1.55 (1.25)</td><td>1.76 (1.06)</td><td>0.016</td></tr><tr><td> Cholesterol, mg/dL</td><td>191.1 (32.9)</td><td>196.1 (35.1)</td><td>0.23</td></tr><tr><td> LDL, mg/dL</td><td>128.0 (31.3)</td><td>125.8 (31.7)</td><td>0.56</td></tr><tr><td> HDL, mg/dL</td><td>53.0 (13.7)</td><td>49.1 (12.8)</td><td>0.02</td></tr><tr><td> TG, mg/dL</td><td>141.9 (103)</td><td>145.8 (85.2)</td><td>0.74</td></tr><tr><td> BUN, mg/dL</td><td>11.8 (3.2)</td><td>12.6 (3.7)</td><td>0.32</td></tr><tr><td> Creatinine, mg/dL</td><td>0.91 (0.18)</td><td>0.97 (0.18)</td><td>0.39</td></tr><tr><td> Uric Acid, mg/dL</td><td>5.6 (1.4)</td><td>6.1 (1.5)</td><td>0.003</td></tr><tr><td> Homocystine, mg/dL</td><td>7.3 (2.1)</td><td>8.4 (2.3)</td><td>0.03</td></tr><tr><td> Hs-CRP, mg/dL</td><td>0.2 (0.35)</td><td>0.32 (0.7)</td><td>0.043</td></tr><tr><td>ECG pattern</td><td></td><td></td><td></td></tr><tr><td> ECG (LVH or myocardial ischemia)</td><td>41 (7.5)</td><td>28 (13.2)</td><td>0.016</td></tr><tr><td> ECG (old infarct)</td><td>5 (1)</td><td>9 (4.2)</td><td>0.002</td></tr><tr><td>Medical history</td><td></td><td></td><td></td></tr><tr><td> Smoking</td><td>84 (24.9)</td><td>42 (29.4)</td><td>0.311</td></tr><tr><td> HTN history</td><td>41 (12)</td><td>35 (23.7)</td><td>0.001</td></tr><tr><td> DM history</td><td>11 (3.2)</td><td>14 (9.5)</td><td>0.004</td></tr><tr><td> Hyperlipidemia</td><td>17 (5.6)</td><td>13 (9.6)</td><td>0.039</td></tr><tr><td> CVD</td><td>12 (3.9)</td><td>12 (8.9)</td><td>0.033</td></tr><tr><td>Family Hx</td><td></td><td></td><td></td></tr><tr><td> Family Hx HTN</td><td>147 (43)</td><td>62 (41.9)</td><td>0.823</td></tr><tr><td> Family Hx DM</td><td>88 (25.8)</td><td>42 (28.4)</td><td>0.554</td></tr><tr><td> Family Hx Stroke</td><td>49 (14.3)</td><td>20 (13.5)</td><td>0.812</td></tr><tr><td> Family Hx CVD</td><td>57 (16.7)</td><td>30 (20.3)</td><td>0.345</td></tr></table>
432f2974ff0e323790e429512471a58a03f4a38e5f0e49a80f57f08608f7ed16.png
complex
<table><tr><td></td><td colspan="3">Week 1<sup>A</sup></td><td colspan="3">Week 2<sup>A</sup></td><td colspan="2"><i>P</i></td></tr><tr><td></td><td>Control</td><td>Canola</td><td>Sunflower</td><td>Control</td><td>Canola</td><td>Sunflower</td><td>Trt<sup>B</sup></td><td>Trt*wk<sup>C</sup></td></tr><tr><td>Cows (n)</td><td>5</td><td>5</td><td>5</td><td>6</td><td>5</td><td>5</td><td></td><td></td></tr><tr><td>LH Mean (ng/mL)</td><td>1.14 &#177; 0.14</td><td>0.84 &#177; 0.23</td><td>0.96 &#177; 0.21</td><td>2.42 &#177; 0.21<sup>&#165;a</sup></td><td>1.66 &#177; 0.23<sup>b</sup></td><td>1.83 &#177; 0.18<sup>&#165;ab</sup></td><td>0.03</td><td>0.05</td></tr><tr><td>LH- Peak (ng/mL) <sup>D</sup></td><td>2.05 &#177; 0.75</td><td>3.21 &#177; 0.80</td><td>2.19 &#177; 0.70</td><td>5.14 &#177; 0.80</td><td>4.07 &#177; 0.73</td><td>3.72 &#177; 0.73</td><td>0.37</td><td>0.11</td></tr><tr><td>LH-Peak-time (min) <sup>E</sup></td><td>32.50 &#177; 13.26</td><td>48.00 &#177; 13.78</td><td>22.50 &#177; 10.27</td><td>81.37 &#177; 21.53</td><td>101.63 &#177; 21.53</td><td>63.37 &#177; 21.53</td><td>0.48</td><td>0.74</td></tr><tr><td>AUC (ng/mL per 4 h) <sup>F</sup></td><td>41.52 &#177; 27.39</td><td>84.65 &#177; 29.26</td><td>48.51 &#177; 25.38</td><td>197.26 &#177; 26.74<sup>&#167;c</sup></td><td>125.73 &#177; 26.74<sup>&#167;cd</sup></td><td>106.99 &#177; 26.74<sup>d</sup></td><td>0.26</td><td>0.06</td></tr><tr><td>Incline rate (ng/mL per min) <sup>H</sup></td><td>0.09 &#177; 0.02</td><td>0.09 &#177; 0.02</td><td>0.08 &#177; 0.02</td><td>0.06 &#177; 0.02</td><td>0.07 &#177; 0.02</td><td>0.07 &#177; 0.02</td><td>0.98</td><td>0.97</td></tr></table>
baad41387d9d9bb0c955d600550056153811b0418b38b66115512f5dfb194530.png
simple
<table><tr><td>Patient</td><td>Breed</td><td>Age</td><td>Sex</td><td>Activity</td><td>Laminitis Stage</td><td>Venography Stage</td><td>Prognosis (before Treatment)</td></tr><tr><td>CASE 1</td><td>QUARTER HORSE</td><td>18</td><td>F</td><td>MARE</td><td>BILATERAL ROTATION</td><td>4</td><td>POOR</td></tr><tr><td>CASE 2</td><td>QUARTER HORSE</td><td>14</td><td>F</td><td>MARE</td><td>BILATERAL CHRONIC ROTATION</td><td>4</td><td>POOR</td></tr><tr><td>CASE 3</td><td>THOROUGHBRED</td><td>13</td><td>G</td><td>PLEASURE</td><td>MONOLATERAL SINKING AND ROTATION</td><td>4</td><td>POOR</td></tr><tr><td>CASE 4</td><td>QUARTER HORSE</td><td>10</td><td>F</td><td>PLEASURE</td><td>MONOLATERAL SINKING</td><td>3</td><td>GUARDED PROGNOSIS</td></tr><tr><td>CASE 5</td><td>WARMBLOOD</td><td>18</td><td>G</td><td>PLEASURE</td><td>BILATERAL SINKING AND ROTATION</td><td>3</td><td>POOR</td></tr><tr><td>CASE 6</td><td>WARMBLOOD</td><td>15</td><td>F</td><td>PLEASURE</td><td>MONOLATERAL SINKING AND ROTATION</td><td>3</td><td>POOR</td></tr><tr><td>CASE 7</td><td>DUTCH WARMBLOOD</td><td>21</td><td>F</td><td>PLEASURE</td><td>BILATERAL SINKING AND ROTATION</td><td>3-4</td><td>POOR</td></tr><tr><td>CASE 8</td><td>THOROUGHBRED</td><td>15</td><td>G</td><td>PLEASURE</td><td>MONOLATERAL ROTATION</td><td>3</td><td>POOR</td></tr><tr><td>CASE 9</td><td>PONY</td><td>16</td><td>G</td><td>PLEASURE</td><td>BILATERAL SINKING AND ROTATION</td><td>4</td><td>POOR</td></tr></table>
e171d0a2ee782d9982764d34e0670ccd4c7929693ebf6fdf98cf0609f5bee55d.png
simple
<table><tr><td>Scales</td><td>N</td><td>Mean</td><td>SD</td><td>Min.</td><td>Q1</td><td>Median</td><td>Q3</td><td>Max.</td><td><i>P</i>-value</td></tr><tr><td>HSQS/EPM (1st administration)</td><td>86</td><td>74.6</td><td>4.6</td><td>60.0</td><td>72.0</td><td>75.5</td><td>78.0</td><td>86.4</td><td>0.005<sup>1</sup></td></tr><tr><td>SEVQUAL scale</td><td>86</td><td>76.7</td><td>5.7</td><td>60.0</td><td>73.0</td><td>78.0</td><td>78.0</td><td>99.0</td><td> </td></tr></table>
384c4efa3ab1654da840069f186923ee5e400fd50219d3264ca49dafc756a8df.png
complex
<table><tr><td colspan="2"></td><td colspan="4">Patients&#8217; characteristics</td></tr><tr><td>Gender</td><td></td><td>Age</td><td>Weight</td><td>Height</td><td>BMI</td></tr><tr><td rowspan="5">Females</td><td><i>n</i></td><td>66</td><td>66</td><td>66</td><td>66</td></tr><tr><td>Mean (SD)</td><td>62.8 (9.28)</td><td>77.4 (18.28)</td><td>166.6 (5.29)</td><td>27.7 (6.01)</td></tr><tr><td>95 % CI</td><td>60.5, 65.0</td><td>72.9, 81.9</td><td>165.3, 167.9</td><td>26.3, 29.2</td></tr><tr><td>Median</td><td>63.2</td><td>74.0</td><td>167.5</td><td>26.0</td></tr><tr><td>Range</td><td>33&#8211;87</td><td>50&#8211;140</td><td>152&#8211;178</td><td>19&#8211;45</td></tr><tr><td rowspan="5">Males</td><td><i>n</i></td><td>85</td><td>85</td><td>85</td><td>85</td></tr><tr><td>Mean (SD)</td><td>63.3 (9.84)</td><td>89.0 (15.10)</td><td>177.7 (6.64)</td><td>28.2 (4.53)</td></tr><tr><td>95 % CI</td><td>61.2, 65.4</td><td>85.8, 92.3</td><td>176.3, 179.2</td><td>27.2, 29.2</td></tr><tr><td>Median</td><td>62.9</td><td>84.0</td><td>178.0</td><td>27.0</td></tr><tr><td>Range</td><td>37&#8211;81</td><td>66&#8211;153</td><td>165&#8211;192</td><td>22&#8211;43</td></tr><tr><td rowspan="5">Total</td><td><i>n</i></td><td>151</td><td>151</td><td>151</td><td>151</td></tr><tr><td>Mean (SD)</td><td>63.1 (9.58)</td><td>83.9 (17.50)</td><td>172.9 (8.21)</td><td>28.0 (5.21)</td></tr><tr><td>95 % CI</td><td>61.5, 64.6</td><td>81.1, 86.7</td><td>171.5, 174.2</td><td>27.1, 28.8</td></tr><tr><td>Median</td><td>62.9</td><td>82.0</td><td>172.0</td><td>27.0</td></tr><tr><td>Range</td><td>33&#8211;87</td><td>50&#8211;153</td><td>152&#8211;192</td><td>19&#8211;45</td></tr></table>
7af61e0fba35c02ef730636d2417ade80ce72212c6233cc51789179cee20affa.png
complex
<table><tr><td rowspan="2">Clinical and epidemiological characteristic</td><td colspan="2">Another malignancy</td><td rowspan="2"><i>P</i></td></tr><tr><td>Postiodine<i>N</i> = 7 (46.66%)</td><td>Preiodine<i>N</i> = 8 (53.33%)</td></tr><tr><td>Males <i>N</i> (%)</td><td>4 (57.14)</td><td>3 (37.5)</td><td>0.6193</td></tr><tr><td>Age at thyroidectomy (years)*</td><td>61 &#177; 17</td><td>51 &#177; 13.7</td><td>0.2295</td></tr><tr><td>Follow-up period (months)**</td><td>75 (48; 336)</td><td>56.5 (20; 60)</td><td>0.1505</td></tr><tr><td>Age at diagnosis of a second neoplasia* (years)</td><td>69.4 &#177; 11.4</td><td>46.1 &#177; 20.2</td><td>0.0187</td></tr><tr><td>Classic nonpapilliferous histological type <i>N</i> (%)</td><td>3 (42.85)</td><td>2 (25)</td><td>0.6084</td></tr></table>
8a8a2ee59494752736aa72444ff5616f3de3c2c435b2f46f904d193213222c05.png
complex
<table><tr><td colspan="2">CONSENSUS CRITERIA FOR DEMENTIA CASE ASCERTAINMENT</td></tr><tr><td>PROBABLE DEMENTIA</td><td>POSSIBLE DEMENTIA</td></tr><tr><td>ANY of the following (without opposing evidence from same/other source):- dementia diagnosis on death certificate (any part)- dementia diagnosed on clinical review (ICD-10/DSM-IV)- dementia diagnosis in electronic general medical records (Trak)- dementia diagnosis in electronic psychiatric records (PIMS)- ICD-10 criteria for dementia diagnosis met by data within any existing records</td><td>ANY of the following (without opposing evidence from same/other source):- recorded cognitive impairment on death certificate- cognitive impairment/decline recorded in notes, but incomplete evidence to meet ICD-10 diagnostic criteria- possibility of dementia recorded in notes but no formal diagnosis/incomplete evidence to meet ICD-10 diagnostic criteria</td></tr></table>
2a74453c80b60f5b2d34a65f6eb9052d58f2693e7e7a509703d041f76d19526a.png
simple
<table><tr><td>Isolate</td><td>ST <sup>1</sup></td><td>CC <sup>2</sup></td><td>LIPI1</td><td>LIPI3</td><td>LIPI4</td><td>InlA </td><td>SSI-1</td></tr><tr><td>MQ130026</td><td>ST-1</td><td>CC1</td><td>+ <sup>3</sup></td><td>+</td><td>&#8722; <sup>4</sup></td><td>+ <sup>5</sup></td><td>&#8722;</td></tr><tr><td>L970</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ130029</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ130032</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ130042</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140025</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140031</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140033</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>L2113</td><td>ST-1</td><td>CC1</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150012</td><td>ST-6</td><td>CC6</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150005</td><td>ST-6</td><td>CC6</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ130058</td><td>ST-6</td><td>CC6</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140030</td><td>ST-4</td><td>CC4</td><td>+</td><td>+</td><td>+</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150004</td><td>ST-54</td><td>CC54</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ130033</td><td>ST-54</td><td>CC54</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>L2259</td><td>ST-54</td><td>CC54</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150013</td><td>ST-2</td><td>CC2</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ130037</td><td>ST-18</td><td>CC18</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>+</td></tr><tr><td>MQ150011</td><td>ST-20</td><td>CC20</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150001</td><td>ST-37</td><td>CC37</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140029</td><td>ST-7</td><td>CC7</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>+</td></tr><tr><td>L1445</td><td>ST-7</td><td>CC7</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>+</td></tr><tr><td>L1976</td><td>ST-8</td><td>CC8</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>+</td></tr><tr><td>MQ140034</td><td>ST-121</td><td>CC121</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>L2256</td><td>ST-121</td><td>CC121</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>&#8722;</td><td>&#8722;</td></tr><tr><td>MQ140035</td><td>ST-121</td><td>CC121</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140032</td><td>ST-425</td><td>CC90</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140012</td><td>ST-101</td><td>CC101</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ140011</td><td>ST-101</td><td>CC101</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150008</td><td>ST-431</td><td>CC101</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr><tr><td>MQ150007</td><td>ST-431</td><td>CC101</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>+</td><td>&#8722;</td></tr></table>
46ee1776e9ce2f096ea20d70c48ad5696654006da7f728f6cc64c53724fa58a2.png
simple
<table><tr><td>Variable</td><td>All patients (n = 102)</td><td>Group 1 (n = 48)</td><td>Group 2 (n = 54)</td></tr><tr><td>FEV<sub>1</sub></td><td>50 (0.84 [0.70;0.98])<sup>a</sup></td><td>31 (1.08 [0.70;1.45])<sup>a</sup></td><td>18 (0.67 [0.46;0.88])<sup>a</sup></td></tr><tr><td>BR</td><td>12 (&#8722;0.62 [&#8722;0.82;-0.42])<sup>a</sup></td><td>6 (&#8722;0.36 [&#8722;0.68;-0.04])<sup>b</sup></td><td>35 (&#8722;0.85 [&#8722;1.10;-0.59])<sup>a</sup></td></tr><tr><td>V<sub>E</sub>/VCO<sub>2</sub> peak</td><td>5 (&#8722;1.13 [&#8722;1.56;-0.69])<sup>a</sup></td><td>15 (&#8722;0.95 [&#8722;1.41;-0.48])<sup>c</sup></td><td>6 (&#8722;1.52 [&#8722;2.22;-0.82])<sup>a</sup></td></tr></table>
15b7a6fbbee3049a5e8e6f31d2dde1cfde7134156e5f788a232b5f3093b998cd.png
simple
<table><tr><td>(1) Memory</td><td>(2) Language</td><td>(3) Perceptual</td><td>(4) Visuospatial</td><td>(5) Calculation</td></tr><tr><td>Rey immediate recall</td><td>Semantic fluency </td><td>VOSP X-detection</td><td>Barrage</td><td>Additions</td></tr><tr><td>Rey delayed recall</td><td>Phonological fluency</td><td>Benton</td><td>Spatial span</td><td>Subtractions</td></tr><tr><td>Recognition accuracy</td><td>Reading</td><td>Famous faces</td><td>H cancellation</td><td> </td></tr><tr><td> </td><td>Naming</td><td> </td><td> </td><td> </td></tr></table>
149db96c33c1f66aa82e37de920bbb8f6bd8c9e307e9c47be019c539684e9ec3.png
complex
<table><tr><td rowspan="3" colspan="2">Change in response variables</td><td colspan="6">Explanatory variables</td></tr><tr><td rowspan="2">Dose of tofacitinib<sup>a</sup></td><td colspan="5">Lymphocyte sub-populations</td></tr><tr><td>T (CD3<sup>+</sup>)</td><td>T<sub>H</sub>(CD3<sup>+</sup>/CD4<sup>+</sup>)</td><td>T<sub>C</sub>(CD3<sup>+</sup>/CD8<sup>+</sup>)</td><td>B (CD19<sup>+</sup>)</td><td>NK (CD16<sup>+</sup>/CD56<sup>+</sup>)</td></tr><tr><td rowspan="3">CMV viral load, copies/500 ng total DNA</td><td>df</td><td>3</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>F value</td><td>1.26</td><td>0.14</td><td>0.04</td><td>0.68</td><td>0.00</td><td>0.03</td></tr><tr><td>p value</td><td>0.2926</td><td>0.7047</td><td>0.8411</td><td>0.4112</td><td>0.9925</td><td>0.8592</td></tr><tr><td rowspan="3">EBV viral load, copies/500 ng total DNA</td><td>df</td><td>3</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>F value</td><td>0.50</td><td>0.54</td><td>1.69</td><td>0.11</td><td>0.02</td><td>0.57</td></tr><tr><td>p value</td><td>0.6807</td><td>0.4627</td><td>0.1955</td><td>0.7430</td><td>0.8906</td><td>0.4501</td></tr><tr><td rowspan="3">CRP level, mg/L</td><td>df</td><td>3</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>F value</td><td>3.18</td><td>1.45</td><td>1.84</td><td>4.18</td><td>0.11</td><td>1.83</td></tr><tr><td>p value</td><td>0.0262</td><td>0.2315</td><td>0.1775</td><td>0.0430</td><td>0.7450</td><td>0.1784</td></tr></table>
8d2eb63b44adbef2f2e21434c3caf7c0e32e9a6de38db60084d0c4dbf9db86b1.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">IOP (mmHg)</td><td></td><td colspan="2">OPP (mmHg)</td><td></td></tr><tr><td>Affected Eye</td><td>Unaffected Eye</td><td><i>P</i> value*</td><td>Affected Eye</td><td>Unaffected Eye</td><td><i>P</i> value*</td></tr><tr><td>T1</td><td>16.6 &#177; 3.4 (10.5&#8211;23.3)</td><td>15.6 &#177; 2.9 (9.5&#8211;20.6)</td><td>0.055</td><td>50.1 &#177; 9.9 (35.4&#8211;77.6)</td><td>51.1 &#177; 11.0 (33.4&#8211;78.3)</td><td>0.055</td></tr><tr><td>T2</td><td>17.8 &#177; 3.5 (11.6&#8211;28.1)</td><td>17.4 &#177; 3.2 (11.8&#8211;24.1)</td><td>0.327</td><td>65.7 &#177; 12.4 (47.6&#8211;92.2)</td><td>66.2 &#177; 12.5 (46.9&#8211;93.7)</td><td>0.139</td></tr><tr><td>T3</td><td>20.2 &#177; 4.2 (13.8&#8211;29.9)</td><td>19.2 &#177; 3.7 (14.6&#8211;28.1)</td><td>0.457</td><td>59.8 &#177; 13.8 (37.3&#8211;83.2)</td><td>60.2 &#177; 14.0 (35.5&#8211;83.0)</td><td>0.355</td></tr><tr><td>T4</td><td>18.2 &#177; 2.7 (11.9&#8211;23.4)</td><td>17.7 &#177; 3.2 (12.6&#8211;25.5)</td><td>0.089</td><td>64.7 &#177; 13.1 (39.9&#8211;92.5)</td><td>65.8 &#177; 12.5 (46.8&#8211;92.1)</td><td>0.089</td></tr><tr><td>T5</td><td>20.3 &#177; 5.6 (14.0&#8211;32.2)</td><td>18.9 &#177; 4.7 (10.8&#8211;30.4)</td><td>0.287</td><td>53.1 &#177; 12.5 (38.4&#8211;81.0)</td><td>54.5 &#177; 13.5 (34.5&#8211;82.2)</td><td>0.422</td></tr><tr><td>T6</td><td>18.0 &#177; 3.6 (9.7&#8211;23.4)</td><td>17.0 &#177; 3.7 (7.9&#8211;24.4)</td><td>0.053</td><td>63.8 &#177; 14.0 (35.0&#8211;95.6)</td><td>64.7 &#177; 13.5 (35.3&#8211;93.8)</td><td>0.420</td></tr><tr><td>Affected eye DLDP<sup>a</sup></td><td>21.4 &#177; 5.4 (14.0&#8211;32.2)</td><td>19.2 &#177; 4.1 (13.8&#8211;31.7)</td><td>0.020</td><td>56.9 &#177; 11.7 (39.4&#8211;79.5)</td><td>57.9 &#177; 12.1 (40.8&#8211;79.5)</td><td>0.041</td></tr><tr><td>Unaffected eye DLDP<sup>a</sup></td><td>18.6 &#177; 5.1 (10.8&#8211;30.4)</td><td>19.6 &#177; 2.9 (14.8&#8211;24.0)</td><td>0.204</td><td>56.0 &#177; 15.3 (37.3&#8211;83.2)</td><td>55.6 &#177; 15.1 (35.5&#8211;83.0)</td><td>0.052</td></tr></table>
b54a3d038c17fa9edd63aa6bddbe672346935860bbb66497556aa40c4182852a.png
simple
<table><tr><td>#</td><td>Nugget Topic</td><td>Nugget Content (3rd ed.)</td></tr><tr><td>6.</td><td><i>Pharmacological management of neuropathic pain</i></td><td>Use a step-wise evidence-based protocol for the management of neuropathic pain in SCI, and review pain management annually.</td></tr><tr><td>10.</td><td><i>Diet &amp; fluid management in neurogenic bowel</i></td><td>Refer spinal cord injured patients with persistent constipation to a specialist with experience with SCI or neurogenic bowel.</td></tr><tr><td>11.</td><td><i>Screening of colorectal cancer</i></td><td>Initiate colorectal cancer screening for patients with SCI using the same principles as those for the general population.</td></tr><tr><td>13.</td><td><i>Recognizing Urinary Tract Infections in SCI Patients</i></td><td>Diagnosis of UTI in SCI patients requires 3 criteria: (1) significant bacteriuria; (2) pyuria; and (3) signs &amp; symptoms.</td></tr><tr><td>14. </td><td><i>Pharmacological management of UTI in SCI</i></td><td>There is no superior agent or class of antibiotics for UTIs in spinal cord injury. Recurrent UTIs should be treated as complicated infections, and treatment must be customized to the patient and the infecting organism. </td></tr><tr><td>15.</td><td><i>Screening for Bladder Cancer</i></td><td>Routine screening for bladder cancer is recommended only for high-risk patients; that is those with indwelling or suprapubic catheters, complete lesions, &gt;10 years since injury, bladder stones, or recurrent urinary tract infections. </td></tr><tr><td>17.</td><td><i>Treatment of Skin Breakdown</i></td><td>Treat Stage I or II wounds with standard wound care. Treat Stage III or IV wounds with specialist/surgical intervention.</td></tr><tr><td>20.</td><td><i>Wheel chair accessibility of your practice</i></td><td>Conduct an accessibility audit of your office or clinic space and procedures using the Primary Care Accessibility Checklist.</td></tr></table>
393be005d439d22c4e3dbdccfc61de8f227335602f79123f14fa4e88de01798f.png
simple
<table><tr><td>CNTs</td><td>Hydroxyl Content % (<i>w</i>/<i>w</i>)</td><td>Carboxyl Content % (<i>w</i>/<i>w</i>)</td><td>Diameter (nm)</td><td>Length (&#956;m)</td><td>SSA (m<sup>2</sup>/g)</td><td>PC Sets</td><td>PC Names</td></tr><tr><td>F1</td><td>_</td><td>_</td><td>10&#8211;20</td><td>30&#8211;100</td><td>&gt;165</td><td>M</td><td>M1</td></tr><tr><td>F2</td><td>_</td><td>_</td><td>8&#8211;15</td><td>~50</td><td>&gt;233</td><td>M</td><td>M2</td></tr><tr><td>F3</td><td>_</td><td>_</td><td>10&#8211;20</td><td>10&#8211;30</td><td>&gt;200</td><td>M</td><td>M3</td></tr><tr><td>F4</td><td>_</td><td>_</td><td>20&#8211;30</td><td>10&#8211;30</td><td>&gt;110</td><td>M</td><td>M4</td></tr><tr><td>F5</td><td>_</td><td>_</td><td>30&#8211;50</td><td>10&#8211;20</td><td>&gt;60</td><td>M</td><td>M5</td></tr><tr><td>F6</td><td>_</td><td>_</td><td>&gt;50</td><td>10&#8211;20</td><td>&gt;40</td><td>M</td><td>M6</td></tr><tr><td>F7</td><td>5.58</td><td>_</td><td>&lt;8</td><td>10&#8211;30</td><td>&gt;500</td><td>H</td><td>H1</td></tr><tr><td>F8</td><td>3.70</td><td>_</td><td>8&#8211;15</td><td>~50</td><td>&gt;233</td><td>H</td><td>H2</td></tr><tr><td>F9</td><td>3.06</td><td>_</td><td>10&#8211;20</td><td>10&#8211;30</td><td>&gt;200</td><td>H</td><td>H3</td></tr><tr><td>F10</td><td>1.76</td><td>_</td><td>20&#8211;30</td><td>~30</td><td>&gt;110</td><td>H</td><td>H4</td></tr><tr><td>F11</td><td>1.06</td><td>_</td><td>30&#8211;50</td><td>~20</td><td>&gt;60</td><td>H</td><td>H5</td></tr><tr><td>F12</td><td>0.71</td><td>_</td><td>&gt;50</td><td>~20</td><td>&gt;40</td><td>H</td><td>H6</td></tr><tr><td>F13</td><td>_</td><td>3.86</td><td>&lt;8</td><td>~30</td><td>&gt;500</td><td>C</td><td>C1</td></tr><tr><td>F14</td><td>_</td><td>2.56</td><td>8&#8211;15</td><td>~50</td><td>&gt;233</td><td>C</td><td>C2</td></tr><tr><td>F15</td><td>_</td><td>2.00</td><td>10&#8211;20</td><td>10&#8211;30</td><td>&gt;200</td><td>C</td><td>C3</td></tr><tr><td>F18</td><td>_</td><td>1.23</td><td>20&#8211;30</td><td>~30</td><td>&gt;110</td><td>C</td><td>C4</td></tr><tr><td>F17</td><td>_</td><td>0.73</td><td>30&#8211;50</td><td>~20</td><td>&gt;60</td><td>C</td><td>C5</td></tr><tr><td>F18</td><td>_</td><td>0.64</td><td>&gt;50</td><td>~20</td><td>&gt;40</td><td>C</td><td>C6</td></tr></table>
21e9a99b219c6e866c53e7ae2d8e8145f34627e216bf6ec561dc5b95e6ffa946.png
complex
<table><tr><td rowspan="3"></td><td colspan="9">Median MET-min/week (IQR)</td></tr><tr><td colspan="2">Erectile dysfunction</td><td rowspan="2"><i>p</i> value</td><td colspan="2">Premature ejaculation</td><td rowspan="2"><i>p</i> value</td><td colspan="2">Libido</td><td rowspan="2"><i>p</i> value</td></tr><tr><td>Absent</td><td>Present</td><td>Absent</td><td>Present</td><td>Normal</td><td>Reduced</td></tr><tr><td colspan="10">All males</td></tr><tr><td> All</td><td>2772 (4122)</td><td>2066 (3532)</td><td>&lt;0.01</td><td>2400 (3851)</td><td>2079 (3465)</td><td>0.226</td><td>2373 (3573)</td><td>2400 (3921)</td><td>0.916</td></tr><tr><td> Europids</td><td>3355 (4340)</td><td>2493 (3768)</td><td>&lt;0.01</td><td>2763 (4382)</td><td>2652 (3400)</td><td>0.283</td><td>2706 (4076)</td><td>2641 (3846)</td><td>0.929</td></tr><tr><td> South Asians</td><td>1985 (2841)</td><td>1662 (3142)</td><td>0.184</td><td>1782 (3442)</td><td>1638 (3465)</td><td>0.931</td><td>1710 (2925)</td><td>1584 (3726)</td><td>0.909</td></tr><tr><td colspan="10">Patients with diabetes</td></tr><tr><td> All</td><td>3816 (7492)</td><td>1980 (3472)</td><td>&lt;0.05</td><td>2424 (3711)</td><td>2079 (4358)</td><td>0.307</td><td>2163 (3721)</td><td>2148 (3465)</td><td>0.887</td></tr><tr><td> Europids</td><td>6075 (7539)</td><td>2446 (3478)</td><td>&lt;0.01</td><td>2739 (3336)</td><td>2706 (5095)</td><td>0.168</td><td>2772 (5013)</td><td>2400 (3057)</td><td>0.652</td></tr><tr><td> South Asians</td><td>1638 (2940)</td><td>1674 (3560)</td><td>0.694</td><td>1680 (3231)</td><td>1538 (4346)</td><td>0.974</td><td>1674 (3123)</td><td>1584 (4510)</td><td>0.910</td></tr><tr><td colspan="10">Patients without diabetes</td></tr><tr><td> All</td><td>2706 (3444)</td><td>2333 (4050)</td><td>0.109</td><td>2272 (4449)</td><td>2493 (2712)</td><td>0.686</td><td>2382 (3420)</td><td>2655 (4180)</td><td>0.644</td></tr><tr><td> Europids</td><td>2836 (4125)</td><td>2641 (4191)</td><td>0.271</td><td>2772 (5174)</td><td>2598 (2475)</td><td>0.827</td><td>2706 (3706)</td><td>3093 (3515)</td><td>0.401</td></tr><tr><td> South Asians</td><td>1853 (2772)</td><td>1538 (3025)</td><td>0.361</td><td>1737 (3699)</td><td>1809 (3304)</td><td>0.879</td><td>1746 (3063)</td><td>1280 (3722)</td><td>0.398</td></tr></table>
c0be9cb44095a3c469a1d0a15d19de4bbaf0bd418806ba7dabeb637f725a7c91.png
simple
<table><tr><td>Subjects</td><td>Age (years)</td><td>Odor threshold (score/16)</td><td>Odor discrimination (score/16)</td><td>Multiple choice identification (score/16)</td><td>TDI composite score (score/48)</td><td>Retronasal testing (score/20)</td></tr><tr><td>EB1</td><td>21</td><td>7.3</td><td>15</td><td>10</td><td>32.3</td><td>19</td></tr><tr><td>EB3</td><td>29</td><td>6.3</td><td>10</td><td>16</td><td>32.3</td><td>16</td></tr><tr><td>EB4</td><td>40</td><td>7.0</td><td>14</td><td>14</td><td>35.0</td><td>17</td></tr><tr><td>EB5</td><td>55</td><td>15.8</td><td>15</td><td>13</td><td>43.8</td><td>18</td></tr><tr><td>EB8</td><td>39</td><td>11.0</td><td>16</td><td>11</td><td>38.0</td><td>17</td></tr><tr><td>EB9</td><td>51</td><td>8.0</td><td>14</td><td>15</td><td>37.0</td><td>17</td></tr><tr><td>EB10</td><td>45</td><td>15.8</td><td>13</td><td>14</td><td>42.8</td><td>18</td></tr><tr><td>EB11</td><td>20</td><td>6.0</td><td>15</td><td>12</td><td>33.0</td><td>18</td></tr><tr><td>Mean (EB)</td><td>37.5</td><td>9.6</td><td>14.0</td><td>13.10</td><td>36.8</td><td>17.5</td></tr><tr><td>SD (EB)</td><td>13.1</td><td>4.08</td><td>1.85</td><td>2.03</td><td>4.54</td><td>0.93</td></tr><tr><td>SC1</td><td>20</td><td>3.5</td><td>14</td><td>16</td><td>33.5</td><td>20</td></tr><tr><td>SC5</td><td>53</td><td>5.0</td><td>9</td><td>14</td><td>28.0</td><td>19</td></tr><tr><td>SC7</td><td>40</td><td>6.3</td><td>9</td><td>13</td><td>28.3</td><td>16</td></tr><tr><td>SC8</td><td>39</td><td>6.0</td><td>14</td><td>11</td><td>31.0</td><td>19</td></tr><tr><td>SC9</td><td>50</td><td>4.8</td><td>11</td><td>13</td><td>28.8</td><td>17</td></tr><tr><td>SC14</td><td>21</td><td>4.5</td><td>14</td><td>14</td><td>32.5</td><td>17</td></tr><tr><td>SC15</td><td>30</td><td>6.3</td><td>13</td><td>14</td><td>33.3</td><td>16</td></tr><tr><td>SC16</td><td>39</td><td>4.0</td><td>10</td><td>14</td><td>28.0</td><td>18</td></tr><tr><td>Mean (SC)</td><td>36.5</td><td>5.0</td><td>11.8</td><td>13.6</td><td>30.4</td><td>17.8</td></tr><tr><td>SD (SC)</td><td>12.1</td><td>1.05</td><td>2.25</td><td>1.41</td><td>2.43</td><td>1.49</td></tr></table>
2e6e7d2429967eb49d0c4d4d40f71e3a1b2a42b7984172719129b925841ce0a7.png
complex
<table><tr><td rowspan="2">Sample</td><td colspan="6">Number of lethality (%)</td></tr><tr><td colspan="2"><i>Tribolium castaneum</i></td><td colspan="2"><i>Rhyzopertha dominica</i></td><td colspan="2"><i>Callosbruchus analis</i></td></tr><tr><td>Crude extract</td><td>0.33 &#177; 0.57</td><td>3.3 &#177; 5.7</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chloroform </td><td>1.33 &#177; 0.57</td><td>13.3 &#177; 5.7</td><td>4.66 &#177; 0.57</td><td>46.6 &#177; 5.7</td><td>0</td><td>0</td></tr><tr><td>Ethyl acetate </td><td>0.66 &#177; 0.57</td><td>6.6 &#177; 5.7</td><td>6.66 &#177; 1.15</td><td>66.6 &#177; 11.5</td><td>6.6 &#177; 5.7</td><td>66.6 &#177; 0</td></tr><tr><td><i>n</i>-butanol </td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.66 &#177; 0.57</td><td>6.6 &#177; 5.7</td></tr><tr><td>Aqueous </td><td>0</td><td>0</td><td>1.33 &#177; 0.57</td><td>13.3 &#177; 5.7</td><td>0</td><td>0</td></tr><tr><td>Permethrin (standard)</td><td>10 &#177; 0</td><td>100</td><td>10 &#177; 0</td><td>100</td><td>10 &#177; 0.01</td><td>100</td></tr><tr><td>Saline</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></table>
0260fff33957cd5e4cea168bd70114418f5ddb64af363a35a1ffa5cd6379242c.png
simple
<table><tr><td></td><td>Sarcoidosis<i>N</i> = 17</td><td>Control disease<i>N</i> = 11</td><td>Tuberculosis<i>N</i> = 8</td><td><i>P</i> Value</td></tr><tr><td>Age, mean &#177; SD (years)</td><td>53.12 &#177; 7.41</td><td>53.55 &#177; 12.75</td><td>45.13 &#177; 20.73</td><td>0.3013</td></tr><tr><td>Male/female ratio</td><td>3/14</td><td>6/5</td><td>6/2</td><td>N/A</td></tr><tr><td>CXR stage: 0/I/II/III/IV number of patients (n)</td><td>0/10/4/3/0</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Tuberculosis examination negative/positive (n)</td><td>17/0</td><td>N/A</td><td>0/8</td><td>N/A</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24.74 &#177; 2.45</td><td>22.75 &#177; 3.87</td><td>22.87 &#177; 2.34</td><td>0.1564</td></tr><tr><td>SACE (IU/L)</td><td>58.47 &#177; 26.86 (<i>n</i> = 15)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>ESR (mm/h)</td><td>24.13 &#177; 15.82 (<i>n</i> = 16)</td><td>31.20 &#177; 19.81 (<i>n</i> = 6)</td><td>34.57 &#177; 39.43 (<i>n</i> = 7)</td><td>0.5996</td></tr><tr><td>24-h urinary calcium</td><td>5.70 &#177; 2.11(<i>n</i> = 12)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>CD3 (%)</td><td>66.56 &#177; 8.07 (<i>n</i> = 14)</td><td>N/A</td><td>58.67 &#177; 15. 58 (<i>n</i> = 7)</td><td>0.1380</td></tr><tr><td>CD4 (%)</td><td>34. 01 &#177; 10.15 <i>(n</i> = 14)</td><td>N/A</td><td>35.66 &#177; 13.03 (<i>n</i> = 7)</td><td>0.7526</td></tr><tr><td>CD8 (%)</td><td>24. 87 &#177; 10.40 (<i>n</i> = 14)</td><td>N/A</td><td>18.99 &#177; 4.51 (<i>n</i> = 7)</td><td>0.1730</td></tr><tr><td>IgG (ng/L)</td><td>12.36 &#177; 2.73 (<i>n</i> = 10)</td><td>N/A</td><td>14.67 &#177; 7.20</td><td>0.3607</td></tr><tr><td>IgA (ng/L)</td><td>1.96 &#177; 0.56 (<i>n</i> = 10)</td><td>N/A</td><td>2.73 &#177; 1.12</td><td>0.0734</td></tr><tr><td>IgM (ng/L)</td><td>1.47 &#177; 0.77 (<i>n</i> = 10)</td><td>N/A</td><td>1.19 &#177; 0.73</td><td>0.4324</td></tr><tr><td>C3 (ng/L)</td><td>1.25 &#177; 0.20 (<i>n</i> = 10)</td><td>N/A</td><td>1.20 &#177; 0.29</td><td>0.6584</td></tr><tr><td>C4 (ng/L)</td><td>0.31 &#177; 0.072 (<i>n</i> = 10)</td><td>N/A</td><td>0.34 &#177; 0.094</td><td>0.4571</td></tr></table>
45004dd263b0a6c8546d91dd99324c5516790b70746bd61c7bf90816ae929d3a.png
simple
<table><tr><td>Comet class</td><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>TCS</td></tr><tr><td>Exposed group</td><td>21.6 &#177; 13.4</td><td>32.5 &#177; 14.2</td><td>15.8 &#177; 11.9</td><td>11.3 &#177; 9.9</td><td>18.7 &#177; 9.4</td><td>173.2 &#177; 50.1*</td></tr><tr><td>Control group</td><td>67.7 &#177; 13.0</td><td>16.2 &#177; 8.0</td><td>7.1 &#177; 4.4</td><td>5.3 &#177; 4.1</td><td>3.7 &#177; 2.3</td><td>61.0 &#177; 25.0</td></tr></table>
99f50d74bb134edb5fe9723d214d32dc2d5233b0171e3bd1575c44a08121ff1b.png
simple
<table><tr><td>Cost<sup>a</sup></td><td>Argentina</td><td>Brazil</td><td>Chile</td><td>Colombia</td><td>Ecuador</td><td>Mexico</td><td>Peru</td></tr><tr><td>&lt; 1</td><td>Rivaroxavan</td><td>Rivaroxavan</td><td>Rivaroxavan</td><td>Rivaroxavan</td><td>&#8211;</td><td>Rivaroxavan</td><td>Rivaroxavan</td></tr><tr><td>1&#8211;4</td><td>Apixaban, Indacaterol, Linagliptin, Ticagrelor</td><td>Apixaban, Roflumilast, Ticagrelor</td><td>Apixaban, Indacaterol</td><td>Apixaban, Indacaterol</td><td>Indacaterol</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>5&#8211;9</td><td>&#8211;</td><td>Belatacept</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>Azilsartan, Linagliptin</td><td>&#8211;</td></tr><tr><td>10&#8211;19</td><td>&#8211;</td><td>&#8211;</td><td>Belimumab</td><td>&#8211;</td><td>&#8211;</td><td>Apixaban, Ticagrelor</td><td>&#8211;</td></tr><tr><td>20&#8211;39</td><td>Aflibercept, Regorafenib</td><td>Aflibercept</td><td>Aflibercept</td><td>Aflibercept</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>40&#8211;59</td><td>Belatacept, Tofacitinib</td><td>Belimumab</td><td>&#8211;</td><td>Tofacitinib</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>60&#8211;99</td><td>Telaprevir</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>100&#8211;149</td><td>&#8211;</td><td>Telaprevir</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>150&#8211;200</td><td>Pasireotide</td><td>Pertuzumab</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>Tofacitinib</td><td>&#8211;</td></tr><tr><td>201&#8211;896</td><td>Ipilimumab, Vandetanib</td><td>Ipilimumab, Vandetanib</td><td>Ipilimumab, Taliglucerase alfa</td><td>&#8211;</td><td>&#8211;</td><td>Pasireotide, Pertuzumab</td><td>&#8211;</td></tr></table>
aa45822eae4371a9168ebbba063a7dcb62cd5b1e3c3ec28c80a2d77d5fb031b3.png
complex
<table><tr><td>Origin</td><td>Methods</td><td>Dysregulated miRNAs</td><td>Study Details</td></tr><tr><td colspan="4"><i>Aortic stenosis</i></td></tr><tr><td>Aortic valve leaflets [24]</td><td>Microarray qPCR</td><td>Downregulated: 26a, 30b, 195</td><td>9 patients with BAV (AS vs. aortic insufficiency requiring AVR)</td></tr><tr><td>Aortic valve leaflets [26]</td><td>qPCR</td><td>Downregulated: 30b</td><td>10 AS patients requiring AVR (calcific vs. adjacent tissue)</td></tr><tr><td>Aortic valve leaflets [27]</td><td>qPCR</td><td>Downregulated: 148a-3p </td><td>4 BAVs vs. healthy aortic valves</td></tr><tr><td>Aortic valve leaflets [28]</td><td>Microarray qPCR</td><td>Upregulated: 125b Downregulated: 374b*, 602, 939</td><td>20 calcific AS valves vs. 6 control valves</td></tr><tr><td>Aortic valve leaflets [25]</td><td>Microarray qPCR</td><td>Upregulated: 151-3p, 152, 030e, 032, 145, 768-5p, 190, 373* Downregulated: 141, 370, 022, 1972, 330-5p, 566-pre, 1469, 1908, 648-pre, 637, 1282, 622, 486-3p, 187, 1909*, 564, 027a, 194*, 125b-1-pre, 551a-pre, 575, 585-pre, 211-pre, 449b*, 124-3-pre, 185-pre, 1202</td><td>19 BAVs vs. 17 TAVs from AS patients requiring AVR</td></tr><tr><td>LV intraoperative biopsies [29]</td><td>qPCR</td><td>Upregulated: 133a</td><td>46 AS patients requiring AVR</td></tr><tr><td>LV intraoperative biopsies [31]</td><td>qPCR</td><td>Upregulated: 21</td><td>75 AS patients requiring AVR vs. 32 surgical controls </td></tr><tr><td>LV intraoperative biopsies [32]</td><td>qPCR</td><td>Downregulated: 1</td><td>5 AS patients before TAVI vs. healthy controls</td></tr><tr><td>Endomyocardial biopsies [33]</td><td>Microarray qPCR</td><td>Downregulated: 18b, 122</td><td>28 AS patients with severe myocardial fibrosis vs. non-severe fibrosis</td></tr><tr><td>LV intraoperative biopsies [30]</td><td>qPCR</td><td>Upregulated: 133a</td><td>74 AS patients requiring AVR</td></tr><tr><td colspan="4"><i>Mitral valve disease</i></td></tr><tr><td>Tissues from the right and the left atrial appendages [37]</td><td>Microarray qPCR</td><td>Upregulated: 4484 Downregulated: 1, 23b-3p, 26a-5p, 30c-5p, 125b-5p, 133b, 143-3p, 145-5p, 4454</td><td>18 rheumatic mitral valve disease patients (10 AF vs. 8 SR) requiring mitral valve surgery</td></tr><tr><td>Tissues from the left atrial appendage [36]</td><td>Microarray qPCR</td><td>Upregulated: 466, 574-3p, 3613-3p Downregulated: 1, 26a-5p </td><td>12 patients with mitral stenosis (6 SR, 6 AF) requiring mitral valve surgery</td></tr><tr><td>Mitral valve leaflets [38]</td><td>RNA-seq</td><td>Upregulated: 656, 379-3p, 664a-3p, 34c-3p </td><td>10 patients with myxomatous mitral valve vs. 10 controls</td></tr><tr><td>Mitral valve leaflets [39]</td><td>whole genome miRNA qPCR</td><td>Upregulated: 500, 3174 Downregulated: 17, 203, 505, 646, 939, 1193, 1273e, 4298</td><td>10 myxomatous mitral valve prolapse vs. fibroelastic deficiency</td></tr></table>
12dc63f046a63ee8c34334c08b8b7182d947bfd99503f2bfea365426324380cd.png
simple
<table><tr><td>Variable</td><td>Base case value</td><td>Distribution</td><td>Parameters</td><td>Source/Notes</td></tr><tr><td>Probability of sustained virological response (SVR) in control group</td><td>0.02%</td><td>Beta</td><td>Alpha = 1 Beta = 559</td><td>Koretz et al.[23]</td></tr><tr><td>Log risk ratio (SVR: interferon versus no-intervention control)</td><td>2.9209 </td><td>Normal</td><td>Mean = 2.9209 Standard deviation = 1.0255</td><td>Koretz et al.[23] Note this yields a base case probability of SVR in the interferon group of 3.31%</td></tr><tr><td>5-year probability of death in no-intervention control group</td><td>6.72%</td><td>Beta</td><td>Alpha = 57 Beta = 791 </td><td>Koretz et al.[23] Annual probability therefore = 1.40% (= SR<sub>c</sub> in Table 2)</td></tr><tr><td>Log risk ratio (death: interferon versus no-intervention control)</td><td>0.3424 (0.1649)</td><td>Normal</td><td>Mean = 0.3424 Standard deviation = 0.1649</td><td>Koretz et al.[23] Note this yields a base case 5 year probability of death with interferon = 9.47%, annual probability = 2.01% = SR<sub>i</sub> in Table 2</td></tr><tr><td>Annual all-cause mortality by age</td><td>0.34% for 50 year male; 0.23% for 50 year female; 0.09% for 30 year male; 0.04% for 30 year female; 2.17% for 70 year old male; 1.41% for 70 year old female</td><td>Constant</td><td>Not applicable</td><td>Interim life tables (based on all reported deaths in the UK)[25], the sample size is assumed large enough for the standard error to be zero</td></tr><tr><td>Discount rate</td><td>3.50%</td><td>Constant</td><td>Not applicable</td><td>HM Treasury Green Book[26]</td></tr></table>
5787aa8eff1d474851080ee9af6c0150ccd83b5ed24a23da92091062d1e946c8.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">CI session</td><td colspan="3">MDMA + CI session</td><td colspan="3"><i>F</i> value</td></tr><tr><td>T1</td><td>T2</td><td>T3</td><td>T1</td><td>T2</td><td>T3</td><td>Session</td><td>Time</td><td>Session &#215; Time</td></tr><tr><td>TPAS&#8212;active</td><td>16.10 (6.04)</td><td>15.40 (5.85)</td><td>11.80 (5.31)</td><td>18.80 (5.07)</td><td>22.05 (5.81)</td><td>17.55 (6.07)</td><td>27.808***</td><td>12.00***</td><td>2.056</td></tr><tr><td>TPAS&#8212;relax</td><td>15.15 (4.61)</td><td>16.05 (4.14)</td><td>18.50 (5.10)</td><td>14.75 (5.31)</td><td>15.40 (4.60)</td><td>20.35 (4.18)</td><td>0.110</td><td>16.056***</td><td>1.770</td></tr><tr><td>TPAS&#8212;warm</td><td>11.10 (2.65)</td><td>12.05 (2.24)</td><td>12.80 (2.55)</td><td>12.35 (2.28)</td><td>12.80 (2.91)</td><td>14.15 (1.90)</td><td>5.652*</td><td>8.591**</td><td>0.450</td></tr></table>
728c3cef161dd94d5a3c6980570a7d68ba8e832cd778c11708141e1dc79ad778.png
complex
<table><tr><td>Tx-type; Cause of Death</td><td>&lt; 12 months</td><td>&gt; 12 months</td><td><i>p</i>-value</td></tr><tr><td>Total: 278</td><td></td><td></td><td></td></tr><tr><td colspan="4">SLTx (<i>n</i> = 97)</td></tr><tr><td> Total number of deaths</td><td>17</td><td>51</td><td>0.158</td></tr><tr><td> Death from Organ Rejection</td><td>2 (12%)</td><td>10 (20%)</td><td></td></tr><tr><td> Death from Infection</td><td>4 (23%)</td><td>16 (31%)</td><td></td></tr><tr><td> Death from Malignancy</td><td>1 (6%)</td><td>10 (20%)</td><td></td></tr><tr><td> Death from Other Causes</td><td>10 (59%)</td><td>15 (29%)</td><td></td></tr><tr><td colspan="4">DLTx (<i>n</i> = 172)</td></tr><tr><td> Total number of deaths</td><td>16</td><td>47</td><td>0.388</td></tr><tr><td> Death from Organ Rejection</td><td>4 (25%)</td><td>20 (42%)</td><td></td></tr><tr><td> Death from Infection</td><td>4 (25%)</td><td>6 (13%)</td><td></td></tr><tr><td> Death from Malignancy</td><td>1 (6%)</td><td>6 (13%)</td><td></td></tr><tr><td> Death from Other Causes</td><td>7 (44%)</td><td>15 (32%)</td><td></td></tr><tr><td colspan="4">HLTx (n = 9)</td></tr><tr><td> Total number of deaths</td><td>1</td><td>4</td><td>0.576</td></tr><tr><td> Death from Organ Rejection</td><td>0 (0%)</td><td>1 (25%)</td><td></td></tr><tr><td> Death from Infection</td><td>0 (0%)</td><td>0 (0%)</td><td></td></tr><tr><td> Death from Malignancy</td><td>0 (0%)</td><td>0 (0%)</td><td></td></tr><tr><td> Death from Other Causes</td><td>1 (100%)</td><td>3 (75%)</td><td></td></tr></table>
8f633e6dab81206083faaa3c3a704cbb871b7f5eb918d651332b94ce10bf08dc.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Bivariate linear regression</td><td colspan="2">Multivariate linear regression</td></tr><tr><td>Coefficient (95 % CI)</td><td><i>P</i>-value</td><td>Coefficient (95 % CI)</td><td><i>P</i>-value</td></tr><tr><td>Male gender</td><td>5.707 (2.887, 8.526)</td><td>&lt;0.001</td><td>5.429 (2.517, 8.341)</td><td>&lt;0.001</td></tr><tr><td>Age (in years)</td><td>0.988 (0.297, 1.679)</td><td>0.005</td><td>0.460 (&#8722;0.241, 1.160)</td><td>0.198</td></tr><tr><td>University educational program</td><td>0.716 (&#8722;2.252, 3.684)</td><td>0.636</td><td>-</td><td></td></tr><tr><td>Number of births managed during training</td><td>0.183 (0.074, 0.291)</td><td>0.001</td><td>0.164 (0.055, 0.273)</td><td>0.003</td></tr><tr><td>Felt classroom resources were available and helpful</td><td>&#8722;0.131 (&#8722;2.888, 2.626)</td><td>0.926</td><td>-</td><td></td></tr><tr><td>Felt number of instructors was adequate</td><td>2.191 (&#8722;0.565, 4.947)</td><td>0.119</td><td>2.428 (&#8722;0.529, 5.385)</td><td>0.107</td></tr><tr><td>Felt instructors were effective in facilitating learning</td><td>&#8722;2.469 (&#8722;5.217, 0.278)</td><td>0.078</td><td>&#8722;3.543 (&#8722;6.360, &#8722;0.726)</td><td>0.014</td></tr><tr><td>Felt instructors were fair and unbiased in assessing</td><td>&#8722;2.742 (&#8722;5.648, 0.164)</td><td>0.064</td><td>&#8722;2.794 (&#8722;5.710, 0.122)</td><td>0.060</td></tr><tr><td>Felt skills lab resources were available and helpful</td><td>3.593 (0.574, 6.612)</td><td>0.020</td><td>2.749 (&#8722;0.528, 6.025)</td><td>0.100</td></tr><tr><td>Felt number of skills lab assistants was adequate</td><td>2.835 (&#8722;0.171, 5.840)</td><td>0.064</td><td>2.239 (&#8722;1.043, 5.520)</td><td>0.181</td></tr><tr><td>Felt skills lab assistants supported students effectively</td><td>0.073 (&#8722;2.678, 2.824)</td><td>0.959</td><td>-</td><td></td></tr><tr><td>Felt number of preceptors was adequate</td><td>2.070 (&#8722;1.254, 5.395)</td><td>0.222</td><td>0.204 (&#8722;3.92, 4.321)</td><td>0.922</td></tr><tr><td>Felt clinical teachers and preceptors supported students</td><td>1.892 (&#8722;1.575, 5.359)</td><td>0.284</td><td>0.636 (&#8722;3.651, 4.923)</td><td>0.771</td></tr><tr><td>Felt clinical experience was sufficient</td><td>4.619 (1.915, 7.323)</td><td>0.001</td><td>4.650 (1.863, 7.437)</td><td>0.001</td></tr></table>
04ee76968c76d4f5db34842a59b5c8b72728dcf16b7edbe54b7af872935d8a7c.png
complex
<table><tr><td> </td><td>Total (<i>n</i> = 370)</td><td>Qi deficiency of spleen and kidney (<i>n</i> = 273)</td><td>Deficiency of both qi and yin (<i>n</i> = 66)</td><td>Other types (<i>n</i> = 31)</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>32 (27&#8211;42)</td><td>33 (27&#8211;42)</td><td>29 (25&#8211;36)</td><td>37 (28&#8211;46)</td><td>0.025<sup>a</sup></td></tr><tr><td>Female, <i>n</i> (%)</td><td>196 (53.0)</td><td>139 (50.9)</td><td>42 (63.6)</td><td>15 (48.4)</td><td>0.154</td></tr><tr><td>Disease course (months)</td><td>6 (2&#8211;23)</td><td>5 (1&#8211;23)</td><td>12 (3&#8211;25)</td><td>6 (2&#8211;13)</td><td>0.186</td></tr><tr><td><i>Inducement, n (%)</i></td><td colspan="5"> </td></tr><tr><td> Infection</td><td>41 (11.1)</td><td>31 (11.4)</td><td>5 (7.6)</td><td>5 (16.1)</td><td rowspan="4">0.780</td></tr><tr><td> Fatigue</td><td>13 (3.5)</td><td>11 (4.0)</td><td>1 (1.5)</td><td>1 (3.2)</td></tr><tr><td> Pregnancy</td><td>25 (6.8)</td><td>19 (7.0)</td><td>5 (7.6)</td><td>1 (3.2)</td></tr><tr><td> No obvious inducement</td><td>291 (78.6)</td><td>212 (77.7)</td><td>55 (83.3)</td><td>24 (77.4)</td></tr><tr><td>Systolic BP (mmHg)</td><td>120 (110&#8211;132)</td><td>120 (110&#8211;132)</td><td>120 (108&#8211;130)</td><td>125 (118&#8211;146)</td><td>0.070</td></tr><tr><td>Diastolic BP (mmHg)</td><td>80 (70&#8211;86)</td><td>80 (70&#8211;89)</td><td>79 (70&#8211;80)</td><td>80 (72&#8211;100)</td><td>0.097</td></tr><tr><td>MAP (mmHg)</td><td>93 (86&#8211;101)</td><td>93 (86&#8211;101)</td><td>91 (82&#8211;97)</td><td>94 (88&#8211;113)</td><td>0.069</td></tr><tr><td>Hypertension, <i>n</i> (%)</td><td>136 (36.8)</td><td>101 (37.0)</td><td>18 (27.3)</td><td>17 (54.8)</td><td>0.031<sup>b</sup></td></tr><tr><td>Macroscopic hematuria, <i>n</i> (%)</td><td>66 (17.8)</td><td>39 (14.3)</td><td>17 (25.8)</td><td>10 (32.3)</td><td>0.008<sup>c</sup></td></tr><tr><td>U-RBC (/<i>&#956;</i>L)</td><td>45 (15&#8211;136)</td><td>32 (11&#8211;134)</td><td>60 (30&#8211;110)</td><td>74 (25&#8211;179)</td><td>0.015<sup>d</sup></td></tr><tr><td>Hemoglobin (g/L)</td><td>128.2 &#177; 20.1</td><td>129.5 &#177; 20.2</td><td>126.1 &#177; 16.2</td><td>121.1 &#177; 25.2</td><td>0.055</td></tr><tr><td>Proteinuria (g/day)</td><td>1.0 (0.5&#8211;2.2)</td><td>1.0 (0.5&#8211;2.1)</td><td>1.1 (0.5&#8211;2.5)</td><td>1.1 (0.5&#8211;2.7)</td><td>0.766</td></tr><tr><td>Uric acid (<i>&#956;</i>mol/L)</td><td>340 (274&#8211;429)</td><td>344 (277&#8211;433)</td><td>316 (255&#8211;408)</td><td>358 (302&#8211;460)</td><td>0.170</td></tr><tr><td>Serum albumin (g/L)</td><td>40.3 (35.8&#8211;43.8)</td><td>40.6 (36.1&#8211;44.0)</td><td>40.2 (36.4&#8211;42.8)</td><td>39.2 (34.2&#8211;42.1)</td><td>0.405</td></tr><tr><td>Serum creatinine (<i>&#956;</i>mol/L)</td><td>79 (59&#8211;108)</td><td>80 (61&#8211;107)</td><td>67 (56&#8211;88)</td><td>123 (63&#8211;183)</td><td>0.001<sup>e</sup></td></tr><tr><td>eGFR (mL/min/1.73 m<sup>2</sup>)</td><td>97.2 (67.2&#8211;120.5)</td><td>97.1 (66.3&#8211;119.9)</td><td>115.3 (82.0&#8211;125.7)</td><td>70.6 (27.7&#8211;114.2)</td><td>&lt;0.001<sup>f</sup></td></tr><tr><td><i>eGFR (mL/min/1.73 m</i><sup><i>2</i></sup>)</td><td colspan="5"> </td></tr><tr><td> &lt;15</td><td>6 (1.6)</td><td>3 (1.1)</td><td>0</td><td>3 (9.7)</td><td rowspan="5">0.001<sup>g</sup></td></tr><tr><td> &gt;15, &#8804;30</td><td>15 (4.1)</td><td>9 (3.3)</td><td>1 (1.5)</td><td>5 (16.1)</td></tr><tr><td> &gt;30, &#8804;60</td><td>53 (14.3)</td><td>44 (16.1)</td><td>4 (6.1)</td><td>5 (16.1)</td></tr><tr><td> &gt;60, &#8804;90</td><td>94 (25.4)</td><td>67 (24.5)</td><td>19 (28.8)</td><td>8 (25.8)</td></tr><tr><td> &gt;90</td><td>202 (54.6)</td><td>150 (54.9)</td><td>42 (63.6)</td><td>10 (32.3)</td></tr><tr><td>Serum IgA (g/L)</td><td>2.85 (2.25&#8211;3.58)</td><td>2.84 (2.28&#8211;3.58)</td><td>2.81 (2.19&#8211;3.39)</td><td>2.97 (2.51&#8211;4.02)</td><td>0.246</td></tr><tr><td>Serum C3 (mg/L)</td><td>0.98 (0.87&#8211;1.11)</td><td>0.98 (0.87&#8211;1.12)</td><td>0.98 (0.85&#8211;1.10)</td><td>0.96 (0.85&#8211;1.08)</td><td>0.611</td></tr><tr><td><i>Oxford MEST scores</i></td><td colspan="5"> </td></tr><tr><td> M1, <i>n</i> (%)</td><td>361 (97.6)</td><td>269 (98.5)</td><td>64 (97.0)</td><td>28 (90.3)</td><td>0.032<sup>h</sup></td></tr><tr><td> E1, <i>n</i> (%)</td><td>54 (14.6)</td><td>41 (15.0)</td><td>11 (16.7)</td><td>2 (6.5)</td><td>0.384</td></tr><tr><td> S1, <i>n</i> (%)</td><td>185 (50.0)</td><td>142 (52.0)</td><td>32 (48.5)</td><td>11 (35.5)</td><td>0.210</td></tr><tr><td> T1, <i>n</i> (%)</td><td>193 (52.2)</td><td>146 (53.5)</td><td>30 (45.5)</td><td>17 (54.8)</td><td rowspan="2">0.242</td></tr><tr><td> T2, <i>n</i> (%)</td><td>68 (18.4)</td><td>48 (17.6)</td><td>12 (18.2)</td><td>8 (25.8)</td></tr></table>
6725e762f54bdd3222790dc6795adfaf3a1ff9c78792d1ea3a867cdc4720208a.png
complex
<table><tr><td>Growth year</td><td>Thickness/&#956;m</td><td>Sheet name</td><td>Brix degree/%</td><td>Acid value/%</td><td>Peel color/a value</td></tr><tr><td rowspan="3">2004</td><td rowspan="3">30</td><td>unmulched</td><td>9.0 &#177; 0.3</td><td>0.68 &#177; 0.05</td><td>21.7 &#177; 1.0</td></tr><tr><td>MS-3,7,0</td><td>10.3 &#177; 0.2</td><td>0.74 &#177; 0.09</td><td>25.3 &#177; 1.4</td></tr><tr><td>MS-3,6,1</td><td>10.9 &#177; 0.6</td><td>0.74 &#177; 0.11</td><td>25.1 &#177; 1.2</td></tr><tr><td rowspan="3">2005</td><td rowspan="3">90</td><td>unmulched</td><td>10.3 &#177; 0.3</td><td>0.86 &#177; 0.10</td><td>19.8 &#177; 1.8</td></tr><tr><td>MS-3,7,0</td><td>13.6 &#177; 0.5</td><td>1.09 &#177; 0.04</td><td>23.3 &#177; 0.6</td></tr><tr><td>MS-3,6,1</td><td>13.9 &#177; 0.5</td><td>1.10 &#177; 0.15</td><td>25.3 &#177; 1.2</td></tr></table>
e281ae665d1292ae93651df0d64ad027e0b0bbf6733e7accf0fcc72f09ebe162.png
complex
<table><tr><td rowspan="2">Post Hoc Test (1 mL)</td><td rowspan="2">Age group (<i>i</i>)</td><td rowspan="2">Age Group (<i>j</i>)</td><td rowspan="2">Mean Difference (&#956;<i><sub>i</sub></i> &#8722; &#956;<i><sub>j</sub></i>)</td><td colspan="2">95% Confidence Interval</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td rowspan="3">Scheffe&#769;&#8217;s *</td><td>51&#8211;60</td><td>21&#8211;30</td><td>0.152</td><td>&#8722;0.077</td><td>0.381</td></tr><tr><td>51&#8211;60</td><td>31&#8211;50</td><td>0.334</td><td>0.118</td><td>0.551</td></tr><tr><td>21&#8211;30</td><td>31&#8211;50</td><td>0.183</td><td>&#8722;0.020</td><td>0.385</td></tr></table>
0560b68fc3e907f3b0ab1e438c45edb6ba05434382f623932635506ea50f3eeb.png
complex
<table><tr><td>Variable</td><td>ALSPAC n (%)(N=6768)</td><td>Pelotas n (%)(N=3508)</td><td>&#967;<sup>2</sup></td></tr><tr><td colspan="4">Exposures</td></tr><tr><td> Low birth weight</td><td>238 (3.5)</td><td>274 (7.8)</td><td>89.99**</td></tr><tr><td> SGA</td><td>512 (7.6)</td><td>496 (14.2)</td><td>113.19**</td></tr><tr><td> Small HC</td><td>264 (4.8)</td><td>470 (13.4)</td><td>211.02**</td></tr><tr><td> Preterm birth</td><td>302 (4.4)</td><td>445 (12.7)</td><td>237.77**</td></tr><tr><td colspan="4">Outcomes</td></tr><tr><td colspan="4"> DAWBA</td></tr><tr><td>Hyperactive-impulsive ADHD</td><td>20 (0.3)</td><td>13 (0.4)</td><td>0.45</td></tr><tr><td>Inattentive ADHD</td><td>54 (0.8)</td><td>11 (0.3)</td><td>8.39*</td></tr><tr><td>Combined ADHD</td><td>68 (1.0)</td><td>56 (1.6)</td><td>7.13*</td></tr><tr><td>Any ADHD disorder</td><td>142 (2.1)</td><td>92 (2.6)</td><td>3.16</td></tr><tr><td colspan="4"> SDQ</td></tr><tr><td>Attention difficulties&#8224;</td><td>719 (10.5)</td><td>480 (13.7)</td><td>22.94**</td></tr></table>
7d957e598a95d7010dfc705d5b42f4fdb0c7f9f9c0ac0158b39826db54a2e372.png
simple
<table><tr><td></td><td>Histopathological score</td><td></td><td></td></tr><tr><td></td><td>Day 7</td><td>Day 21</td><td>Day 35</td></tr><tr><td>Gb</td><td>2(1-2)</td><td>6(5-7)</td><td>8,5(7-10)</td></tr><tr><td>C</td><td>2(1-2)</td><td>5(4-6)</td><td>6(6-7)</td></tr><tr><td>p</td><td>0,535</td><td>0,009*</td><td>0,001*</td></tr></table>
b4f209366490f439e916f653e885ac45dc201668c39fcf71553f5d54b0837dab.png
complex
<table><tr><td rowspan="2">Systemic organ class and preferred term<sup>a</sup></td><td colspan="2">Total (<i>N</i> = 209)</td></tr><tr><td>Number of Subjects (%)</td><td>Number of Adverse Events</td></tr><tr><td colspan="3">Resistance mechanism disorders</td></tr><tr><td> Infection susceptibility increased</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Polyomavirus infection</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Gastro-intestinal system disorders</td></tr><tr><td> Diarrhoea</td><td>5 (2.39)</td><td>5</td></tr><tr><td> Stomatitis</td><td>3 (1.44)</td><td>3</td></tr><tr><td> Stomatitis ulcerative</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Abdominal pain</td><td>2 (0.96)</td><td>2</td></tr><tr><td> Nausea</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Urinary system disorders</td></tr><tr><td> Azotaemia</td><td>6 (2.87)</td><td>6</td></tr><tr><td> Albuminuria</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Oliguria</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Skin and appendages disorders</td></tr><tr><td> Acne</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Rash</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Rash erythematous</td><td>2 (0.96)</td><td>2</td></tr><tr><td> Dermatitis</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Metabolic and nutritional disorders</td></tr><tr><td> Diabetes mellitus</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Diabetes mellitus aggravated</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Plasma osmolality increased</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Body as a whole&#8211; general disorders</td></tr><tr><td> Edema peripheral</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Face edema</td><td>2 (0.96)</td><td>2</td></tr><tr><td> Anaphylactic reaction</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Liver and biliary system disorders</td></tr><tr><td> Hepatic function abnormal</td><td>1 (0.48)</td><td>1</td></tr><tr><td> Cholangitis</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Musculo-skeletal system disorders</td></tr><tr><td> Avascular necrosis bone</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">Secondary terms &#8211; events</td></tr><tr><td> Transplant rejection</td><td>2 (0.96)</td><td>2</td></tr><tr><td colspan="3">Respiratory system disorders</td></tr><tr><td> Coughing (&#8805; 4 weeks)</td><td>1 (0.48)</td><td>1</td></tr><tr><td colspan="3">White cell and RES disorders</td></tr><tr><td> Leucopenia</td><td>1 (0.48)</td><td>1</td></tr></table>
633adc2003522ca566a40b37a5f22a2f81297b6bee44f2f1f9dd5124677dbab9.png
complex
<table><tr><td rowspan="2">Variable</td><td rowspan="2">Category</td><td>IIR</td><td>Non- IIR</td><td>Total</td></tr><tr><td><i>n</i> (%)</td><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td>Age</td><td>&#8805; 35 years</td><td>31 (38.3)</td><td>31 (38.3)</td><td>62 (38.3)</td></tr><tr><td>Marital status</td><td>Married</td><td>74 (91.4)</td><td>72 (88.9)</td><td>146 (90.1)</td></tr><tr><td rowspan="3">Family type</td><td>Nuclear</td><td>38 (46.9)</td><td>47 (58)</td><td>85 (52.5)</td></tr><tr><td>Extended nuclear</td><td>13 (16)</td><td>10 (12.3)</td><td>23 (14.2)</td></tr><tr><td>Joint</td><td>30 (37)</td><td>24 (29.6)</td><td>54 (33.3)</td></tr><tr><td>Education</td><td>&#8805; Primary education</td><td>65 (80.2)</td><td>48 (59.2)</td><td>113 (69.7)</td></tr><tr><td>Literacy</td><td>Read and write</td><td>59 (72.8)</td><td>41 (50.6)</td><td>100 (61.7)</td></tr><tr><td>Household visit /week</td><td>Mean (&#177;SD)</td><td>52 (&#177;42)</td><td>42 (&#177;68)</td><td>47 (&#177;57)</td></tr><tr><td>Serving population</td><td>Mean (&#177;SD)</td><td>255 (&#177;134)</td><td>206 (&#177;147)</td><td>231 (&#177;142)</td></tr><tr><td>Focus group discussion held prior to join Mitanin program</td><td>Yes</td><td>54 (66.7)</td><td>60 (74.1)</td><td>114 (70.4)</td></tr><tr><td>Village meeting held prior to join Mitanin program</td><td>Yes</td><td>38 (33.3)</td><td>43 (53.1)</td><td>81 (50)</td></tr><tr><td>Prior work experience</td><td>Yes</td><td>14 (17.3)</td><td>09 (11.1)</td><td>23 (14.2)</td></tr><tr><td rowspan="6">Primary reason of join Mitanin program</td><td>Financial incentives</td><td>04 (4.9)</td><td>04 (4.9)</td><td>08 (4.9)</td></tr><tr><td>Opportunity to learn</td><td>07 (8.6)</td><td>06 (7.4)</td><td>13 (8)</td></tr><tr><td>Support village health facilities</td><td>23 (28.4)</td><td>13 (16)</td><td>36 (22.2)</td></tr><tr><td>Social prestige</td><td>01 (1.2)</td><td>01 (1.2)</td><td>02 (1.2)</td></tr><tr><td>Pressure from family and relatives</td><td>37 (45.7)</td><td>47 (58)</td><td>84 (51.9)</td></tr><tr><td>Other</td><td>9 (11.1)</td><td>10 (12.3)</td><td>19 (11.7)</td></tr></table>
a5e345fd37dd238b8f174b92561039c6bc603505bad4ec2d70a0c7093ef71f96.png
simple
<table><tr><td>ID</td><td>Study</td><td>IQC</td><td>EQC</td><td>CQCg</td><td>CQCp</td><td>AQCg</td><td>AQCp</td><td>SMR</td><td>Quality</td></tr><tr><td>1</td><td>GSE43264</td><td>4.02</td><td>4</td><td>2.51</td><td>3.32</td><td>2.63</td><td>4.54</td><td>2.67</td><td>high</td></tr><tr><td>2</td><td>GSE48301_eSF</td><td>9.49</td><td>2.82</td><td>8.89</td><td>2.44</td><td>12.97</td><td>1.17*</td><td>2.83</td><td>high</td></tr><tr><td>3</td><td>GSE1615</td><td>2.43</td><td>3</td><td>1.92*</td><td>2.64</td><td>0.92*</td><td>2.78</td><td>4.67</td><td>high</td></tr><tr><td>4</td><td>GSE10946_obese</td><td>7.45</td><td>4</td><td>0.27*</td><td>2.89</td><td>0.1*</td><td>0.7*</td><td>5.17</td><td>high</td></tr><tr><td>5</td><td>GSE48301_eMSC</td><td>6.1</td><td>2.62</td><td>7.12</td><td>0.59*</td><td>8.35</td><td>0.49*</td><td>5.33</td><td>high</td></tr><tr><td>6</td><td>GSE48301_eEP</td><td>6.25</td><td>3.1</td><td>1.88*</td><td>0.23*</td><td>0.46*</td><td>1.16*</td><td>5.5</td><td>borderline</td></tr><tr><td>7</td><td>GSE34526</td><td>1.74*</td><td>4</td><td>0.35*</td><td>1.36*</td><td>0.14*</td><td>0.05*</td><td>7.17</td><td>low</td></tr><tr><td>8</td><td>GSE48301_eEN</td><td>4.17</td><td>2.34*</td><td>0.46*</td><td>1.06*</td><td>0.63*</td><td>0.08*</td><td>7.17</td><td>low</td></tr><tr><td>9</td><td>GSE5090</td><td>0.98*</td><td>1.68*</td><td>0.51*</td><td>0.77*</td><td>1.86*</td><td>0.05*</td><td>8.33</td><td>low</td></tr><tr><td>10</td><td>GSE5850</td><td>0*</td><td>2.32*</td><td>0.05*</td><td>3.07</td><td>0.07*</td><td>0.41*</td><td>8.5</td><td>low</td></tr><tr><td>11</td><td>GSE10946_lean</td><td>3.15</td><td>2.8</td><td>0*</td><td>0.03*</td><td>0.05*</td><td>0.99*</td><td>8.67</td><td>low</td></tr></table>
b7d63750bb0e9784ddf9336a9fcd918a62ad453fd97d29edc0848c1db7d4a969.png
complex
<table><tr><td rowspan="2">Variables</td><td colspan="2">Univariable</td><td colspan="2">Multivariable</td></tr><tr><td>HR (95% CI)</td><td><i>P</i></td><td>HR (95% CI)</td><td><i>P</i></td></tr><tr><td>Age (&#8804;54/&gt;54)</td><td>1.698 (0.860&#8211;3.354)</td><td>0.127</td><td></td><td></td></tr><tr><td>Gender (F/M)</td><td>0.551 (0.282&#8211;1.075)</td><td>0.080</td><td></td><td></td></tr><tr><td>Tumor location (pyloric/nonpyloric antrum)</td><td>1.130 (0.580&#8211;2.204)</td><td>0.719</td><td></td><td></td></tr><tr><td>HER-2 (positive/negative)</td><td>1.818 (0.698&#8211;4.736)</td><td>0.221</td><td></td><td></td></tr><tr><td>RDW (&#8804;13.4%/&gt;13.4%)</td><td>3.497 (1.713&#8211;7.140)</td><td>0.001</td><td></td><td></td></tr><tr><td>WBC (&#8804;5.69/&gt;5.69 g/L)</td><td>2.165 (1.084&#8211;4.324)</td><td>0.029</td><td>1.323 (0.584&#8211;2.997)</td><td>0.502</td></tr><tr><td>MO (&#8804;0.42/&gt;0.42 g/L)</td><td>2.125 (1.067&#8211;4.232)</td><td>0.032</td><td>1.205 (0.521&#8211;2.790)</td><td>0.663</td></tr><tr><td>NLR (&#8804;2.755/&gt;2.755)</td><td>6.482 (3.131&#8211;13.418)</td><td>&lt;0.001</td><td></td><td></td></tr><tr><td>CA125 (&#8804;26.6/&gt;26.6 U/mL)</td><td>2.241 (1.128&#8211;4.453)</td><td>0.021</td><td>1.858 (0.924&#8211;3.734)</td><td>0.082</td></tr><tr><td>CA199 (&#8804;11.9/&gt;11.9 U/mL)</td><td>1.479 (0.761&#8211;2.872)</td><td>0.248</td><td></td><td></td></tr><tr><td>CEA (&#8804;2.4/&gt;2.4 <i>&#956;</i>g/L)</td><td>1.513 (0.773&#8211;2.961)</td><td>0.227</td><td></td><td></td></tr><tr><td>RDW + NLR</td><td>3.252 (1.289&#8211;8.203)</td><td>&lt;0.001</td><td>3.197 (1.248&#8211;8.191)</td><td>&lt;0.001</td></tr></table>
277d7aac02dc1b79c8c35cf73cbd14dad12b4efbab0cb9393316c4dee0735d4e.png
complex
<table><tr><td></td><td>Parent, <i>N</i> = 100/217</td><td>Child, <i>N</i> = 63/130</td></tr><tr><td>Missing values (1st&#8211;3rd quartiles)</td><td>No missing values</td><td>No missing values</td></tr><tr><td>Response pattern</td><td>PF and HRQoL positively skewed</td><td>PF and HRQoL positively skewed</td></tr><tr><td colspan="3">Floor effect, median</td></tr><tr><td> PF</td><td>92.0%</td><td>90.5%</td></tr><tr><td> HRQoL PhH</td><td>60.0%</td><td>71.4%</td></tr><tr><td> HRQoL PsH</td><td>66.0%</td><td>69.8%</td></tr><tr><td> Pain VAS</td><td>47.0%</td><td>36.5%</td></tr><tr><td> Disease activity VAS</td><td>39.0%</td><td>36.5%</td></tr><tr><td> Well-being VAS</td><td>48.0%</td><td>50.8%</td></tr><tr><td colspan="3">Ceiling effect, median</td></tr><tr><td> PF</td><td>0.0%</td><td>0.0%</td></tr><tr><td> HRQoL PhH</td><td>4.0%</td><td>1.6%</td></tr><tr><td> HRQoL PsH</td><td>0.0%</td><td>0.0%</td></tr><tr><td> Pain VAS</td><td>1.0%</td><td>0.0%</td></tr><tr><td> Disease activity VAS</td><td>3.0%</td><td>1.6%</td></tr><tr><td> Well-being VAS</td><td>0.0%</td><td>0.0%</td></tr><tr><td>Items with equivalent item-scale correlation</td><td>87% for PF, 90% for HRQoL</td><td>73% for PF, 90% for HRQoL</td></tr><tr><td>Items with items-scale correlation &#8805; 0.4</td><td>87% for PF, 100% for HRQoL</td><td>67% for PF, 100% for HRQoL</td></tr><tr><td colspan="3">Cronbach&#8217;s alpha</td></tr><tr><td> PF-LL</td><td>0.82</td><td>0.84</td></tr><tr><td> PF-HW</td><td>0.74</td><td>0.89</td></tr><tr><td> PF-US</td><td>0.64</td><td>0.47</td></tr><tr><td> HRQoL-PhH</td><td>0.86</td><td>0.86</td></tr><tr><td> HRQoL-PsH</td><td>0.85</td><td>0.76</td></tr><tr><td>Items with item-scale correlation lower than the Cronbach alpha</td><td>93% for PF, 100% for HRQoL</td><td>100% for PF, 100% for HRQoL</td></tr><tr><td colspan="3">Test&#8211;retest intraclass correlation</td></tr><tr><td> PF total score</td><td>0.60</td><td>&#8211;</td></tr><tr><td> HRQoL-PhH</td><td>0.62</td><td>&#8211;</td></tr><tr><td> HRQoL-PsH</td><td>0.97</td><td>&#8211;</td></tr><tr><td colspan="3">Spearman&#8217;s correlation with JIA core-set variables, median</td></tr><tr><td> PF</td><td>0.4</td><td>0.4</td></tr><tr><td> HRQoL PhH</td><td>0.4</td><td>0.4</td></tr><tr><td> HRQoL PsH</td><td>0.3</td><td>0.2</td></tr><tr><td> Pain VAS</td><td>0.2</td><td>0.3</td></tr><tr><td> Disease activity VAS</td><td>0.3</td><td>0.4</td></tr><tr><td> Well-being VAS</td><td>0.3</td><td>0.4</td></tr></table>
4c2da8a8a8c57b298f97601aea9fe745c20be56afb969de1c93a48c046ac98e1.png
complex
<table><tr><td></td><td colspan="3"><i>n</i> (%) of sites</td></tr><tr><td></td><td>Dacron (<i>N</i> = 38<sup>b</sup>)</td><td>PTFE (<i>N</i> = 19<sup>b</sup>)</td><td>Any material (<i>N</i> = 57<sup>b</sup>)</td></tr><tr><td colspan="4">Bleeding<sup>a</sup> at 0 min</td></tr><tr><td>&#8220;No bleeding&#8221;</td><td>34 (89)</td><td>19 (100)</td><td>53 (93)</td></tr><tr><td>&#8220;Oozing&#8221;</td><td>4 (11)</td><td>0 (0)</td><td>4 (7)</td></tr><tr><td>&#8220;No bleeding&#8221; or &#8220;oozing&#8221;</td><td>38 (100)</td><td>19 (100)</td><td>57 (100)</td></tr><tr><td colspan="4">Bleeding<sup>a</sup> at 10 min</td></tr><tr><td>&#8220;No bleeding&#8221;</td><td>37 (97)</td><td>19 (100)</td><td>56 (98)</td></tr><tr><td>&#8220;Oozing&#8221;</td><td>1 (3)</td><td>0 (0)</td><td>1 (2)</td></tr><tr><td>&#8220;No bleeding&#8221; or &#8220;oozing&#8221;</td><td>38 (100)</td><td>19 (100)</td><td>57 (100)</td></tr></table>
13dfe521296df7fa05b3256b8b83bbd296979b235b7721ed57f5d1ba1021f733.png
complex
<table><tr><td></td><td colspan="3">Fraction in state (f)</td><td>z<sub>2t</sub></td><td colspan="4">Rates of transfer (Eqs. (20)&#8211;(21))</td></tr><tr><td>Time</td><td>U</td><td>J</td><td>A</td><td></td><td><i>m</i><sub>UJ</sub></td><td><i>m</i><sub>JU</sub></td><td><i>m</i><sub>JA</sub></td><td><i>m</i><sub>AJ</sub></td></tr><tr><td colspan="9">A. Interval by interval calculations (Eq. (1))</td></tr><tr><td> 0</td><td>.85</td><td>.10</td><td>.05</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> 1</td><td>.82925</td><td>.10985</td><td>.06090</td><td>.70</td><td>.01317</td><td>.06586</td><td>.08474</td><td>.12106</td></tr><tr><td> 2</td><td>.81243</td><td>.11769</td><td>.06988</td><td>.71</td><td>.01335</td><td>.06674</td><td>.08291</td><td>.11678</td></tr><tr><td> 3</td><td>.79876</td><td>.12391</td><td>.07733</td><td>.72</td><td>.01357</td><td>.06785</td><td>.08026</td><td>.11147</td></tr><tr><td> 4</td><td>.78759</td><td>.12885</td><td>.08356</td><td>.73</td><td>.01384</td><td>.06921</td><td>.07698</td><td>.10545</td></tr><tr><td> 5</td><td>.77844</td><td>.13275</td><td>.08881</td><td>.74</td><td>.01419</td><td>.07093</td><td>.07318</td><td>.09890</td></tr><tr><td colspan="9">B. Stable population values (&#964;<sub>j5</sub>) implied by time 5 rates</td></tr><tr><td> 5</td><td>.74184</td><td>.14837</td><td>.10979</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">C. Time 5 values calculated directly from time 0 populations and z values (Eq. (2))</td><td></td></tr><tr><td> 5</td><td>.77844</td><td>.13275</td><td>.08881</td><td></td><td></td><td></td><td></td><td></td></tr></table>
22e89c02e27d163cde0028fa562cb4f415e9fb6b68dd99b7ab1221cdb5606fd8.png
complex
<table><tr><td>Variable</td><td>N</td><td>%</td></tr><tr><td colspan="3"><i>Child&#8217;s gender</i></td></tr><tr><td>Male</td><td>232</td><td>48.54</td></tr><tr><td>Female</td><td>246</td><td>52.46</td></tr><tr><td colspan="3"><i>Child&#8217;s age (months)</i></td></tr><tr><td>12&#8211;35</td><td>186</td><td>38.91</td></tr><tr><td>36&#8211;59</td><td>292</td><td>61.09</td></tr><tr><td colspan="3"><i>Child&#8217;s skin color</i></td></tr><tr><td>White</td><td>379</td><td>79.29</td></tr><tr><td>Non-White</td><td>99</td><td>20.71</td></tr><tr><td colspan="3"><i>Household income</i></td></tr><tr><td>&gt;1 BMW*</td><td>338</td><td>74.78</td></tr><tr><td>&#8804;1 BMW*</td><td>114</td><td>25.22</td></tr><tr><td colspan="3"><i>Mother&#8217;s level of education</i></td></tr><tr><td>&#8805;8 years</td><td>268</td><td>56.78</td></tr><tr><td>&lt;8 years</td><td>204</td><td>43.22</td></tr><tr><td colspan="3"><i>Father&#8217;s level of education</i></td></tr><tr><td>&#8805;8 years</td><td>247</td><td>55.38</td></tr><tr><td>&lt;8 years</td><td>199</td><td>44.62</td></tr><tr><td colspan="3"><i>Does the child brush his/her teeth?</i></td></tr><tr><td>Yes</td><td>434</td><td>90.99</td></tr><tr><td>No</td><td>43</td><td>9.01</td></tr><tr><td colspan="3"><i>Children&#8217;s dental caries</i></td></tr><tr><td>dmft = 0</td><td>317</td><td>66.32</td></tr><tr><td>dmft &#8805; 1</td><td>161</td><td>33.68</td></tr><tr><td colspan="3"><i>Children&#8217;s previous visit to the dentist</i></td></tr><tr><td>Yes</td><td>112</td><td>23.68</td></tr><tr><td>No</td><td>361</td><td>76.32</td></tr><tr><td colspan="3"><i>Reason for dental visit</i></td></tr><tr><td>Preventive</td><td>82</td><td>67.77</td></tr><tr><td>Others than preventive</td><td>39</td><td>32.23</td></tr><tr><td colspan="3"><i>Type of healthcare system</i></td></tr><tr><td>Private</td><td>45</td><td>36.89</td></tr><tr><td>Public</td><td>77</td><td>63.11</td></tr></table>
964e522bced69f89d6f6c8e189e6e9b58b2cb17039b55c178bfd7ea803ba7087.png
complex
<table><tr><td colspan="5">Box D. Content validity (including face validity)</td></tr><tr><td colspan="2"><i>General requirements</i></td><td>yes</td><td>no</td><td>?</td></tr><tr><td>1</td><td>Was assessed if all items refer to relevant aspects of the construct to be measured?</td><td>&#9633;</td><td>&#9633;</td><td>&#9633;</td></tr><tr><td>2</td><td>Was assessed if all items are relevant for the study population? Considering e.g. age, gender, disease characteristics, country, setting</td><td>&#9633;</td><td>&#9633;</td><td>&#9633;</td></tr><tr><td>3</td><td>Was assessed if all items are relevant for the purpose of the application of the measurement instrument? i.e. (1) discriminative (distinguish between groups at one point in time), (2) evaluative (assess change over time), and/or (3) predictive (predict future values)</td><td>&#9633;</td><td>&#9633;</td><td>&#9633;</td></tr><tr><td>4</td><td>Was assessed if all items together comprehensively reflect the construct to be measured in terms of (1) content coverage and description of domains, and (2) the theoretical foundation?</td><td>&#9633;</td><td>&#9633;</td><td>&#9633;</td></tr><tr><td>5</td><td>Were there any important flaws in the design or methods of the study?</td><td>&#9633;</td><td>&#9633;</td><td></td></tr></table>
4105867cb645b53ed2e2c5e2d0b3a5ed8acdc2c0b7c54a220037ffac017649ed.png
simple
<table><tr><td></td><td>Single cellular RNA sample</td><td>Pooled RNA sample</td><td>Pooled DNA sample</td></tr><tr><td>TNF-&#945;</td><td>95</td><td>95</td><td>100</td></tr><tr><td>&#946;2-MG</td><td>90</td><td>90</td><td>100</td></tr><tr><td>MIF</td><td>88</td><td>88</td><td>100</td></tr><tr><td>UBC</td><td>81</td><td>80</td><td>100</td></tr></table>
84c8014a7543ba13b5894da15608468b8b4c5731816a896bf53098368adb6334.png
complex
<table><tr><td rowspan="2"></td><td>Total <i>n</i> = 1645</td><td>non-JIA <i>n</i> = 1316</td><td>JIA <i>n</i> = 329</td><td></td></tr><tr><td><i>n</i> %</td><td><i>n</i> %</td><td><i>n</i> %</td><td><i>P</i>-value</td></tr><tr><td>Age (year), mean &#177; SD<sup>a</sup></td><td>11.3 &#177; 3.47</td><td>11.3 &#177; 3.47</td><td>11.3 &#177; 3.47</td><td>0.95</td></tr><tr><td>Stratified age</td><td></td><td></td><td></td><td>0.99</td></tr><tr><td> &lt;12</td><td>645 (39.2)</td><td>516 (39.2)</td><td>129 (39.2)</td><td></td></tr><tr><td> &#8805;12</td><td>1000 (60.8)</td><td>800 (60.8)</td><td>200 (60.8)</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td>0.99</td></tr><tr><td> Girls</td><td>840 (51.1)</td><td>672 (51.1)</td><td>168 (51.1)</td><td></td></tr><tr><td> Boys</td><td>805 (48.9)</td><td>644 (48.9)</td><td>161 (48.9)</td><td></td></tr><tr><td>Urbanization<sup>b</sup></td><td></td><td></td><td></td><td>0.99</td></tr><tr><td> 1 (highest)</td><td>495 (30.1)</td><td>396 (30.1)</td><td>99 (30.1)</td><td></td></tr><tr><td> 2</td><td>490 (29.8)</td><td>392 (29.8)</td><td>98 (29.8)</td><td></td></tr><tr><td> 3</td><td>270 (16.4)</td><td>216 (16.4)</td><td>54 (16.4)</td><td></td></tr><tr><td> 4 (lowest)</td><td>390 (23.7)</td><td>312 (23.7)</td><td>78 (23.7)</td><td></td></tr><tr><td>Co-morbidity</td><td></td><td></td><td></td><td></td></tr><tr><td> Allergic conjunctivitis</td><td></td><td></td><td></td><td>0.02</td></tr><tr><td>No</td><td>1354 (82.3)</td><td>1098 (83.4)</td><td>256 (77.8)</td><td></td></tr><tr><td>Yes</td><td>291 (17.7)</td><td>218 (16.6)</td><td>73 (22.2)</td><td></td></tr><tr><td> Allergic rhinitis</td><td></td><td></td><td></td><td>0.003</td></tr><tr><td>No</td><td>1226 (74.5)</td><td>1002 (76.1)</td><td>224 (68.1)</td><td></td></tr><tr><td>Yes</td><td>419 (25.5)</td><td>314 (23.9)</td><td>105 (31.9)</td><td></td></tr><tr><td> Asthma</td><td></td><td></td><td></td><td>0.06</td></tr><tr><td>No</td><td>1477 (89.8)</td><td>1191 (90.5)</td><td>286 (86.9)</td><td></td></tr><tr><td>Yes</td><td>168 (10.2)</td><td>125 (9.50)</td><td>43 (13.1)</td><td></td></tr><tr><td> Atopic dermatitis</td><td></td><td></td><td></td><td>0.10</td></tr><tr><td>No</td><td>1555 (94.5)</td><td>1250 (95.0)</td><td>305 (92.7)</td><td></td></tr><tr><td>Yes</td><td>90 (5.47)</td><td>66 (5.02)</td><td>24 (7.29)</td><td></td></tr></table>
8563bda3f8b8b277dbe27c0b23a2a4e335b1fda2e9532282996d1ec70add75cb.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">cn/cn</td><td colspan="3">cn/+</td></tr><tr><td>Growth plates studied</td><td># Histologic sections</td><td>Range of # of sections per growth plate</td><td>Growth plates studied</td><td># Histologic sections</td><td>Range of # of sections per growth plate</td></tr><tr><td>Humerus</td><td>12</td><td>46</td><td>(1&#8211;9)</td><td>8</td><td>23</td><td>(2&#8211;5)</td></tr><tr><td>Femur</td><td>7</td><td>31</td><td>(1&#8211;7)</td><td>7</td><td>31</td><td>(2&#8211;11)</td></tr><tr><td>Tibia</td><td>7</td><td>40</td><td>(2&#8211;12)</td><td>9</td><td>30</td><td>(2&#8211;6)</td></tr><tr><td></td><td>26</td><td>117</td><td></td><td>24</td><td>87</td><td></td></tr></table>
ad22a0feeee4c72b94078e88f31aec3a1861aafda486b24a981d629fa31442c8.png
complex
<table><tr><td colspan="2"></td><td>Homicides (per 100,000)</td><td>DALY (thousands)</td></tr><tr><td colspan="2">World</td><td>7.9</td><td>21,701,428</td></tr><tr><td colspan="2">High income countries</td><td>2.7</td><td>886,297</td></tr><tr><td rowspan="6">Low&#8211;middle income countries</td><td>Africa</td><td>20.1</td><td>6,333,294</td></tr><tr><td>The Americas</td><td>24.1</td><td>6,024,751</td></tr><tr><td>Eastern Mediterranean</td><td>3.9</td><td>1,346,008</td></tr><tr><td>Europe</td><td>9.8</td><td>1,826,177</td></tr><tr><td>South-East Asia</td><td>5.8</td><td>3,444,677</td></tr><tr><td>Western Pacific</td><td>2.8</td><td>1,775,947</td></tr><tr><td colspan="2">Guatemala (1)</td><td>61.3</td><td>175</td></tr><tr><td colspan="2">El Salvador (2)</td><td>54.9</td><td>113</td></tr><tr><td colspan="2">Co&#770;te d'Ivoire (3)</td><td>52.5</td><td>324</td></tr><tr><td colspan="2">Brazil (13)</td><td>29.6</td><td>2488</td></tr><tr><td colspan="2">South Africa (17)</td><td>27.3</td><td>1006</td></tr><tr><td colspan="2">Russian Federation (39)</td><td>18.4</td><td>1276</td></tr><tr><td colspan="2">Mexico (43)</td><td>17.9</td><td>415</td></tr><tr><td colspan="2">Indonesia (76)</td><td>8.3</td><td>611</td></tr><tr><td colspan="2">United States of America (93)</td><td>6.2</td><td>599</td></tr><tr><td colspan="2">India (102)</td><td>4.4</td><td>1866</td></tr><tr><td colspan="2">Pakistan (108)</td><td>3.4</td><td>174</td></tr><tr><td colspan="2">Turkey (113)</td><td>2.8</td><td>67</td></tr><tr><td colspan="2">China (142)</td><td>1.6</td><td>993</td></tr><tr><td colspan="2">Iran (150)</td><td>1.4</td><td>89</td></tr><tr><td colspan="2">France (152)</td><td>1.4</td><td>17</td></tr><tr><td colspan="2">United Kingdom (162)</td><td>1.1</td><td>33</td></tr><tr><td colspan="2">Italy (163)</td><td>1.1</td><td>15</td></tr><tr><td colspan="2">Germany (178)</td><td>0.8</td><td>19</td></tr><tr><td colspan="2">Egypt (185)</td><td>0.6</td><td>27</td></tr><tr><td colspan="2">Japan (189)</td><td>0.5</td><td>21</td></tr></table>
73cc8244051bf2aa3d890c9e1f711fb82c5e92887d897b597c27cfa20cfd51f3.png
complex
<table><tr><td rowspan="2">Gene</td><td colspan="2">Fraction of <i>est2&#8710; rad51&#8710; xxx&#8710;</i> that are able to form survivors</td><td rowspan="2">Reference</td></tr><tr><td>in BY4741 background<i><sup>a</sup></i></td><td>in W303 background</td></tr><tr><td><i>CCR4</i><i><sup>b</sup></i></td><td></td><td>0/10 (0%)</td><td></td></tr><tr><td><i>CDC55</i></td><td>0/12 (0%)</td><td>2/9 (22%)</td><td></td></tr><tr><td><i>CHK1</i></td><td>5/14 (36%)</td><td>2/10 (20%)</td><td></td></tr><tr><td><i>CLB2</i></td><td>2/14 (14%)</td><td></td><td>Grandin and Charbonneau 2003</td></tr><tr><td><i>DOA4</i></td><td>5/14 (36%)</td><td>3/10 (30%)</td><td></td></tr><tr><td><i>DUN1</i></td><td>2/12 (17%)</td><td>1/25 (4%)</td><td></td></tr><tr><td><i>LSM1</i></td><td>5/14 (36%)</td><td>0/7 (0%)</td><td></td></tr><tr><td><i>MOT2</i></td><td>0/10 (0%)</td><td>1/4 (25%)</td><td></td></tr><tr><td><i>NMD2</i></td><td>0/12 (0%)</td><td></td><td>Hu <i>et al.</i> 2013</td></tr><tr><td><i>PPH3</i></td><td>2/12 (17%)</td><td>2/10 (20%)</td><td></td></tr><tr><td><i>RAD50</i></td><td>2/10 (20%)</td><td></td><td>Chen <i>et al.</i> 2001</td></tr><tr><td><i>RAD52</i></td><td>0/11 (0%)</td><td></td><td>Lundblad and Blackburn 1993</td></tr><tr><td><i>RAD59</i></td><td>4/11 (36%)</td><td></td><td>Chen <i>et al.</i> 2001</td></tr><tr><td><i>RGI1</i></td><td>0/4 (0%)</td><td>2/10 (20%)</td><td></td></tr><tr><td><i>RMI1</i></td><td>1/7 (14%)</td><td>0/10 (0%)</td><td></td></tr><tr><td><i>RPL8B</i></td><td>1/8 (13%)</td><td>2/10 (20%)</td><td></td></tr><tr><td><i>RPN4</i></td><td>1/9 (11%)</td><td>3/10 (30%)</td><td></td></tr><tr><td><i>RRM3</i></td><td>4/12 (33%)</td><td>3/10 (30%)</td><td></td></tr><tr><td><i>SGS1</i></td><td>0/11 (0%)</td><td></td><td>Huang <i>et al.</i> 2001; Johnson <i>et al.</i> 2001</td></tr><tr><td><i>SPT20</i></td><td>0/5 (0%)</td><td>0/10 (0%)</td><td></td></tr><tr><td><i>VMA22</i></td><td>1/10 (10%)</td><td>3/10 (30%)</td><td></td></tr><tr><td><i>YLR235C</i></td><td>1/16 (6%)</td><td>0/10 (0%)</td><td></td></tr><tr><td><i>YLR358C</i></td><td>1/5 (20%)</td><td>4/9 (44%)</td><td></td></tr></table>
7579a10b0761bd239950113d71845deedda1a85dd9e8f87f631417670d05f90f.png
complex
<table><tr><td></td><td colspan="7">Parity</td></tr><tr><td>Measurements</td><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6 or later</td></tr><tr><td>Number of serviced records</td><td>93,604</td><td>78,243</td><td>70,596</td><td>62,258</td><td>53,371</td><td>43,634</td><td>52,352</td></tr><tr><td>Number of first return records</td><td>11,458</td><td>8734</td><td>5625</td><td>4730</td><td>3772</td><td>2694</td><td>2614</td></tr><tr><td>First return occurrences, %</td><td>12.2</td><td>11.2</td><td>8.0</td><td>7.6</td><td>7.1</td><td>6.2</td><td>5.0</td></tr><tr><td>Number of second return records</td><td>2325</td><td>1324</td><td>834</td><td>695</td><td>490</td><td>297</td><td>290</td></tr><tr><td>Number of culled records after the second return<sup>a</sup></td><td>246</td><td>142</td><td>87</td><td>105</td><td>68</td><td>55</td><td>49</td></tr><tr><td>Number of removed records after the second return<sup>b</sup></td><td>394</td><td>232</td><td>168</td><td>136</td><td>90</td><td>68</td><td>64</td></tr><tr><td>Number of SRB females<sup>c</sup></td><td>532</td><td>235</td><td>145</td><td>104</td><td>70</td><td>34</td><td>38</td></tr><tr><td>SRB risk for first-served females, %</td><td>0.57</td><td>0.30</td><td>0.21</td><td>0.17</td><td>0.13</td><td>0.08</td><td>0.07</td></tr></table>
4201751865a366a73f50c1598b6c856f75d34b3770ceb1116299faaed94945de.png
simple
<table><tr><td>Kidney cancer dataset</td><td>CANOVA</td><td>Kendall</td><td>Pearson</td><td>Spearman</td><td>Hoeffding</td><td>Distance</td><td>MIC</td></tr><tr><td>Significant gene number</td><td>5901</td><td>11569</td><td>8239</td><td>11629</td><td>4953</td><td>10946</td><td>8081</td></tr><tr><td>Computing time (seconds)</td><td>24</td><td>65</td><td>32</td><td>32</td><td>44</td><td>~10<sup>6</sup></td><td>114</td></tr></table>
fe90ee019ad0e3f5e6ea67eb798a19b18b3beca6a467f525016c89ea031c1bbe.png
simple
<table><tr><td>Article</td><td>Number (M/F)<sup>1</sup></td><td>C/R/R-S<sup>2</sup></td><td>Age Mean &#177; SD<sup>3</sup>/Median (range)</td><td>ST<sup>4</sup></td><td>Cut-off</td><td>Rate(+)<sup>5</sup></td><td>Follow up Mean &#177; SD/Median (range)</td><td>OM<sup>6</sup></td><td>Surgery</td><td>MA<sup>7</sup></td></tr><tr><td>Sotelo 2014 [24]</td><td>472(254/218)</td><td>425/47/0</td><td>Median:66(31&#8211;87)</td><td>Baseline</td><td>&#8805;1/7.5 ml</td><td>166/472</td><td>Median:40(NR<sup>8</sup>)</td><td>OS<sup>9</sup>; PFS<sup>10</sup></td><td>YES</td><td>NO</td></tr><tr><td></td><td>472(254/218)</td><td>425/47/0</td><td>Median:66(31&#8211;87)</td><td>Baseline</td><td>&#8805;2/7.5 ml</td><td>93/472</td><td>Median:40(NR)</td><td>OS; PFS</td><td>YES</td><td>NO</td></tr><tr><td></td><td>472(254/218)</td><td>425/47/0</td><td>Median:66(31&#8211;87)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>57/472</td><td>Median:40(NR)</td><td>OS; PFS</td><td>YES</td><td>NO</td></tr><tr><td></td><td>472(254/218)</td><td>425/47/0</td><td>Median:66(31&#8211;87)</td><td>Baseline</td><td>&#8805;5/7.5 ml</td><td>34/472</td><td>Median:40(NR)</td><td>OS; PFS</td><td>YES</td><td>NO</td></tr><tr><td>Seeberg 2014 [25]</td><td>194(105/89)</td><td>124/70</td><td>Median:65(31&#8211;93)</td><td>Baseline</td><td>&#8805;1/7.5 ml</td><td>37/189</td><td>Median:22.5(1&#8211;61)</td><td>OS; PFS</td><td>153YES</td><td>NO</td></tr><tr><td></td><td>194(105/89)</td><td>124/70</td><td>Median:65(31&#8211;93)</td><td>Baseline</td><td>&#8805;2/7.5 ml</td><td>26/189</td><td>Median:22.5(1&#8211;61)</td><td>OS; PFS</td><td>153YES</td><td>YES</td></tr><tr><td></td><td>194(105/89)</td><td>124/70</td><td>Median:65(31&#8211;93)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>17/189</td><td>Median:22.5(1&#8211;61)</td><td>OS; PFS</td><td>153YES</td><td>NO</td></tr><tr><td>Gazzaniga 2013 [26]</td><td>119(68/51)</td><td>NR</td><td>Median:64(29&#8211;84)</td><td>Baseline</td><td>&#8805;1/7.5 ml</td><td>44/119</td><td>Median:12(1&#8211;26)</td><td>PFS</td><td>NR</td><td>YES</td></tr><tr><td></td><td>119(68/51)</td><td>NR</td><td>Median:64(29&#8211;84)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>24/119</td><td>Median:12(1&#8211;26)</td><td>PFS</td><td>NR</td><td>YES</td></tr><tr><td>Aggarwal 2013 [27]</td><td>Baseline:209(NR)</td><td>NR</td><td>Mean:63.0 &#177; 12.6 Median: 64 (22&#8211;92)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>62/209</td><td>median: NR(0.2-39.1)</td><td>OS</td><td>NR</td><td>YES</td></tr><tr><td></td><td>3-5 W:115(NR) 6-12 W:134(NR)</td><td>NR</td><td>NR</td><td>During-treatment: 3-5 W,6-12 W<sup>11</sup></td><td>&#8805;3/7.5 ml</td><td>3-5 W: 17/115; 6-12 W: 10/134</td><td>NR</td><td>OS</td><td>NR</td><td>YES</td></tr><tr><td>Kuboki 2013 [14]</td><td>63(34/29)</td><td>41/22/0</td><td>Median: 61(33&#8211;81)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>19/63</td><td>Median:8.7(NR)</td><td>OS; PFS</td><td>NR</td><td>YES</td></tr><tr><td>Deneve 2013 [13]</td><td>69(43/26)</td><td>66/8/1</td><td>Median: 75(38&#8211;95)</td><td>Baseline</td><td>&#8805;1/7.5 ml</td><td>20/69</td><td>Mean:31 &#177; NR Median:36 (0&#8211;52)</td><td>NR</td><td>YES</td><td>NO</td></tr><tr><td>Sastre 2012 [28]</td><td>Baseline:180(118/62)</td><td>40/121/19</td><td>Median: 65(40&#8211;82)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>85/180</td><td>NR</td><td>OS; PFS</td><td>123YES</td><td>YES</td></tr><tr><td></td><td>Cycle3:147(NR)</td><td>NR</td><td>NR</td><td>Cycle3</td><td>&#8805;3/7.5 ml</td><td>23/147</td><td>NR</td><td>OS; PFS</td><td>123YES</td><td>NO</td></tr><tr><td>Sato 2012 [29]</td><td>25(NR)</td><td>NR</td><td>NR</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>14/25</td><td>NR</td><td>OS</td><td>M1:NO<sup>12</sup></td><td>NO</td></tr><tr><td></td><td>25(NR)</td><td>NR</td><td>NR</td><td>Baseline</td><td>&#8805;1/7.5 ml</td><td>18/25</td><td>NR</td><td>OS</td><td>M1:NO</td><td>NO</td></tr><tr><td>Papavasiliou 2010 [30]</td><td>20(13/7)</td><td>NR</td><td>Median: 54 (41&#8211;81)</td><td>Baseline During-treatment</td><td>&#8805;3/7.5 ml</td><td>Pre:2/20 intra: 10/20; post: 1/18</td><td>Median:11.5 (5&#8211;25)</td><td>OS; PFS</td><td>YES</td><td>NO</td></tr><tr><td>Tol 2010 [31]</td><td>467 (284/183)</td><td>225/122/ 120</td><td>Median: 63(27&#8211;83)</td><td>Baseline</td><td>&#8805;3/7.5 ml</td><td>Baseline: 129/451</td><td>Median: 16.8(NR)</td><td>OS; PFS</td><td>NR</td><td>YES</td></tr><tr><td></td><td>1-2 W: 368(NR) 3-5 W:320(NR) 6-12 W:336(NR) 13-20 W: 254(NR)</td><td>NR</td><td>Median: 63(27&#8211;83)</td><td>During-treatment: 1-2/3-5/6-12/13-20 W</td><td>&#8805;3/7.5 ml</td><td>1-2 W: 21/368; 3-5 W: 17/320; 6-12 W: 18/336; 13-20 W: 16/254</td><td>NR</td><td>OS; PFS</td><td>NR</td><td>YES</td></tr><tr><td>Hiraiwa 2008 [15]</td><td>40(NR)</td><td>NR</td><td>NR</td><td>Baseline + During-treatment</td><td>&#8805;2/7.5 ml</td><td>14/40</td><td>NR</td><td>OS</td><td>YES</td><td>YES</td></tr></table>
9cea7c1dcc75bee28acca0f18898512416b6c9898e8435191b7fb6a1b7f39664.png
simple
<table><tr><td>Biomolecule</td><td>Molecular weight (kDa)</td><td>Isoelectric point</td><td>Charge</td><td>Hydrodynamic radius (A&#778;)</td><td>Amount (&#956;g)</td></tr><tr><td>AcSDKP peptide</td><td>0.4</td><td>5.5</td><td>Negative</td><td>7<sup>a</sup></td><td>1000</td></tr><tr><td>Insulin</td><td>5.73</td><td>5.3</td><td>Negative</td><td>13</td><td>111</td></tr><tr><td>PEG-QK</td><td>11.27</td><td>9.4</td><td>Positive</td><td>36.9<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></td><td>27</td></tr><tr><td>Lysozyme</td><td>14.3</td><td>11.35</td><td>Positive</td><td>19.1</td><td>1200 (transwell) 350 (release)</td></tr><tr><td>VEGF</td><td>45.5</td><td>9.22</td><td>Positive</td><td>30.2</td><td>7.5</td></tr><tr><td>BSA</td><td>66.4</td><td>4.7</td><td>Negative</td><td>36.3</td><td>1200</td></tr></table>
05df35fd3cb6e167b0b2597e7edb7ebccd0c08aae4ef304d3bf20e52bd1a91dc.png
simple
<table><tr><td>Delivery system</td><td>Diameter (mm)</td><td>Headspace (ml)</td><td>Milk-to-air interface (cm<sup>2</sup>)</td></tr><tr><td>Gerber (G)</td><td>52</td><td>176</td><td>21.23</td></tr><tr><td>Ventaire (V)</td><td>54</td><td>183</td><td>22.89</td></tr><tr><td>Dr. Brown's (DB)</td><td>50</td><td>66*</td><td>19.63</td></tr><tr><td>Elan (EL)</td><td>67</td><td>180</td><td>35.24*</td></tr><tr><td>BornFree (BF)</td><td>65</td><td>127*</td><td>33.17*</td></tr><tr><td>Playtex Drop-Ins (PD)</td><td>56</td><td>158</td><td>24.62*</td></tr><tr><td>Avent Natural (AN)</td><td>66</td><td>205</td><td>34.19*</td></tr><tr><td>Control</td><td>52</td><td>74*</td><td>20.42</td></tr></table>
688fcf8fff88d85403b3a87cad259fb7bd8ef65414b7f5e0ccc8af021f60a8db.png
complex
<table><tr><td colspan="4">Medium scale construction sites</td></tr><tr><td>Site</td><td>Total (max. = 120)</td><td>Mean</td><td>Correlation coefficient</td></tr><tr><td>1</td><td>58</td><td>4.83</td><td>0.56</td></tr><tr><td>2</td><td>48</td><td>4.00</td><td>&#8722;0.22</td></tr><tr><td>3</td><td>50</td><td>4.17</td><td>&#8722;0.14</td></tr><tr><td>4</td><td>47</td><td>3.92</td><td>&#8722;0.59</td></tr><tr><td>5</td><td>51</td><td>4.25</td><td>0.33</td></tr><tr><td>6</td><td>52</td><td>4.33</td><td>&#8722;0.06</td></tr><tr><td>7</td><td>53</td><td>4.42</td><td>0.03</td></tr><tr><td>8</td><td>41</td><td>3.42</td><td>0.69</td></tr><tr><td>9</td><td>43</td><td>3.58</td><td>&#8722;0.09</td></tr><tr><td>10</td><td>51</td><td>4.25</td><td>0.00</td></tr><tr><td>11</td><td>53</td><td>4.42</td><td>&#8722;0.39</td></tr><tr><td>12</td><td>50</td><td>4.17</td><td>&#8722;0.33</td></tr><tr><td>13</td><td>51</td><td>4.25</td><td>0.05</td></tr><tr><td>14</td><td>53</td><td>4.42</td><td>&#8722;0.60</td></tr><tr><td>15</td><td>60</td><td>5.00</td><td>&#8722;0.24</td></tr><tr><td>16</td><td>55</td><td>4.58</td><td>0.18</td></tr><tr><td>17</td><td>49</td><td>4.08</td><td>&#8722;0.74</td></tr><tr><td>18</td><td>47</td><td>3.92</td><td>&#8722;0.47</td></tr><tr><td>19</td><td>51</td><td>4.25</td><td>&#8722;0.13</td></tr><tr><td>20</td><td>50</td><td>4.17</td><td>0.19</td></tr><tr><td>21</td><td>68</td><td>5.67</td><td>&#8722;0.06</td></tr><tr><td>22</td><td>54</td><td>4.50</td><td>&#8722;0.35</td></tr><tr><td>23</td><td>54</td><td>4.50</td><td>&#8722;0.45</td></tr><tr><td>24</td><td>52</td><td>4.33</td><td>0.56</td></tr><tr><td>25</td><td>54</td><td>4.50</td><td>&#8722;0.37</td></tr><tr><td>26</td><td>59</td><td>4.92</td><td>&#8722;0.26</td></tr><tr><td>27</td><td>51</td><td>4.25</td><td>&#8722;0.19</td></tr><tr><td>28</td><td>57</td><td>4.75</td><td>0.42</td></tr></table>
17f0e45152d67e9e521daa569b7e0dc79d2d9c24142a23c2e5b73d30f665b1fe.png
simple
<table><tr><td>Dataset</td><td>Nematode hits </td><td>Trematode hits </td><td>Cestode hits </td></tr><tr><td><i>C. elegans </i>proteins (Wormpep)</td><td>8457</td><td>345</td><td>280</td></tr><tr><td><i>S. mansoni </i>proteins</td><td>3440</td><td>598</td><td>419</td></tr><tr><td>Human proteins</td><td>4539</td><td>408</td><td>326</td></tr><tr><td>NR protein database</td><td>10116</td><td>652</td><td>497</td></tr><tr><td><i>S. japonicum </i>proteins</td><td>3456</td><td>612</td><td>416</td></tr></table>
39462305c108655fc7de9e8950594a52417cfcdc39122c472519f1367636e3fd.png
complex
<table><tr><td>Variables</td><td></td><td>Frequency</td><td>Percent</td></tr><tr><td rowspan="2">Abdomen palpated to rule out the presence of second baby</td><td>Yes</td><td>331</td><td>62.7</td></tr><tr><td>No</td><td>197</td><td>37.3</td></tr><tr><td rowspan="4">Uterotonic drugs given</td><td>Oxytocin</td><td>432</td><td>81.8</td></tr><tr><td>Ergometrine</td><td>61</td><td>11.6</td></tr><tr><td>Misoprostol</td><td>30</td><td>5.7</td></tr><tr><td>Not given</td><td>5</td><td>0.9</td></tr><tr><td rowspan="4">Dose of uterotonic drugs given</td><td>0.5 mg</td><td>24</td><td>4.5</td></tr><tr><td>10 IU</td><td>486</td><td>96.6</td></tr><tr><td>0.5 mg</td><td>12</td><td>2.3</td></tr><tr><td>Others</td><td>6</td><td>1.1</td></tr><tr><td rowspan="3">Route of uterotonic drugs given</td><td>IM</td><td>519</td><td>97.2</td></tr><tr><td>IV</td><td>9</td><td>1.7</td></tr><tr><td>Oral</td><td>6</td><td>1.1</td></tr><tr><td rowspan="2">Wait uterine contraction 2&#8211;3 min to apply CCT</td><td>Yes</td><td>243</td><td>46</td></tr><tr><td>No</td><td>285</td><td>54</td></tr><tr><td rowspan="2">Wait gush of blood</td><td>Yes</td><td>283</td><td>53.6</td></tr><tr><td>No</td><td>245</td><td>46.4</td></tr><tr><td rowspan="2">Counter cord traction applied</td><td>Yes</td><td>472</td><td>89.4</td></tr><tr><td>No</td><td>56</td><td>10.6</td></tr><tr><td rowspan="2">Placenta supported by two hands during placenta delivery</td><td>Yes</td><td>421</td><td>79.7</td></tr><tr><td>No</td><td>107</td><td>20.3</td></tr><tr><td rowspan="2">Membrane extracted gently with lateral movement</td><td>Yes</td><td>293</td><td>55.5</td></tr><tr><td>No</td><td>235</td><td>44.5</td></tr><tr><td rowspan="2">Uterine massage immediately after delivery of placenta</td><td>Yes</td><td>227</td><td>43</td></tr><tr><td>No</td><td>301</td><td>57</td></tr><tr><td rowspan="2">Uterine relaxation ensured</td><td>Yes</td><td>161</td><td>30.5</td></tr><tr><td>No</td><td>367</td><td>69.5</td></tr><tr><td rowspan="2">Inform and demonstrate the mother massage uterus</td><td>Yes</td><td>196</td><td>37.1</td></tr><tr><td>No</td><td>332</td><td>62.9</td></tr><tr><td>Skill</td><td>Skilled</td><td>173</td><td>32.8</td></tr><tr><td></td><td>Not skilled</td><td>355</td><td>67.2</td></tr></table>
a35c170936ee5639cea34c5d5c562b3ed537c55511a61e66e199aa39b4dd3d4b.png
complex
<table><tr><td>Cutoff</td><td>Results</td><td>African population<i>N</i> (%)</td><td>Caucasian population<i>N</i> (%)</td><td><i>p</i></td></tr><tr><td rowspan="2">AR &#8805; 1%</td><td>Negative</td><td>22 (33.8)</td><td>22 (16.9)</td><td></td></tr><tr><td>Positive</td><td>43 (66.2)</td><td>108 (83.1)</td><td>0.008</td></tr><tr><td rowspan="2">AR &#8805; 10%</td><td>Negative</td><td>25 (38.5)</td><td>27 (20.8)</td><td></td></tr><tr><td>Positive</td><td>40 (61.5)</td><td>103 (79.2)</td><td>0.009</td></tr></table>
79cbc6e09c3de35e399ac3fd8dc9312ef2ebfc25e2e63ec1c7c60d426dcec33f.png
simple
<table><tr><td>Species</td><td>Title of publication</td><td>cDNAs used for reprogramming</td><td>Origin of cDNAs</td></tr><tr><td>Rhesus macaque (<i>Macaca mulatta</i>)</td><td>Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts [24]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Rhesus</td></tr><tr><td>Common marmoset (<i>Callithrix jacchus</i>)</td><td>Generation of induced pluripotent stem cells from newborn marmoset skin fibroblasts [25]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Human</td></tr><tr><td>Common marmoset (<i>Callithrix jacchus</i>)</td><td>Generating induced pluripotent stem cells from common marmoset (<i>Callithrix jacchus</i>) fetal liver cells using defined factors, including Lin28 [26]</td><td><i>POU5F1, SOX2, KLF4, MYC, NANOG</i> and <i>LIN28 </i></td><td>Human</td></tr><tr><td>Rhesus macaque (<i>Macaca mulatta</i>)</td><td>Reprogramming Huntington monkey skin cells into pluripotent stem cells [27]</td><td><i>POU5F1, SOX2</i> and <i>KLF4 </i></td><td>Rhesus</td></tr><tr><td>Pigtailed macaque (<i>Macaca nemestrina</i>)</td><td>Efficient generation of nonhuman primate induced pluripotent stem cells [28]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Human</td></tr><tr><td>Cynomolgus monkey (<i>Macaca fascicularis</i>)</td><td>Development of histocompatible primate induced pluripotent stem cells for neural transplantation [29]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Human</td></tr><tr><td>Rhesus macaque (<i>Macaca mulatta</i>)</td><td>Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells [30]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Rhesus</td></tr><tr><td>Pigtailed macaque (<i>Macaca nemestrina</i>)</td><td>Safeguarding nonhuman primate iPS cells with suicide genes [31]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Human</td></tr><tr><td>Drill (<i>Mandrillus leucophaeus</i>)</td><td>Induced pluripotent stem cells from highly endangered species [32]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Human</td></tr><tr><td>Cynomolgus monkey (<i>Macaca fascicularis</i>)</td><td>Induction of retinal pigment epithelial cells from monkey iPS cells [33]</td><td><i>POU5F1, SOX2 KLF4</i> and <i>MYC </i></td><td>Human</td></tr></table>
7cc8a2688bb7dd9b857025034048d4a4965777d0d6725017be0c2ffaf6aca49e.png
simple
<table><tr><td>Age</td><td>Sex</td><td>Cause of death</td></tr><tr><td>60</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>56</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>25</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>40</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>50</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>28</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>43</td><td>F</td><td>Traumatic brain injury</td></tr><tr><td>20</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>58</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>20</td><td>M</td><td>Hypoxic brain injury</td></tr><tr><td>19</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>19</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>35</td><td>M</td><td>Hemorrhagic stroke</td></tr><tr><td>49</td><td>M</td><td>Hemorrhagic stroke</td></tr><tr><td>55</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>33</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>27</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>18</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>23</td><td>M</td><td>Traumatic brain injury</td></tr><tr><td>52</td><td>M</td><td>Hemorrhagic stroke</td></tr><tr><td>56</td><td>M</td><td>Hemorrhagic stroke</td></tr><tr><td>45</td><td>F</td><td>Hemorrhagic stroke</td></tr><tr><td>55</td><td>F</td><td>Hemorrhagic stroke</td></tr></table>
ee8b4497dd2e6bb9c23550929b6e0cdb8522c4ce1ec218c5eb9c116dd1f7d508.png
complex
<table><tr><td></td><td>Respimat&#174; 5 &#956;g</td><td>HandiHaler&#174; 18 &#956;g</td><td>Placebo</td></tr><tr><td colspan="4">Average heart rate (BPM), mean &#177; SD (min&#8211;max)</td></tr><tr><td colspan="4"> <i>Study 205.284</i></td></tr><tr><td>Baseline</td><td>&#8211;</td><td>79.89 &#177; 10.88 (59&#8211;108)</td><td>81.35 &#177; 9.14 (52&#8211;97)</td></tr><tr><td>Day 84</td><td>&#8211;</td><td>80.19 &#177; 9.78 (61&#8211;103)</td><td>81.12 &#177; 12.36 (54&#8211;140)</td></tr><tr><td colspan="4"> <i>Studies 205.254/255</i></td></tr><tr><td>Baseline</td><td>77.64 &#177; 10.05 (50&#8211;100)</td><td>&#8211;</td><td>79.26 &#177; 11.56 (55&#8211;136)</td></tr><tr><td>Day 281</td><td>77.23 &#177; 9.68 (56&#8211;99)</td><td>&#8211;</td><td>77.62 &#177; 11.21 (53&#8211;111)</td></tr><tr><td colspan="4"> <i>Study 205.458</i></td></tr><tr><td>Day 26</td><td>75.36 &#177; 10.77 (51&#8211;108)</td><td>75.83 &#177; 10.35 (58&#8211;100)</td><td>75.91 &#177; 10.91 (56&#8211;106)</td></tr><tr><td>Day 29</td><td>76.87 &#177; 10.82 (54&#8211;104)</td><td>77.39 &#177; 10.44 (55&#8211;104)</td><td>77.02 &#177; 10.36 (59&#8211;103)</td></tr><tr><td colspan="4">Pauses, n/N (%)</td></tr><tr><td colspan="4"> <i>Study 205.284</i></td></tr><tr><td>Baseline</td><td>&#8211;</td><td>2/74 (2.7)</td><td>1/65 (1.5)</td></tr><tr><td>Day 84</td><td>&#8211;</td><td>3/86 (3.5)</td><td>0</td></tr><tr><td colspan="4"> <i>Studies 205.254/255</i></td></tr><tr><td>Baseline</td><td>2/121 (1.7)</td><td>&#8211;</td><td>3/109 (2.8)</td></tr><tr><td>Day 281</td><td>1/103 (1.0)</td><td>&#8211;</td><td>2/73 (2.7)</td></tr><tr><td colspan="4"> <i>Study 205.458</i></td></tr><tr><td>Day 26</td><td>0</td><td>1/113 (0.9)</td><td>0</td></tr><tr><td>Day 29</td><td>0</td><td>0</td><td>0</td></tr><tr><td colspan="4">VPB singles, n/N (%)</td></tr><tr><td colspan="4"> <i>Study 205.284</i></td></tr><tr><td>Baseline</td><td>&#8211;</td><td>61/74 (82.4)</td><td>54/65 (83.1)</td></tr><tr><td>Day 84</td><td>&#8211;</td><td>71/86 (82.6)</td><td>58/78 (74.4)</td></tr><tr><td colspan="4"> <i>Studies 205.254/255</i></td></tr><tr><td>Baseline</td><td>112/121 (92.6)</td><td>&#8211;</td><td>95/109 (87.2)</td></tr><tr><td>Day 281</td><td>86/103 (83.5)</td><td>&#8211;</td><td>66/73 (90.4)</td></tr><tr><td colspan="4"> <i>Study 205.458</i></td></tr><tr><td>Day 26</td><td>90/112 (80.4)</td><td>88/113 (77.9)</td><td>93/117 (79.5)</td></tr><tr><td>Day 29</td><td>94/116 (81.0)</td><td>96/114 (84.2)</td><td>91/116 (78.4)</td></tr><tr><td colspan="4">SVPB singles, n/N (%)</td></tr><tr><td colspan="4"> <i>Study 205.284</i></td></tr><tr><td>Baseline</td><td>&#8211;</td><td>66/74 (89.2)</td><td>60/65 (92.3)</td></tr><tr><td>Day 84</td><td>&#8211;</td><td>82/86 (95.3)</td><td>74/78 (94.9)</td></tr><tr><td colspan="4"> <i>Studies 205.254/255</i></td></tr><tr><td> Baseline</td><td>113/121 (93.4)</td><td>&#8211;</td><td>101/109 (92.7)</td></tr><tr><td> Day 281</td><td>96/103 (93.2)</td><td>&#8211;</td><td>68/73 (93.2)</td></tr><tr><td colspan="4"> <i>Study 205.458</i></td></tr><tr><td>Day 26</td><td>100/112 (89.3)</td><td>105/113 (92.9)</td><td>111/117 (94.9)</td></tr><tr><td>Day 29</td><td>108/116 (93.1)</td><td>107/114 (93.9)</td><td>109/116 (94.0)</td></tr></table>
b1b9d46699a492b115a349ee3a417f9686f3494723449b188b3224d3442f40ca.png
complex
<table><tr><td>Predictor</td><td><i>B</i></td><td><i>SE</i></td><td><i>t</i></td></tr><tr><td colspan="4">MEDIATOR&#8212;PERCEPTIONS OF INJUSTICE</td></tr><tr><td>Control: Negative affectivity</td><td>0.13</td><td>0.02</td><td>8.27<sup>***</sup></td></tr><tr><td>Predictor: Observed incivility toward women</td><td>0.61</td><td>0.04</td><td>17.51<sup>***</sup></td></tr><tr><td>Moderator: Observer gender</td><td>0.02</td><td>0.02</td><td>1.04</td></tr><tr><td>Interaction: Observed Incivility &#215; Observer Gender</td><td>0.09</td><td>0.04</td><td>2.50<sup>*</sup></td></tr><tr><td colspan="4">OUTCOME&#8212;PERCEPTIONS OF SAFETY</td></tr><tr><td>Control: Negative affectivity</td><td>&#8722;0.19</td><td>0.03</td><td>&#8722;6.25<sup>***</sup></td></tr><tr><td>Mediator: Perceptions of injustice</td><td>&#8722;0.14</td><td>0.05</td><td>&#8722;2.68<sup>**</sup></td></tr><tr><td>Predictor: Observed incivility toward women</td><td>&#8722;0.07</td><td>0.07</td><td>0.85</td></tr><tr><td>Moderator: Observer gender</td><td>0.54</td><td>0.03</td><td>16.58<sup>***</sup></td></tr><tr><td>Interaction: Observed incivility &#215; Observer gender</td><td>0.13</td><td>0.07</td><td>1.94<sup>&#8224;</sup></td></tr><tr><td>Direct and indirect effects</td><td><i>B</i></td><td><i>SE</i></td><td>95% CI</td></tr><tr><td colspan="4">CONDITIONAL DIRECT EFFECTS ON PERCEPTIONS OF SAFETY</td></tr><tr><td>Men</td><td>&#8722;0.07</td><td>0.11</td><td>&#8722;0.15, 0.28</td></tr><tr><td>Women</td><td>&#8722;0.19<sup>*</sup></td><td>0.08</td><td>&#8722;0.36, &#8722;0.02</td></tr><tr><td colspan="4">CONDITIONAL INDIRECT EFFECTS ON PERCEPTIONS OF SAFETY</td></tr><tr><td colspan="4">(THROUGH PERCEPTIONS OF INJUSTICE)</td></tr><tr><td>Men</td><td>&#8722;0.10</td><td>0.04</td><td>&#8722;0.14, &#8722;0.00</td></tr><tr><td>Women</td><td>&#8722;0.07</td><td>0.03</td><td>&#8722;0.18, &#8722;0.00</td></tr><tr><td>Index of moderated mediation</td><td>&#8722;0.02</td><td>0.02</td><td>&#8722;0.07, &#8722;0.00</td></tr></table>
f4703a7cc0a64e9bbf758c31560b7070c9cff8d37f8cd788c0ee07b0976efeea.png
complex
<table><tr><td>Rat strains</td><td colspan="2">WKY</td><td colspan="2">SHR</td><td colspan="2">SHRSP5/Dmcr</td></tr><tr><td></td><td>Control</td><td>HFC</td><td>Control</td><td>HFC</td><td>Control</td><td>HFC</td></tr><tr><td>Body weight (g)</td><td>365 &#177; 22.6</td><td>331 &#177; 7.8 <sup>a</sup></td><td>339 &#177; 14.5</td><td>301 &#177; 10.8 <sup>a</sup></td><td>283 &#177; 16.4</td><td>260 &#177; 9.1 <sup>a</sup></td></tr><tr><td>Liver weight (g)</td><td>9.1 &#177; 0.6</td><td>23.2 &#177; 1.4 <sup>a</sup> (2.5)</td><td>9.8 &#177; 0.4</td><td>28.5 &#177; 2.5 <sup>a</sup> (2.9) <sup>b</sup></td><td>8.0 &#177; 0.4</td><td>27.4 &#177; 1.8 <sup>a</sup> (3.4) <sup>b,d</sup></td></tr><tr><td>Liver/body weight(%) </td><td>2.5 &#177; 0.1</td><td>7.0 &#177; 0.3 <sup>a</sup> (2.8)</td><td>2.9 &#177; 0.0 <sup>c</sup></td><td>9.5 &#177; 0.8 <sup>a</sup> (3.3) <sup>b</sup></td><td>2.8 &#177; 0.1 <sup>c</sup></td><td>10.6 &#177; 0.8 <sup>a</sup> (3.7) <sup>b,d</sup></td></tr><tr><td>Serum</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TG (mg/dL)</td><td>12.3 &#177; 1.9</td><td>12.2 &#177; 2.6(1.0)</td><td>17.7 &#177; 3.3 <sup>c</sup></td><td>17.0 &#177; 2.8(1.0)</td><td>25.5 &#177; 4.1 <sup>c</sup></td><td>17.7 &#177; 4.6 <sup>a</sup> (0.7) <sup>b,d</sup></td></tr><tr><td>TC (mg/dL)</td><td>103 &#177; 7.8</td><td>140.3 &#177; 17.4 <sup>a</sup> (1.4)</td><td>61.3 &#177; 5.4 <sup>c</sup></td><td>134 &#177; 19.6 <sup>a</sup> (2.2)</td><td>53.5 &#177; 2.6 <sup>c</sup></td><td>149.2 &#177; 50.1 <sup>a</sup> (2.8) <sup>b</sup></td></tr><tr><td>AST (IU/L)</td><td>168.7 &#177; 47.6</td><td>424 &#177; 94.5 <sup>a</sup> (2.5)</td><td>245.7 &#177; 49.1 <sup>c</sup></td><td>479.2 &#177; 93.9 <sup>a</sup> (2.0)</td><td>177.8 &#177; 30.6 <sup>e</sup></td><td>633.8 &#177; 81.8 <sup>a</sup> (3.7) <sup>b,d</sup></td></tr><tr><td>ALT (IU/L)</td><td>33.8 &#177; 1.7</td><td>134.2 &#177; 50.0 <sup>a</sup> (4.0)</td><td>51.7 &#177; 6.3 <sup>c</sup></td><td>205.7 &#177; 47.5 <sup>a</sup> (4.0)</td><td>61 &#177; 11.0 <sup>c</sup></td><td>318.5 &#177; 55.0 <sup>a</sup> (5.2)</td></tr><tr><td>GGT (IU/L) </td><td>1.5</td><td>1.8 &#177; 0.6(1.2)</td><td>1.5</td><td>3.6 &#177; 1.6 <sup>a</sup> (2.4)</td><td>1.5</td><td>4.8 &#177; 1.0 <sup>a</sup> (3.2)</td></tr><tr><td>Liver</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TG (mg/dL)</td><td>23.9 &#177; 3.1</td><td>64.6 &#177; 9.4 <sup>a</sup> (2.7)</td><td>29.6 &#177; 7.1</td><td>63.6 &#177; 8.0 <sup>a</sup> (2.1)</td><td>26.8 &#177; 7.3</td><td>68.6 &#177; 15.8 <sup>a</sup> (2.6)</td></tr><tr><td>TC (mg/dL)</td><td>3.4 &#177; 0.4</td><td>176.2 &#177; 9.1 <sup>a</sup> (51.8)</td><td>3.9 &#177; 0.6</td><td>167 &#177; 10.7 <sup>a</sup> (42.8) <sup>b</sup></td><td>3.5 &#177; 1.0</td><td>150.9 &#177; 15.4 <sup>a</sup> (43.1) <sup>b</sup></td></tr></table>
e989b33c4d13f94d02434bbc584f3373a99944eb02acfdd65938e923f21da48f.png
simple
<table><tr><td>Source</td><td>Patients</td><td>Inclusion criteria</td><td>Antioxidant agent</td><td>Dose</td><td>Route</td><td>Endpoints</td><td>Followup</td><td>Events</td></tr><tr><td>CHAOS [106]</td><td>2002</td><td>Angiographically demonstrated CAD</td><td>Vit E</td><td>400/800 IU</td><td>PO</td><td>CV death + MI; nonfatal MI</td><td>510 d</td><td>CV death: 27 vit E, 23 pl; nonfatal MI: 14 vit E, 41 pl</td></tr><tr><td>WHS [107]</td><td>39876</td><td>Healthy women</td><td>Vit E</td><td>600 IU q48 h</td><td>PO</td><td>Composite endpoint (CV death, MI, and stroke)</td><td>10.1 y</td><td>CV events: Vit E 482, pl 517; CV death: Vit E 106, pl 140; MI: Vit E 196, pl 195</td></tr><tr><td>SPACE [108]</td><td>196</td><td>Hemodialysis CV disease pts</td><td>Vit E</td><td>800 IU</td><td>PO</td><td>Composite endpoint (MI, ACS, PAD, and stroke)</td><td>519 d</td><td>Composite endpoint: Vit E 15, pl 33;CV death: vit E 9, pl 15; nonfatal MI: vit E 8, pl 18</td></tr><tr><td>Tepel et al. [109]</td><td>134</td><td>Hemodialysis CV disease pts</td><td>Acetylcysteine</td><td>1200 mg </td><td>PO</td><td>Composite endpoint (CV death, MI, PTCA/CABG, PAD, and stroke)</td><td>14.5 m</td><td>Composite endpoint: acetylcysteine 18, pl 33</td></tr><tr><td>Milman et al. [110]</td><td>1434</td><td>Diabetes mellitus Hp 2-2 genotype</td><td>Vit E</td><td>400 IU</td><td>PO</td><td>Composite endpoint (CV death, MI, and stroke)</td><td>18 m</td><td>Composite endpoint: Vit E 16, pl 33</td></tr></table>
3deb7c19e964369795e70997cf9c0332ca2acab34ec1e63d834fa62a5b978d89.png
simple
<table><tr><td>Language version ofsurvey</td><td>Responses</td></tr><tr><td>English</td><td>17785</td></tr><tr><td>Spanish</td><td>1052</td></tr><tr><td>French</td><td>955</td></tr><tr><td>Russian</td><td>330</td></tr><tr><td>Chinese</td><td>265</td></tr><tr><td>Japanese</td><td>258</td></tr><tr><td>Arabic</td><td>18</td></tr><tr><td>Total</td><td>20663</td></tr></table>
8d1e0a5834a586ff841c9b7f54c845c82766fb2a168fee98bd55c418ac9dcdd7.png
simple
<table><tr><td> </td><td>Correlation coefficient (<i>r</i>)</td><td><i>P</i> value</td></tr><tr><td>Tissue estriol-tissue OxLDL</td><td>0.36</td><td> 0.004</td></tr><tr><td>Tissue estriol-GW</td><td>0.25</td><td> &gt;0.05</td></tr><tr><td>Tissue OxLDL-GW</td><td>0.04</td><td> &gt;0.05</td></tr><tr><td>Tissue estriol-infant's birth weight </td><td>0.39</td><td> 0.002</td></tr><tr><td>Tissue estriol-systolic BP </td><td>&#8722;0.44</td><td>0.001</td></tr><tr><td>Tissue estriol-diastolic BP </td><td>&#8722;0.48</td><td>0.001</td></tr></table>
0bbfc63d1bae84c537315c893d7afae66d3d90af5e9c4d6e5b3c88a0cec21754.png
simple
<table><tr><td>Strain No.</td><td>SGSC No.</td><td>PCR results</td></tr><tr><td>RKS4587</td><td>2289</td><td>-</td></tr><tr><td>RKS4620</td><td>2291</td><td>-</td></tr><tr><td>33K</td><td>2419</td><td>-</td></tr><tr><td>CN13/87</td><td>2712</td><td>-</td></tr><tr><td>RKS4585</td><td>2998</td><td>+</td></tr><tr><td>RKS4586</td><td>2999</td><td>+</td></tr><tr><td>RKS4588</td><td>3000</td><td>-</td></tr><tr><td>RKS4589</td><td>3001</td><td>+</td></tr><tr><td>RKS4590</td><td>3002</td><td>+</td></tr><tr><td>RKS4591</td><td>3003</td><td>+</td></tr><tr><td>RKS4592</td><td>3004</td><td>+</td></tr><tr><td>RKS4593</td><td>3005</td><td>-</td></tr><tr><td>RKS4595</td><td>3006</td><td>+</td></tr><tr><td>RKS4596</td><td>3007</td><td>-</td></tr></table>
cd0a8b8a02756338c1c1c3595927cc59ddc51f433d191580569cdedbc7baec0b.png
simple
<table><tr><td>Variable</td><td>N</td><td>Median</td><td>Mean</td><td>SD</td></tr><tr><td>Programs offering residential treatment*</td><td></td><td></td><td></td><td></td></tr><tr><td> Average daily client census</td><td>49</td><td>26.0</td><td>43.4</td><td>59.0</td></tr><tr><td> Client occupancy ratio (%)<sup>&#8224;</sup></td><td>49</td><td>87.7</td><td>86.2</td><td>0.1</td></tr><tr><td> Average length of stay (days)</td><td>47</td><td>96.0</td><td>118.8</td><td>92.8</td></tr><tr><td> Daily residential reimbursement ($)</td><td>38</td><td>183.00</td><td>200.92</td><td>99.72</td></tr><tr><td> Quality Score<sup>#</sup></td><td>78</td><td>15.0</td><td>14.6</td><td>1.6</td></tr><tr><td>Programs offering outpatient treatment*</td><td></td><td></td><td></td><td></td></tr><tr><td> Average daily client census</td><td>59</td><td>20.0</td><td>39.7</td><td>57.1</td></tr><tr><td> Client occupancy ratio (%)<sup>&#8224;</sup></td><td>47</td><td>50.0</td><td>55.9</td><td>0.3</td></tr><tr><td> Average treatment duration (days)</td><td>47</td><td>120.0</td><td>131.7</td><td>92.8</td></tr><tr><td> Daily outpatient reimbursement ($)</td><td>26</td><td>50.50</td><td>55.73</td><td>26.47</td></tr><tr><td> Quality Score<sup>#</sup></td><td>93</td><td>15.0</td><td>14.3</td><td>1.9</td></tr></table>
eb4559f6bc6bdc028cc6f336dd0e6abe81ffe2868bf47785b81cecd0ef91e746.png
simple
<table><tr><td>Subject No.<sup>a</sup></td><td>Sex (age)<sup>c</sup></td><td>CD4 Count (cells/&#956;l)</td><td>CD8 Count (cells/&#956;l)</td><td>Plasma Viral Load (copies/ml)</td><td>HCV<sup>b</sup></td><td>HBV<sup>b</sup></td><td>HIV Subtype</td></tr><tr><td>1</td><td>M(42)</td><td>332</td><td>1326</td><td>18800</td><td>P</td><td>P</td><td>CRF07-BC</td></tr><tr><td>2</td><td>F(38)</td><td>412</td><td>1373</td><td>92300</td><td>N</td><td>N</td><td>CRF01-AE</td></tr><tr><td>3</td><td>M(45)</td><td>368</td><td>463</td><td>71000</td><td>P</td><td>N</td><td>B</td></tr><tr><td>4</td><td>M(22)</td><td>484</td><td>1333</td><td>60100</td><td>N</td><td>N</td><td>B</td></tr><tr><td>5</td><td>M(40)</td><td>364</td><td>842</td><td>3200</td><td>N</td><td>N</td><td>CRF01-AE</td></tr><tr><td>6</td><td>M(46)</td><td>265</td><td>421</td><td>140000</td><td>N</td><td>N</td><td>CRF01-AE</td></tr><tr><td>7</td><td>M(33)</td><td>328</td><td>485</td><td>63000</td><td>N</td><td>N</td><td>CRF01-AE</td></tr><tr><td>8</td><td>F(45)</td><td>480</td><td>737</td><td>&lt; 10</td><td>P</td><td>N</td><td>B'</td></tr><tr><td>9</td><td>F(45)</td><td>359</td><td>1064</td><td>3600</td><td>N</td><td>P</td><td>B'</td></tr><tr><td>10</td><td>M(32)</td><td>276</td><td>869</td><td>830000</td><td>P</td><td>P</td><td>B'</td></tr></table>
199b093abc2020d4a9729cd553070b6f0e10493b2215a02e2486a86b1860130b.png
complex
<table><tr><td rowspan="2">COX4 Expression</td><td colspan="4">Hsp60 Expression</td><td rowspan="2">Total, N</td></tr><tr><td>-</td><td>+</td><td>++</td><td>+++</td></tr><tr><td>-</td><td>11</td><td>15</td><td>5</td><td>0</td><td>31</td></tr><tr><td>+</td><td>8</td><td>36</td><td>29</td><td>37</td><td>110</td></tr><tr><td>++</td><td>4</td><td>17</td><td>12</td><td>31</td><td>64</td></tr><tr><td>+++</td><td>3</td><td>15</td><td>11</td><td>41</td><td>70</td></tr><tr><td>Total, N</td><td>26</td><td>83</td><td>57</td><td>109</td><td>275</td></tr></table>
cdda26b1942494e93a9ea6c8abf238575afd0ffe52da0cce26e1bc13b6926673.png
simple
<table><tr><td>Name</td><td>Fold Change (T/N)</td><td>log2Fold Change(T/N)</td><td><i>P</i> Value</td><td>FDR</td></tr><tr><td>hsa-mir-210</td><td>31.74</td><td>4.99</td><td>2.54E-05</td><td>0.004</td></tr><tr><td>hsa-mir-183</td><td>7.22</td><td>2.85</td><td>6.03E-05</td><td>0.007</td></tr><tr><td>hsa-mir-10b</td><td>0.34</td><td>&#8722;1.55</td><td>0.00037</td><td>0.026</td></tr><tr><td>hsa-mir-100</td><td>0.25</td><td>&#8722;2.02</td><td>1.47E-05</td><td>0.003</td></tr><tr><td>hsa-mir-30a</td><td>0.24</td><td>&#8722;2.08</td><td>6.49E-09</td><td>0.000</td></tr><tr><td>hsa-mir-145</td><td>0.20</td><td>&#8722;2.31</td><td>3.6E-06</td><td>0.001</td></tr><tr><td>hsa-let-7c</td><td>0.17</td><td>&#8722;2.53</td><td>7.75E-06</td><td>0.002</td></tr><tr><td>hsa-mir-383</td><td>0.09</td><td>&#8722;3.45</td><td>8.97E-05</td><td>0.008</td></tr><tr><td>hsa-mir-133a</td><td>0.08</td><td>&#8722;3.72</td><td>0.000229</td><td>0.018</td></tr><tr><td>hsa-mir-143</td><td>0.07</td><td>&#8722;3.90</td><td>7.27E-05</td><td>0.007</td></tr><tr><td>hsa-mir-1-2</td><td>0.06</td><td>&#8722;4.01</td><td>4.55E-05</td><td>0.006</td></tr></table>
83b1e00b645689b658a2e7d8746378c183c7b6eb51c440b577b1d2093712b649.png
complex
<table><tr><td>MMCO Metrics</td><td>Metrics Detail</td><td>MMCO V2.0 (Existing Work) [6]</td><td>MMCO V3.0 (Extended Work)</td></tr><tr><td rowspan="8">Metrics</td><td>Axioms</td><td>793</td><td>1092</td></tr><tr><td>Logical Axioms</td><td>624</td><td>859</td></tr><tr><td>Class count</td><td>45</td><td>225</td></tr><tr><td>Object Property count</td><td>3</td><td>25</td></tr><tr><td>Individual count</td><td>114</td><td>157</td></tr><tr><td>DL Expressivity</td><td>ALCO</td><td>ALCHOF(D)</td></tr><tr><td>Asserted Triples</td><td>0</td><td>3312</td></tr><tr><td>Inferred Triples</td><td>0</td><td>6041</td></tr><tr><td rowspan="3">Class Axioms</td><td>SubClassOf</td><td>32</td><td>222</td></tr><tr><td>Equivalent Classes</td><td>9</td><td>17</td></tr><tr><td>Disjoint Classes</td><td>5</td><td>14</td></tr><tr><td rowspan="3">Individual Axioms</td><td>Class Assertion</td><td>360</td><td>58</td></tr><tr><td>Object Property Assertion</td><td>212</td><td>27</td></tr><tr><td>Data Property Assertion</td><td>0</td><td>1</td></tr></table>
53bce9d71952b908921878f063b7cd1937091240a9efeac9739d6a32610b4533.png
simple
<table><tr><td>Variables</td><td>Pretraining</td><td>Posttraining</td><td>t</td><td>p</td></tr><tr><td>Basic rhythm (left)</td><td>74.23 &#177; 6.84</td><td>75.07 &#177; 9.04</td><td>&#8722;0.189</td><td>0.856</td></tr><tr><td>Basic rhythm (right)</td><td>75.40 &#177; 9.70</td><td>72.85 &#177; 10.20</td><td>0.363</td><td>0.729</td></tr><tr><td>Self-control index</td><td>48.47 &#177; 14.28</td><td>51.93 &#177; 13.50</td><td>&#8722;0.393</td><td>0.708</td></tr><tr><td>Attention index (left)</td><td>66.67 &#177; 9.54</td><td>64.07 &#177; 8.35</td><td>0.449</td><td>0.669</td></tr><tr><td>Attention index (right)</td><td>64.18 &#177; 12.60</td><td>65.97 &#177; 9.23</td><td>&#8722;0.347</td><td>0.741</td></tr><tr><td>Activation index (left)</td><td>76.11 &#177; 9.56</td><td>71.82 &#177; 14.88</td><td>0.509</td><td>0.629</td></tr><tr><td>Activation index (right)</td><td>77.44 &#177; 13.87</td><td>74.06 &#177; 12.39</td><td>0.374</td><td>0.721</td></tr><tr><td>Emotion index</td><td>83.82 &#177; 2.45</td><td>82.68 &#177; 3.45</td><td>0.883</td><td>0.411</td></tr><tr><td>Anti-stress index (left)</td><td>75.27 &#177; 9.28</td><td>75.36 &#177; 17.38</td><td>&#8722;0.012</td><td>0.991</td></tr><tr><td>Anti-stress index (right)</td><td>74.44 &#177; 9.25</td><td>74.71 &#177; 15.86</td><td>&#8722;0.045</td><td>0.965</td></tr><tr><td>Left and right brain balance index</td><td>77.04 &#177; 9.48</td><td>78.54 &#177; 11.14</td><td>&#8722;0.348</td><td>0.740</td></tr><tr><td>Brain index</td><td>72.10 &#177; 5.12</td><td>71.55 &#177; 5.67</td><td>0.162</td><td>0.877</td></tr></table>
551318c979d7522f8ecce068f116bd8e13a36a4fc1d6bc5259b2c416978dacd9.png
complex
<table><tr><td colspan="6">Canagliflozin (300 mg q.d.) and cyclosporine A (400 mg q.d.)</td></tr><tr><td rowspan="2">Parameter</td><td colspan="2">Arithmetic mean (SD)</td><td colspan="3">Geometric mean<sup>a</sup></td></tr><tr><td>Canagliflozin alone (n = 18)</td><td>Canagliflozin + cyclosporine A (n = 17)</td><td>Canagliflozin alone (reference) (n = 17)</td><td>Canagliflozin + cyclosporine A (test) (n = 17)</td><td>Estimated ratio (test/reference), % (90% CI)</td></tr><tr><td>C<sub>max.ss</sub> (ng/mL)</td><td>2,887 (735)</td><td>2,923 (467)</td><td>2,864.03</td><td>2,887.13</td><td>100.81 (91.31; 111.30)</td></tr><tr><td>AUC<sub>&#964;.ss</sub> (ng&#215;h/mL)</td><td>22,158 (4203)</td><td>27,819 (5267)</td><td>22,243.50</td><td>27,355.78</td><td>122.98 (118.66; 127.46)</td></tr><tr><td>t<sub>max.ss</sub> (h)<sup>b</sup></td><td>2.00 (1.00 &#8211; 3.00)</td><td>4.00 (1.50 &#8211; 6.00)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr></table>
bd15bddfba32369388463b73fa493572c355105ad57887674bf996eaf5e5a7bb.png
complex
<table><tr><td>Collection Season</td><td colspan="4">District</td></tr><tr><td></td><td>Pampulha</td><td>North</td><td>East</td><td>All districts</td></tr><tr><td></td><td>IF/CF (IR%)</td><td>IF/CF (IR%)</td><td>IF/CF (IR%)</td><td>IF/CF (IR%)</td></tr><tr><td>1st</td><td>14/67 (20.8)</td><td>9/22 (40.9)</td><td>3/28 (10.7)</td><td>26/117 (22.2)</td></tr><tr><td>2nd</td><td>15/17 (88.2)</td><td>11/13 (84.6)</td><td>11/14 (78.5)</td><td>37/44 (84.0)</td></tr><tr><td>3rd</td><td>3/89 (3.3)</td><td>4/49 (8.1)</td><td>4/61 (6.5)</td><td>11/199 (5.5)</td></tr><tr><td>4th</td><td>1/61 (1.6)</td><td>0/15 (0.0)</td><td>4/75 (5.3)</td><td>5/151 (3.3)</td></tr><tr><td>Total</td><td>33/234 (14.1)</td><td>24/99 (24.2)</td><td>22/178 (12.3)</td><td>79/511 (15.4)</td></tr></table>
ae56985ca37a236e3f20856824981db67dab10e2a0e299b496e8ef4279204b28.png
complex
<table><tr><td rowspan="2">Variables</td><td colspan="2">Diarrhoea</td><td colspan="2">Fever</td><td colspan="2">Cough</td></tr><tr><td>COR</td><td>AOR</td><td>COR</td><td>AOR</td><td>COR</td><td>AOR</td></tr><tr><td>Toilet facilities (yes)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1.104 (0.950&#8211;1.283)</td><td>0.972 (0.841&#8211;1.124)</td><td>1.054 (0.456&#8211;2.438)</td><td>1.029 (0.480&#8211;2.203)</td><td>1.240 (0.629&#8211;2.443)</td><td>1.149 (0.627&#8211;2.107)</td></tr><tr><td>Water facilities (yes)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1.179(1.010&#8211;1.376)</td><td>1.602(1.217&#8211;2.343)</td><td>1.428 (0.616&#8211;3.311)</td><td>2.193(1.544&#8211;4.618)</td><td>1.310 (0.721&#8211;2.379)</td><td>1.059 (0.924&#8211;1.214)</td></tr><tr><td>Child&#8217;s excretaDisposal facilities (yes)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>0.927 (0.804&#8211;1.069)</td><td>1.172(1.022&#8211;1.344)</td><td>1.013 (0.442&#8211;2.325)</td><td>1.393(1.041&#8211;3.028)</td><td>1.388 (0.771&#8211;2.498)</td><td>1.245 (0.673&#8211;2.303)</td></tr><tr><td>Toilet + water + disposal facilities (yes)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1.137 (0.968&#8211;1.336)</td><td>1.329(1.046&#8211;1.947)</td><td>1.180 (0.568&#8211;2.449)</td><td>1.242(1.050&#8211;1.468)</td><td>1.220(1.050&#8211;1.418)</td><td>1.432(1.113&#8211;2.902)</td></tr></table>
a1e8f4e48b1d6f7fa511e41f06e210a0de145bc2771dd4da243f9f3af2138794.png
simple
<table><tr><td>Factor</td><td>HR</td><td>95 % confidence interval</td><td>P value</td></tr><tr><td>Acute kidney injury 3</td><td>7.35</td><td>2.15&#8211;25.07</td><td>0.001</td></tr><tr><td>Peripheral vascular disease</td><td>1.95</td><td>1.12&#8211;3.39</td><td>0.019</td></tr><tr><td>Chronic renal failure</td><td>1.59</td><td>0.96&#8211;2.62</td><td>0.07</td></tr><tr><td>Diabetes mellitus</td><td>0.83</td><td>0.49&#8211;1.40</td><td>0.48</td></tr><tr><td>Female gender</td><td>0.47</td><td>0.28&#8211;0.80</td><td>0.005</td></tr></table>
21cdf96cca7f5cf2074c7ce56d8c46cea207b6a921b75d333e8f2d6ec7c710cd.png
complex
<table><tr><td></td><td colspan="2">MIC (&#956;g/mL)</td></tr><tr><td>Formulation</td><td>MS-Lac</td><td>Estimated Gentamicin in Microspheres *</td></tr><tr><td>MS-Lac1</td><td>2.16</td><td>0.31</td></tr><tr><td>MS-Lac2</td><td>2.92</td><td>0.31</td></tr><tr><td>MS-Lac3</td><td>4.00</td><td>0.31</td></tr></table>
538e9ee5f34c3224c2631be90703d75b1e8baa105cf4934e53f70627adeb4779.png
complex
<table><tr><td>Variable</td><td>Adjusted PR (95%CI)</td><td><i>p</i>-value<sup>a</sup></td></tr><tr><td colspan="3"><i>Housing area</i></td></tr><tr><td>Urban</td><td>1</td><td> </td></tr><tr><td>Rural</td><td>1.15 (1.0-1.3)</td><td>0.030</td></tr><tr><td colspan="3"> </td></tr><tr><td colspan="3"><i>School type</i></td></tr><tr><td>Municipal</td><td>3.30 (1.1-9.4)</td><td>0.026</td></tr><tr><td>State</td><td>3.40 (1.1-9.6)</td><td>0.022</td></tr><tr><td>Particular</td><td>1</td><td> </td></tr><tr><td colspan="3"> </td></tr><tr><td colspan="3"><i>School education of mother</i></td></tr><tr><td>Illiterate or up to the 4th grade</td><td>1.67 (1.1-2.4)</td><td>0.005</td></tr><tr><td>High school</td><td>1.54 (1.0-2.2)</td><td>0.023</td></tr><tr><td>Completed college</td><td>1</td><td> </td></tr><tr><td colspan="3"> </td></tr><tr><td colspan="3"><i>Flossing</i></td></tr><tr><td>Yes/daily</td><td>0.97 (0.8-1.1)</td><td>0.703</td></tr><tr><td>Sometimes</td><td>0.80 (0.7-0.9)</td><td>0.003</td></tr><tr><td>Never</td><td>1</td><td> </td></tr></table>
fd336328d6f03c11a80f820469e8165b1983af5c8b2d888a312cc09e6ad16bea.png
simple
<table><tr><td>Clinicopathological parameters</td><td>Relative risk ( 95%CI)</td><td>p value</td></tr><tr><td>Age(&#8805;65years)</td><td>0.884(0.561-1.395)</td><td>0.597</td></tr><tr><td>Sex(Female)</td><td>0.817(0.520-1.283)</td><td>0.380</td></tr><tr><td>Depth of invasion (T<sub>2-4</sub>)</td><td>5.873(2.058-16.762)</td><td>0.001</td></tr><tr><td>Lymphatic invasion(+)</td><td>1.269(0.756-2.129)</td><td>0.367</td></tr><tr><td>Venous invasion(+)</td><td>1.088(0.646-1.830)</td><td>0.752</td></tr><tr><td>Lymph node metastasis(+)</td><td>1.638(0.482-5.568)</td><td>0.429</td></tr><tr><td>Liver metastasis</td><td>0.357(0.071-1.793)</td><td>0.211</td></tr><tr><td>Distant metastasis</td><td>11.330(2.466-52.057)</td><td>0.002</td></tr><tr><td>TNM staging(I-II)</td><td>1.746(0.453-6.729)</td><td>0.418</td></tr><tr><td>Differentiation (moderately and poorly)</td><td>1.131(0.792-1.616)</td><td>0.497</td></tr><tr><td>BTG3 expression (++~+++)</td><td>1.227(0.775-1.942)</td><td>0.384</td></tr></table>
dde9f88a0e9195e24ecc376f6197f8585bdd12c75cc7d8d9712c84b1bce37bba.png
simple
<table><tr><td>Variable</td><td>Patients (%)</td></tr><tr><td>Gender</td><td></td></tr><tr><td> Male</td><td>74 (71.8)</td></tr><tr><td> Female</td><td>29 (28.2)</td></tr><tr><td>Age (y)</td><td></td></tr><tr><td> Mean</td><td>58.3</td></tr><tr><td> Range</td><td>26&#8211;75</td></tr><tr><td>Tumor location</td><td></td></tr><tr><td> EGJ</td><td>41 (39.8)</td></tr><tr><td> Body</td><td>27 (26.2)</td></tr><tr><td> Antrum</td><td>35 (34.0)</td></tr><tr><td>Treatment</td><td></td></tr><tr><td> FOLFOX</td><td>19 (18.5)</td></tr><tr><td> SOX</td><td>46 (44.7)</td></tr><tr><td> XELOX</td><td>24 (23.3)</td></tr><tr><td> XP</td><td>6 (5.8)</td></tr><tr><td> Other</td><td>8 (7.7)</td></tr><tr><td>Clinical tumor stage</td><td></td></tr><tr><td> II</td><td>33 (32.0)</td></tr><tr><td> III</td><td>70 (68.0)</td></tr><tr><td>Tumor regression grade (TRG)</td><td></td></tr><tr><td> 1a</td><td>8 (7.8)</td></tr><tr><td> 1b</td><td>9 (8.7)</td></tr><tr><td> 2</td><td>23 (22.3)</td></tr><tr><td> 3</td><td>63 (61.2)</td></tr></table>
8c509a01a9e2d7b09f2a6925bda74a6e9f33214a63eb8e54ff0eec4ea593b890.png
simple
<table><tr><td>Patients</td><td>n = 3191</td></tr><tr><td>Age, years</td><td>70 &#177; 10</td></tr><tr><td>&#8804;65 years, %</td><td>30</td></tr><tr><td>66-79 years, %</td><td>54</td></tr><tr><td>&#8805;80 years, %</td><td>16</td></tr><tr><td>Gender, male vs. female, %</td><td>43 vs. 57</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>23 &#177; 3</td></tr><tr><td>SBP at entry, mmHg</td><td>147 &#177; 17</td></tr><tr><td>Uncontrolled SBP (&#8805;140 mmHg) at entry, %</td><td>66</td></tr><tr><td>DBP at entry, mmHg</td><td>83 &#177; 11</td></tr><tr><td>Uncontrolled DBP (&#8805;90 mmHg) at entry, %</td><td>37</td></tr><tr><td>Uncontrolled SBP and/or uncontrolled DBP at entry, %</td><td>68</td></tr><tr><td>Diabetes, %</td><td>32</td></tr><tr><td>Smoking, %</td><td>12</td></tr><tr><td>Drinking, %</td><td>14</td></tr></table>
6eb37bfbc5d49bf05046c90b57d73a9e4113a5377a6895addcea67ccc356b506.png
simple
<table><tr><td> </td><td>Progression-free survival</td><td>Overall survival</td></tr><tr><td>AUC (95% CIs)</td><td>0.71 (0.57&#8211;0.83)</td><td>0.65 (0.50&#8211;0.78)</td></tr><tr><td>Criterion (cut-off)</td><td>&#8805;19%</td><td>&#8805;13%</td></tr><tr><td>Sensitivity</td><td>73%</td><td>58%</td></tr><tr><td>Specificity</td><td>77%</td><td>70%</td></tr><tr><td><i>p</i> value</td><td><i>0.0054</i></td><td>0.057</td></tr></table>
d7b950d8e878af7b386e539fd036b4ba778120703c992f7889a28e3d8fdcb2c4.png
complex
<table><tr><td rowspan="3">Run</td><td colspan="6">Parameters</td><td colspan="2">HPR (ml H<sub>2</sub>/L h)</td></tr><tr><td colspan="2">Initial pH (<i>X</i><sub>1</sub>)</td><td colspan="2">Light intensity (<i>X</i><sub>2</sub>)</td><td colspan="2">Mo concentration (<i>X</i><sub>3</sub>)</td><td rowspan="2">Observed</td><td rowspan="2">Predicted</td></tr><tr><td>Code</td><td>Actual</td><td>Code</td><td>Actual (klux)</td><td>Code</td><td>Actual (mg/L)</td></tr><tr><td>1</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>8.9 &#177; 0.4</td><td>8.8</td></tr><tr><td>2</td><td>&#8722;1.00</td><td>7.00</td><td>1.00</td><td>10.00</td><td>1.00</td><td>0.50</td><td>7.4 &#177; 0.6</td><td>7.3</td></tr><tr><td>3</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>8.8 &#177; 0.2</td><td>8.8</td></tr><tr><td>4</td><td>&#8722;1.68</td><td>6.32</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>5.6 &#177; 0.5</td><td>5.7</td></tr><tr><td>5</td><td>0.00</td><td>8.00</td><td>1.68</td><td>11.36</td><td>0.00</td><td>0.30</td><td>7.5 &#177; 0.1</td><td>7.7</td></tr><tr><td>6</td><td>0.00</td><td>8.00</td><td>&#8722;1.68</td><td>4.64</td><td>0.00</td><td>0.30</td><td>5.8 &#177; 0.4</td><td>6.5</td></tr><tr><td>7</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>8.8 &#177; 0.3</td><td>8.8</td></tr><tr><td>8</td><td>1.00</td><td>9.00</td><td>&#8722;1.00</td><td>6.00</td><td>&#8722;1.00</td><td>0.10</td><td>6.2 &#177; 0.2</td><td>5.7</td></tr><tr><td>9</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>9.0 &#177; 0.6</td><td>8.8</td></tr><tr><td>10</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>9.1 &#177; 0.4</td><td>8.8</td></tr><tr><td>11</td><td>1.00</td><td>9.00</td><td>&#8722;1.00</td><td>6.00</td><td>0.20</td><td>0.50</td><td>6.6 &#177; 0.1</td><td>6.0</td></tr><tr><td>12</td><td>1.00</td><td>9.00</td><td>1.00</td><td>10.00</td><td>&#8722;1.00</td><td>0.10</td><td>6.8 &#177; 0.4</td><td>6.5</td></tr><tr><td>13</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>8.5 &#177; 0.4</td><td>8.8</td></tr><tr><td>14</td><td>&#8722;1.00</td><td>7.00</td><td>1.00</td><td>10.00</td><td>&#8722;1.00</td><td>0.10</td><td>7.3 &#177; 0.5</td><td>7.3</td></tr><tr><td>15</td><td>&#8722;1.00</td><td>7.00</td><td>&#8722;1.00</td><td>6.00</td><td>&#8722;1.00</td><td>0.10</td><td>6.7 &#177; 0.4</td><td>6.5</td></tr><tr><td>16</td><td>&#8722;1.00</td><td>7.00</td><td>&#8722;1.00</td><td>6.00</td><td>1.00</td><td>0.50</td><td>7.0 &#177; 0.2</td><td>6.7</td></tr><tr><td>17</td><td>1.00</td><td>9.00</td><td>1.00</td><td>10.00</td><td>1.00</td><td>0.50</td><td>7.0 &#177; 0.4</td><td>6.5</td></tr><tr><td>18</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>1.68</td><td>0.64</td><td>7.5 &#177; 0.4</td><td>8.0</td></tr><tr><td>19</td><td>1.68</td><td>9.68</td><td>0.00</td><td>8.00</td><td>0.00</td><td>0.30</td><td>3.5 &#177; 0.2</td><td>4.3</td></tr><tr><td>20</td><td>0.00</td><td>8.00</td><td>0.00</td><td>8.00</td><td>&#8722;1.68</td><td>&#8722;0.04</td><td>7.4 &#177; 0.0</td><td>7.8</td></tr></table>
0d8680db68e2ae7a7cc371c929b7e27e8a32b9dc5c4a34b0da54c97624aeeea2.png
complex
<table><tr><td>Patient characteristics</td><td>Value</td></tr><tr><td>Age (years), median (IQR)</td><td>38.0 (29.0&#8211;43.0)</td></tr><tr><td colspan="2">Sex, <i>n</i> (%)</td></tr><tr><td> Female</td><td>13 (68.4)</td></tr><tr><td> Male</td><td>6 (31.6)</td></tr><tr><td colspan="2">Race, <i>n</i> (%)</td></tr><tr><td> White</td><td>19 (100)</td></tr><tr><td colspan="2">Main comorbidities, <i>n</i> (%)<sup>a</sup></td></tr><tr><td> Hypertension</td><td>3 (15.8)</td></tr><tr><td> Asthma</td><td>2 (10.5)</td></tr><tr><td> Hypercholesterolaemia</td><td>2 (10.5)</td></tr><tr><td colspan="2">Major features for TSC diagnosis, n (%)<sup>a</sup></td></tr><tr><td> Renal AML</td><td>19 (100)</td></tr><tr><td> Facial angiofibromas/forehead plaque</td><td>15 (79.0)</td></tr><tr><td> Cortical tuber</td><td>10 (52.6)</td></tr><tr><td> Hypomelanotic macules (&#8805;3)</td><td>7 (36.8)</td></tr><tr><td> Subependymal nodule</td><td>7 (36.8)</td></tr><tr><td> Non-traumatic ungual/periungual fibroma</td><td>4 (21.1)</td></tr><tr><td> Single/multiple cardiac rhabdomyoma</td><td>4 (21.1)</td></tr><tr><td> Lymphangiomyomatosis</td><td>3 (15.8)</td></tr><tr><td> Connective tissue nevus</td><td>2 (10.5)</td></tr><tr><td colspan="2">Minor features for TSC diagnosis, <i>n</i> (%)<sup>a</sup></td></tr><tr><td> Multiple renal cysts</td><td>11 (57.9)</td></tr><tr><td> Multiple randomly distributed pits in dental enamel</td><td>3 (15.8)</td></tr><tr><td> Bone cysts</td><td>3 (15.8)</td></tr><tr><td> Non-renal hamartoma</td><td>2 (10.5)</td></tr><tr><td> &#8220;Confetti&#8221; skin lesions</td><td>1 (5.26)</td></tr><tr><td>Sum of volumes of target renal AML lesions (cm<sup>3</sup>), median (IQR)</td><td>260.0 (127.8&#8211;322.2)</td></tr><tr><td>Volume of right kidney (cm<sup>3</sup>), median (IQR)</td><td>329.4 (193.0&#8211;979.7)<sup>b</sup></td></tr><tr><td>Volume of left kidney (cm<sup>3</sup>), median (IQR)</td><td>299.0 (184.2&#8211;404.7)<sup>c</sup></td></tr></table>
f0958074927e3ed747b9ae853e17889050f15ee24411412bf967f4f12acba006.png
complex
<table><tr><td></td><td colspan="5">Inpatient hospital contact (1987&#8211;2012)</td><td colspan="5">Any hospital contact (2001&#8211;2012)</td></tr><tr><td></td><td colspan="2">No bereavement</td><td colspan="3">Bereavement</td><td colspan="2">No bereavement</td><td colspan="3">Bereavement</td></tr><tr><td></td><td>N</td><td>Crude IR (100,000 PYs)</td><td>N</td><td>Crude IR (100,000 PYs)</td><td>IRR (95 % CI)</td><td>N</td><td>Crude IR (100,000 PYs)</td><td>N</td><td>Crude IR (100,000 PYs)</td><td>IRR (95 % CI)</td></tr><tr><td>Any STI</td><td>5903</td><td>17.00</td><td>1188</td><td>14.50</td><td>1.16 (1.08&#8211;1.24)</td><td>71061</td><td>453.00</td><td>9309</td><td>304.00</td><td>1.06 (1.01&#8211;1.11) <sup><i>b</i></sup></td></tr><tr><td> Condyloma <sup><i>a</i></sup></td><td>2833</td><td>8.14</td><td>700</td><td>8.54</td><td>1.18 (1.08&#8211;1.30)</td><td>42652</td><td>272.00</td><td>5334</td><td>174.00</td><td>1.06 (1.00&#8211;1.12) <sup><i>b</i></sup></td></tr><tr><td> Gonorrhea</td><td>123</td><td>0.35</td><td>33</td><td>0.40</td><td>1.51 (0.97&#8211;2.28)</td><td>466</td><td>2.97</td><td>75</td><td>2.45</td><td>1.49 (1.14&#8211;1.92)</td></tr><tr><td> Chlamydia</td><td>952</td><td>2.74</td><td>136</td><td>1.66</td><td>1.23 (1.01&#8211;1.48)</td><td>10098</td><td>64.40</td><td>1185</td><td>38.60</td><td>1.14 (1.04&#8211;1.26) <sup><i>b</i></sup></td></tr><tr><td> Syphilis</td><td>65</td><td>0.19</td><td>20</td><td>0.24</td><td>1.17 (0.66&#8211;2.01)</td><td>72</td><td>0.46</td><td>16</td><td>0.52</td><td>1.05 (0.57&#8211;1.84)</td></tr><tr><td> GHS</td><td>1946</td><td>5.59</td><td>302</td><td>3.68</td><td>1.06 (0.93&#8211;1.21)</td><td>17828</td><td>114.00</td><td>2709</td><td>88.30</td><td>1.04 (0.99&#8211;1.09) <sup><i>b</i></sup></td></tr><tr><td>Acute salpingitis</td><td>11361</td><td>32.60</td><td>3540</td><td>43.20</td><td>1.28 (1.13&#8211;1.44)<sup><i>b</i></sup></td><td>2929</td><td>18.70</td><td>1000</td><td>32.60</td><td>1.24 (1.15&#8211;1.34)</td></tr><tr><td>HIV</td><td>120</td><td>0.34</td><td>96</td><td>1.17</td><td>2.36 (1.76&#8211;3.17)</td><td>220</td><td>1.40</td><td>112</td><td>3.65</td><td>1.98 (1.53&#8211;2.53)</td></tr><tr><td>HBV</td><td>435</td><td>1.25</td><td>161</td><td>1.96</td><td>1.59 (1.30&#8211;1.94)</td><td>411</td><td>2.62</td><td>141</td><td>4.60</td><td>2.20 (1.78&#8211;2.71)</td></tr></table>
1414d8411c051cc88e93471a16972aa5a39a7386744d6b346ec90c0095bd499b.png
simple
<table><tr><td>No.</td><td>IUPAC Name</td></tr><tr><td>BDE-209</td><td>Deca-bromodiphenyl ether</td></tr><tr><td>BDE-208</td><td>2,2',3,3',4,5,5',6, 6'- nona-bromodiphenyl ether</td></tr><tr><td>BDE-207</td><td>2,2',3,3',4,4',5,6,6'-nona-bromodiphenyl ether</td></tr><tr><td>BDE-206</td><td>2,2',3,3',4,4',5,5',6-nona-bromodiphenyl ether</td></tr><tr><td>BDE-203</td><td>2,2',3,4,4',5,5',6-octa-bromodiphenyl ether</td></tr><tr><td>BDE-196</td><td>2,2',3,3',4,4',5,6'-octa-bromodiphenyl ether</td></tr><tr><td>BDE-190</td><td>2,3,3',4,4',5,6-hepta-bromodiphenyl ether</td></tr><tr><td>BDE-183</td><td>2,2',3,4,4',5',6-hepta-bromodiphenyl ether</td></tr><tr><td>BDE-181</td><td>2,2',3,4,4',5,6-hepta-bromodiphenyl ether</td></tr><tr><td>BDE-155</td><td>2,2',4,4',6,6'-hexa-bromodiphenyl ether</td></tr><tr><td>BDE-154</td><td>2,2',4,4',5,6'-hexa-bromodiphenyl ether</td></tr><tr><td>BDE-153</td><td>2,2',4,4',5,5'-hexa-bromodiphenyl ether</td></tr><tr><td>BDE-139</td><td>2,2',3,4,4',6-hexa-bromodiphenyl ether</td></tr><tr><td>BDE-138</td><td>2,2',3,4,4',5'-hexa-bromodiphenyl ether</td></tr><tr><td>BDE-100</td><td>2,2',4,4',6-penta-bromodiphenyl ether</td></tr><tr><td>BDE-99</td><td>2,2',4,4',5-penta-bromodiphenyl ether</td></tr><tr><td>BDE-85</td><td>2,2',3,4,4'-penta-bromodiphenyl ether</td></tr><tr><td>BDE-77</td><td>3,3',4,4'-tetra-bromodiphenyl ether</td></tr><tr><td>BDE-47</td><td>2,2',4,4'-tetra-bromodiphenyl ether</td></tr><tr><td>BDE-28</td><td>2,4,4'-Tri-bromodiphenyl ether</td></tr></table>
fb1505b0f1f1112c759282ec93397d63051e7b6a6e6f773270d7b8caad42eff8.png
simple
<table><tr><td></td><td>Appearance</td></tr><tr><td>Rich looking/smart/elegant</td><td>Liked the colors</td></tr><tr><td>Different</td><td>Simple/neat</td></tr><tr><td>Looks cold/refreshing/clean</td><td>Eye-catching/bold</td></tr><tr><td>Bright</td><td>Attractive</td></tr><tr><td>Happy</td><td>Modern and up-to-date</td></tr><tr><td>Ordinary</td><td>Plain</td></tr><tr><td>Similar to others</td><td>Cheap looking</td></tr><tr><td>Dull/drab</td><td>Unattractive</td></tr><tr><td>Messy/chopped up/gaudy/cluttered</td><td></td></tr><tr><td></td><td>Functionality</td></tr><tr><td>Was easier to open</td><td>Did a better job keeping tobacco out of your pocket or purse</td></tr><tr><td>Was easier to close</td><td>Did a better job of keeping cigarettes from spilling out</td></tr><tr><td>Protected the cigarettes better</td><td>Did a better job of keeping cigarettes fresh</td></tr><tr><td>Was more pleasing to look at</td><td>Did a better job of keeping cigarettes from being crushed</td></tr><tr><td>Felt more comfortable in your hand</td><td>Was more different from other cigarette packages</td></tr><tr><td>Fit better in your pocket or purse</td><td></td></tr></table>
0d2354a290d68441aff09411f8a7b2de1a8b9bc9711cf8aec412a74598189839.png
simple
<table><tr><td>Variable</td><td>Baseline (2004)</td><td>5-year follow-up (2009)</td><td>P-value<sup>a</sup></td></tr><tr><td>Age, mean (SD)</td><td>43.6 (9.5)</td><td>48.6 (9.5)</td><td></td></tr><tr><td>SMBQ score, mean (SD)</td><td>2.86 (0.91)</td><td>2.71 (1.05)</td><td>&lt;0.001</td></tr><tr><td>SMBQ score &gt; 4.0, N (%)</td><td>74/623 (11.8)</td><td>82/623 (13.2)</td><td>0.37</td></tr><tr><td>Marital status, N (%)</td><td></td><td></td><td></td></tr><tr><td>Married or cohabiting</td><td>493/609 (81.0)</td><td>501/609 (82.3)</td><td></td></tr><tr><td>Unmarried, divorced or widowed</td><td>116/609 (19.0)</td><td>108/609 (17.7)</td><td>0.36</td></tr><tr><td>Living with children, N (%)</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>362/610 (59.3)</td><td>312/610 (51.1)</td><td></td></tr><tr><td>No</td><td>248/610 (40.7)</td><td>298/610 (48.9)</td><td>&lt;0.001</td></tr><tr><td>Social support (integration), N (%)</td><td></td><td></td><td></td></tr><tr><td>High</td><td>389/577 (67.4)</td><td>374/577 (64.8)</td><td></td></tr><tr><td>Low</td><td>188/577 (32.6)</td><td>203/577 (35.2)</td><td>0.24</td></tr><tr><td>Education, N (%)</td><td></td><td></td><td></td></tr><tr><td>University or similar</td><td>232/620 (37.4)</td><td>236/620 (38.1)</td><td></td></tr><tr><td>Other</td><td>388/620 (62.6)</td><td>384/620 (61.9)</td><td>0.45</td></tr><tr><td>Socioeconomic index (SEI), N (%)</td><td></td><td></td><td></td></tr><tr><td>Blue-collar</td><td>243/621 (39.1)</td><td>233/621 (37.5)</td><td></td></tr><tr><td>White-collar</td><td>320/621 (51.5)</td><td>344/621 (55.4)</td><td></td></tr><tr><td>Self-employed</td><td>58/621 (9.3)</td><td>44/621 (7.1)</td><td>0.001</td></tr><tr><td>Number of work hours, N (%)</td><td></td><td></td><td></td></tr><tr><td>Full-time</td><td>510/601 (84.9)</td><td>507/601 (84.4)</td><td></td></tr><tr><td>Part-time (&lt;35 hours per week)</td><td>91/601 (15.1)</td><td>94/601 (15.6)</td><td>0.76</td></tr><tr><td>Demand at work, N (%)</td><td></td><td></td><td></td></tr><tr><td>Low</td><td>428/605 (70.7)</td><td>405/605 (66.9)</td><td></td></tr><tr><td>High</td><td>177/605 (29.3)</td><td>200/605 (33.0)</td><td>0.07</td></tr><tr><td>Control at work, N (%)</td><td></td><td></td><td></td></tr><tr><td>High</td><td>475/607 (78.3)</td><td>470/607 (77.4)</td><td></td></tr><tr><td>Low</td><td>132/607 (21.7)</td><td>137/607 (22.6)</td><td>0.65</td></tr><tr><td>Job strain, N (%)</td><td></td><td></td><td></td></tr><tr><td>No</td><td>563/595 (94.6)</td><td>554/595 (93.1)</td><td></td></tr><tr><td>Yes</td><td>32/595 (5.4)</td><td>41/595 (6.9)</td><td>0.23</td></tr><tr><td>Risk for unemployment, N (%)</td><td></td><td></td><td></td></tr><tr><td>Low</td><td>544/603 (90.2)</td><td>541/603 (89.7)</td><td></td></tr><tr><td>High</td><td>59/603 (9.8)</td><td>62/603 (10.3)</td><td>0.73</td></tr><tr><td>New job possibilities, N (%)</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>351/609 (57.6)</td><td>293/609 (48.1)</td><td></td></tr><tr><td>No</td><td>258/609 (42.4)</td><td>316/609 (51.9)</td><td>&lt;0.001</td></tr><tr><td>Perceived economic situation, N (%)</td><td></td><td></td><td></td></tr><tr><td>Satisfied</td><td>454/617 (73.6)</td><td>405/617 (65.6)</td><td></td></tr><tr><td>Dissatisfied</td><td>163/617 (26.4)</td><td>212/617 (34.4)</td><td>&lt;0.001</td></tr></table>
7de9a028338bd4d9ddb838e0ccdf7b0302b0aaa73337a7efa6c358617d9ed598.png
complex
<table><tr><td></td><td colspan="3">Prior to 1:1 matching</td><td colspan="3">After 1:1 matching<sup>*</sup></td></tr><tr><td>Variables</td><td>Vulvar cancer patients</td><td>Controls</td><td><i>P</i>-value<sup>*</sup></td><td>Vulvar cancer patients</td><td>Controls</td><td><i>P</i>-value<sup>*</sup></td></tr><tr><td>N</td><td>505</td><td>569,648</td><td></td><td>505</td><td>505</td><td></td></tr><tr><td>Variables used for matched-pairs</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age (years)</td><td>60.8 (15.6)</td><td>40.8 (16.5)</td><td>&lt; 0.001</td><td>60.8 (15.6)</td><td>60.8 (15.6)</td><td>1.000</td></tr><tr><td>Age &#8804; 40</td><td>10.3</td><td>55.4</td><td>&lt; 0.001</td><td>10.3</td><td>10.3</td><td>1.000</td></tr><tr><td>Age 41&#8211;50</td><td>17.5</td><td>17.6</td><td>0.956</td><td>17.5</td><td>17.5</td><td>1.000</td></tr><tr><td>Age 51&#8211;60</td><td>19.5</td><td>12.1</td><td>&lt; 0.001</td><td>19.5</td><td>19.5</td><td>1.000</td></tr><tr><td>Age 61&#8211;70</td><td>19.3</td><td>8.5</td><td>&lt; 0.001</td><td>19.3</td><td>19.3</td><td>1.000</td></tr><tr><td>Age &gt; 70</td><td>33.4</td><td>6.4</td><td>&lt; 0.001</td><td>33.4</td><td>33.4</td><td>1.000</td></tr><tr><td>Private health insurance coverage</td><td>4.8</td><td>9.3</td><td>&lt; 0.001</td><td>4.8</td><td>4.8</td><td>1.000</td></tr><tr><td>Index year</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2000&#8211;2005</td><td>7.2</td><td>16.4</td><td>1.000</td><td>7.2</td><td>7.2</td><td>1.000</td></tr><tr><td>2006&#8211;2010</td><td>21.4</td><td>22.4</td><td>0.625</td><td>21.4</td><td>21.4</td><td>1.000</td></tr><tr><td>2011&#8211;2015</td><td>71.4</td><td>61.2</td><td>&lt; 0.001</td><td>71.4</td><td>71.4</td><td>1.000</td></tr><tr><td>Other variables<sup>**</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Vulva dysplasia (ICD10: N90.0-90.3)</td><td>8.3</td><td>0.1</td><td>&lt; 0.001</td><td>8.3</td><td>0.2</td><td>&lt; 0.001</td></tr><tr><td>Leukoplakia of vulva (ICD10: N90.4)</td><td>14.5</td><td>0.6</td><td>&lt; 0.001</td><td>14.5</td><td>1.4</td><td>&lt; 0.001</td></tr><tr><td>Benign neoplasm of vagina (ICD10: D28.1)</td><td>1.2</td><td>0.0</td><td>&lt; 0.001</td><td>1.2</td><td>0.0</td><td>0.014</td></tr></table>
ad96958877aba67ee3bf20beb974606fecc3f49a360be0dc9bd01b8efd28c4b7.png
simple
<table><tr><td></td><td>Arm A IRI+LV+5FU</td><td>Arm B LV+5FU</td><td><i>P </i>(log-rank)</td></tr><tr><td>Disease-free survival (DFS)</td><td></td><td></td><td>0.436</td></tr><tr><td> Progressions, <i>n (%)</i></td><td>110 (24.9)</td><td>112 (25.9)</td><td></td></tr><tr><td> Median (months)</td><td>Not reached yet</td><td>Not reached yet</td><td></td></tr><tr><td> three-year DFS (%)</td><td>78</td><td>76</td><td></td></tr><tr><td> five-year DFS (%)</td><td>70</td><td>68</td><td></td></tr><tr><td> seven-year DFS (%)</td><td>66</td><td>63</td><td></td></tr><tr><td>Overall survival (OS)</td><td></td><td></td><td>0.334</td></tr><tr><td> Deaths, <i>n (%)</i></td><td>118 (26.8)</td><td>128 (29.6)</td><td></td></tr><tr><td> Median (months)</td><td>Not reached yet</td><td>Not reached yet</td><td></td></tr><tr><td> three-year OS (%)</td><td>88</td><td>86</td><td></td></tr><tr><td> five-year OS (%)</td><td>78</td><td>76</td><td></td></tr><tr><td> seven-year OS (%)</td><td>72</td><td>69</td><td></td></tr></table>
dda653adc92487b365e871ef74f69bdbef5c96192a74af8a7daadec8bc4c96b0.png
complex
<table><tr><td>Deliveries in six months</td><td colspan="2">Total number %</td><td colspan="2">Without malformation number %</td><td colspan="2">With malformation number %</td></tr><tr><td>Ayder referral hospital</td><td>503**</td><td>33</td><td>484</td><td>32</td><td>19</td><td>3.8</td></tr><tr><td>Mekelle hospital</td><td>1013**</td><td>67</td><td>1000</td><td>66</td><td>13</td><td>1.3</td></tr><tr><td>Males</td><td>684</td><td>45</td><td>662*</td><td>44</td><td>22*</td><td>3.2</td></tr><tr><td>Females</td><td>832</td><td>55</td><td>822</td><td>54</td><td>10</td><td>1.2</td></tr><tr><td>LBW</td><td>822</td><td>54</td><td>800</td><td>97</td><td>22</td><td>2.7</td></tr><tr><td>LBW Male</td><td>374</td><td>25</td><td>362</td><td>97</td><td>12</td><td>3.2</td></tr><tr><td>LBW Female</td><td>448</td><td>30</td><td>438</td><td>98</td><td>10</td><td>2.2</td></tr><tr><td>VLBW</td><td>530</td><td>35</td><td>515</td><td>97</td><td>15</td><td>2.8</td></tr><tr><td>VLBW Male</td><td>243</td><td>16</td><td>238</td><td>98</td><td>5</td><td>2.1</td></tr><tr><td>VLBW Female</td><td>287</td><td>19</td><td>277</td><td>97</td><td>10</td><td>3.5</td></tr><tr><td>Total deliveries</td><td>1516</td><td>100</td><td>1484</td><td>98</td><td>32</td><td>2.1</td></tr></table>
c70088f31f802d5f2fe232c57c2136f84c5fb2e22d2a288c625bd01684a662ba.png
simple
<table><tr><td></td><td>ypN0</td><td>ypN1</td><td>ypN2</td><td>Total</td></tr><tr><td>yN0</td><td>41</td><td>-</td><td>-</td><td>41 (66.1)</td></tr><tr><td>yN+</td><td>7</td><td>11</td><td>3</td><td>21 (33.9)</td></tr><tr><td>Total</td><td>48 (77.4)</td><td>11 (17.8)</td><td>3 (4.8)</td><td>62 (100)</td></tr></table>